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General introduction
For the immediate management of chest pain patients suspected of an acute coronary 
syndrome an approach that integrates information from history, physical examination, 
12-lead electrocardiogram (ECG) and cardiac markers is recommended 1. In about 30% of 
acute coronary syndrome patients the ECG shows ST-segment elevation 2. This most often 
reflects occlusion of an epicardial coronary artery as a result of thrombus formation on 
a ruptured atherosclerotic plaque 3. Prompt reperfusion of the occluded coronary artery 
is warranted to salvage jeopardized myocardium 4. Reperfusion can be achieved either 
pharmacologically with fibrinolytic agents or mechanically with primary percutaneous 
coronary intervention (primary PCI). Fibrinolytic therapy has been shown to reduce 35-
day mortality with 2-3% in patients with ST-elevation myocardial infarction (STEMI) in an 
overview of randomized placebo-controlled trials including a total of 45,000 patients 5. 
The greatest benefit was observed in patients treated within 6 hours of symptom onset. 
A more recent meta-analysis on about 7,700 patients included in randomized trials, 
showed a further 2% reduction in 30-day mortality with primary PCI when compared 
with fibrinolysis 6. To date the number of STEMI patients undergoing primary PCI is 
increasing, but worldwide a large proportion is still treated with fibrinolysis 7. 
Prognostic importance of early angiography after fibrinolysis
In patients treated with fibrinolysis for STEMI important prognostic information can be 
obtained from history, physical examination and the ECG. The TIMI risk score for STEMI 
(Table 1, 8) can be used to estimate 30-day mortality after fibrinolysis based on these 
non-invasive parameters. However, data from angiographic studies have shown that 
left ventricular function and early infarct artery patency (i.e. brisk antegrade flow) are 
the major determinants of prognosis 9-11. 
Although in the late 1980s the European Cooperative Study Group proposed a 
classification of coronary patency based on stenosis grade 12, the qualitative TIMI flow 
grade classification has become the gold standard for the assessment of coronary flow 
in reperfusion trials (Table 2, 13). Coronary flow as assessed by this classification has been 
shown to be strongly predictive of short-term outcome 10,11. In patients with successful 
reperfusion (TIMI flow grade 3) 90 minutes after fibrinolysis the 30-day mortality rate is 
less than 4%, when compared with 6% in patients with TIMI flow grade 2 and more than 
9% in patients with TIMI flow grade 0-1.
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Table 1  TIMI risk score for ST-elevation myocardial infarction
Points
Risk score = 
total points (0-14)
30-day 
mortality (%)
Historical
Age ≥ 75 y
 65-74 y
Diabetes, hypertension or previous angina
Physical examination
Systolic blood pressure < 100 mmHg
Heart rate > 100 bpm
Killip II – IV
Weight < 67 kg
Presentation
Anterior MI or left bundle branch block
Symptoms to treatment > 4 hours
3
2
1
3
2
2
1
1
1
0
1
2
3
4
5
6
7
8
>8
0.8
1.6
2.2
4.4
7.3
12
16
23
27
36
Adapted from Morrow et al. 8
Table 2  TIMI flow grading system
TIMI 0
TIMI 1
TIMI 2
TIMI 3
No perfusion: 
no antegrade flow beyond the point of occlusion 
Penetration without perfusion:
The contrast material passes beyond the area of obstruction but ‘hangs’ up and fails 
to opacify the entire coronary bed distal to the obstruction for the duration of the 
cineangiographic filming sequence
Partial perfusion:
The contrast material passes across the obstruction and opacifies the coronary bed 
distal to the obstruction. However, the rate of entry of contrast material into the 
vessel distal to the obstruction or its rate of clearance from the distal bed (or both) 
are perceptibly slower than its entry into or clearance from comparable areas not 
perfused by the previously occluded vessel – e.g. the opposite coronary artery or 
the coronary bed proximal to the obstruction
Complete perfusion:
Antegrade flow into the bed distal to the obstruction occurs as promptly as 
antegrade flow into the bed proximal to the obstruction, and clearance of contrast 
material from the involved bed is as rapid as clearance from an uninvolved bed in 
the same vessel or the opposite artery
Adapted from the TIMI study group 13
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Adjunctive antithrombotic therapy
Antithrombotic therapy is used adjunctive to fibrinolysis both for the facilitation of 
reperfusion and the prevention of recurrent ischemic events. Since the ISIS-2 trial 14, the 
early survival benefit of aspirin in patients with myocardial infarction is undisputed. In 
GUSTO-1, the superior reperfusion strategy with respect to survival and early coronary 
patency was accelerated alteplase and a 48-hour infusion of unfractionated heparin in 
combination with aspirin 10,15. After these landmark trials, aspirin and unfractionated 
heparin were recommended as standard antithrombotic therapy in patients receiving 
fibrinolysis for STEMI.
Reocclusion
Unfortunately, part of the initial benefit of successful reperfusion with fibrinolysis is 
often offset by reocclusion of the infarct artery 16. Reocclusion is a time-dependent 
phenomenon, which occurs in about 10% of patients before discharge 17, with an incidence 
of up to 30% within the first year, despite the use of aspirin 18,19. Early reocclusion is 
associated with a two-fold increased risk of in-hospital mortality 20. Early recurrent 
ischemic events are often attributed to reocclusion 16. After the acute phase reocclusion 
portends an increased risk of reinfarction and revascularization both on the short- and 
the long term 21. Whether late reocclusion is also associated with an increased risk of 
long-term cardiac mortality remains to be determined.
The APRICOT study group is one of the few research groups worldwide that 
systematically studies reocclusion. Although the formal study of reocclusion requires 
three angiograms, it is generally accepted to study reocclusion with two angiograms: 
one demonstrating a patent infarct artery after reperfusion therapy and a second 
angiogram for the detection of reocclusion 16. The ST-segment elevations on the initial 
ECG are considered to be diagnostic of the initial occlusion. In the APRICOT-1 and 
APRICOT-2 trials clinically stable patients who had a patent infarct artery at 24-48 hour 
angiography after fibrinolysis for STEMI were randomized to different antithrombotic 
regimens 18,22. Per protocol a second angiogram was scheduled at three months to assess 
reocclusion, which was the primary endpoint of both trials. No less than 90% of patients 
underwent follow-up angiography, which was expedited in case of recurrent ischemia. 
As a secondary endpoint of the APRICOT-1 and APRICOT-2 main trials clinical follow-
up was assessed at the time of the 3-month repeat angiogram. In the era in which the 
APRICOT trials were conducted, guidelines did not recommend routine angioplasty 
after successful fibrinolysis. This recommendation was based on a meta-analysis in 
which this strategy failed to improve clinical outcome 23. In APRICOT-1 revascularization 
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was only to be performed in case of recurrent ischemia despite maximal anti-ischemic 
medication 18. The APRICOT-2 study protocol allowed revascularization in case of 
spontaneous or stress inducible recurrent ischemia 22. Studies supporting the rationale 
behind an ischemia-guided revascularization strategy were published a few years after 
the initiation of this trial 24,25. 
Scope of the thesis
The increased risk of early mortality associated with in-hospital reocclusion and related 
events as early reinfarction and recurrent ischemia has clearly been demonstrated 20,25,26. 
However, the consequences of late reocclusion on survival remain a matter of debate. 
Studies with systematic follow-up angiography after successful fibrinolysis have shown 
that the majority of late reocclusions occur without clinical signs of reinfarction 19,21. Even in 
these cases reocclusion impairs recovery of left ventricular function 27, the main prognostic 
determinant 9. In only one study, in which angioplasty was routinely performed 10 days 
after fibrinolysis, an adverse prognostic impact of late reocclusion was demonstrated, 
independent of left ventricular function 28.
Three-year follow-up of the APRICOT-1 trial showed that three-month reocclusion was 
associated with an increased risk of reinfarction and revascularization. In this population, 
with a good a priori prognosis, mortality rates were low, which precluded the detection 
of a possible adverse effect of reocclusion on survival. To study the impact of reocclusion 
on long-term survival it was therefore decided to extend clinical follow-up to 10 years. 
The specific design of the APRICOT-1 trial with routine follow-up angiography in all 
patients would also allow us to determine whether reocclusion adversely affects long-
term clinical outcome when it occurs without signs of reinfarction or recurrent ischemia. 
If so, this could have important consequences for the future treatment of patients after 
successful fibrinolysis. Even patients who appear to be clinically stable when visiting 
the outpatient clinic, could be at increased risk of adverse long-term clinical outcome as 
they may have suffered a silent reocclusion.
Early observations after successful fibrinolysis suggested a relationship between a 
high-grade residual stenosis and reocclusion, which prompted the assumption that 
patients with a high-grade lesion are at increased risk of death and reinfarction 29,30. 
Consequently, a reduction of the residual lumen narrowing was thought to reduce 
the incidence of reocclusion and subsequently to lead to improved clinical outcome. 
Unexpectedly, in a meta-analysis of trials from the 1980s, and 1990s routine angioplasty 
of in most cases severe residual stenoses did not reduce death and reinfarction 
when compared with an ischemia-guided revascularization strategy 23. The lack of 
Peter Kievit-boek.indb   14 12-02-2009   17:49:12
 General introduction and outline of the thesis
15
benefit from routine angioplasty was attributed to high periprocedural event rates. 
Unfortunately, angiographic reocclusion was not addressed in those trials. Later studies 
demonstrated that in the majority of patients reocclusion occurs asymptomatically, 
that is without death or clinical reinfarction 19-21. This implicates that there is no 1-to-1 
relationship between reocclusion and the occurrence of these events. Therefore, the 
attainable clinical benefit from angioplasty depends on the proportion of symptomatic 
reocclusions occurring in patients with a severe stenosis. The rather conservative 
ischemia-guided revascularization strategy in APRICOT-1 (3-month revascularization 
rate only ~11%) allowed us to study the natural course of patients with a high-grade 
residual stenosis after successful fibrinolysis. Knowing that in APRICOT-1 a visually 
assessed >90% stenosis independently predicted reocclusion 31, we used quantitative 
coronary angiography to assess the optimal stenosis severity cut-point for reocclusion. 
Subsequently, we sought to assess whether patients with a high-grade stenosis, who are 
at increased risk of reocclusion, are also at increased risk of clinical reinfarction.
Reocclusion has been shown to impair recovery of left ventricular function 27, the main 
determinant of survival after myocardial infarction 9. This implicates that reocclusion may 
be associated with impaired prognosis. Given the strong relationship between stenosis 
severity and reocclusion 31, a high-grade stenosis may also be predictive of long-term 
mortality. This could have important implications for the future treatment of patients 
after successful fibrinolysis. In the current era of improved techniques, stents and 
modern antithrombotic therapy routine angioplasty of a high-grade residual stenosis 
may not only reduce the risk of reinfarction, a reduction in the risk of reocclusion may 
also confer a beneficial effect on left ventricular recovery and eventually on long-term 
survival. 
Besides routine revascularization, improved antithrombotic strategies may also reduce 
the risk of reocclusion. Despite the use of aspirin reocclusion occurs in up to 30% 
of patients in the first year after fibrinolysis 18,19. Only recently aspirin-resistance has 
been implicated as a potential mechanism for the failure of aspirin monotherapy 32. In 
the last decades of the past century, when currently used agents as clopidogrel were 
not yet introduced in clinical practice, oral anticoagulation was already shown to be 
markedly effective in coronary artery disease. As monotherapy the clinical benefit of 
oral anticoagulation has clearly been demonstrated 33, and combined with aspirin an 
angiographic study after non-ST-elevation acute coronary syndromes showed promising 
results 34. In APRICOT-1 aspirin and oral anticoagulation had a similar efficacy in the 
prevention of reocclusion in patients with a patent infarct artery after fibrinolysis for 
STEMI 18. Based on the results of these studies, the APRICOT-2 main trial compared a 
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regimen of moderate-intensity oral anticoagulation combined with aspirin with aspirin 
monotherapy in the prevention of reocclusion. Combination therapy markedly reduced 
the risk of 3-month reocclusion, and was associated with a lower rate of early recurrent 
ischemic events 22. Although reocclusion is strongly associated with these events, it has 
not yet been demonstrated that a reduction in reocclusion leads to a reduction in long-
term death and reinfarction. Therefore, we performed a long-term clinical follow-up 
study of APRICOT-2 to investigate whether the initial clinical benefit with combination 
therapy is sustained in the long-term and if so, to assess whether the observed benefit is 
attributed to the reduction in reocclusion. With this design we may be able to elucidate 
a potential mechanistic explanation for the long-term clinical benefit of medium-
intensity oral anticoagulation added to aspirin, which has previously been observed in 
several large scale clinical trials 35.
So far, only severity of the residual culprit stenosis has been identified as an independent 
predictor of reocclusion after successful fibrinolysis 31,36. Although this implicates that 
on average stenoses are more severe in patients with reocclusion, a clinically useful 
cut-point for stenosis severity to predict reocclusion has never been established. 
Current guidelines advocate early angiography and a liberal revascularization strategy 
in all patients after fibrinolysis 37. This recommendation is mainly based on studies 
including mixed populations of both patients with patent infarct arteries and patients 
with occluded vessels. In the well-defined population of patients with successful 
reperfusion after fibrinolysis it remains a matter of debate whether early PCI should 
target all amenable infarct lesions, or only those with a severe residual stenosis. Instead 
of stenosis severity, the use of non-invasive risk factors would be more ideal in the 
prediction of reocclusion and associated adverse events. These non-invasive parameters 
should be easy to assess and clearly discriminate between high and low risk patients. 
With respect to baseline variables, we hypothesized that smoking status might be 
related to the risk of reocclusion. Epidemiological studies have shown that in the general 
population of individuals without a history of cardiac events smokers are at increased 
risk of myocardial infarction and death from coronary artery disease 38,39. Interestingly, in 
patients receiving fibrinolysis for STEMI short-term clinical outcome is more favorable 
in smokers than in non-smokers. This so called ‘smoker’s paradox’ has been attributed 
to a better response to fibrinolysis and more favorable clinical and angiographic 
baseline characteristics in smokers 40-42. As outcome after successful fibrinolysis is 
strongly related to reocclusion, an effect of smoking on reocclusion could be another 
mechanism explaining their favorable outcome. After combining the APRICOT-1 and 
APRICOT-2 databases we assessed differences in clinical and angiographic baseline 
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variables between smokers and non-smokers after successful fibrinolysis, and studied 
the effect of smoking on reocclusion and short- and long-term cardiac outcome.
The results of exercise electrocardiography (X-ECG) have never been studied with 
regard to the non-invasive prediction of reocclusion. After myocardial infarction, X-
ECG is a class I guideline recommendation for the detection of ischemia, assessment of 
exercise capacity and prognostic stratification 43-46. The APRICOT-2 protocol prescribed 
an ischemia-guided revascularization strategy, and recommended stress testing in 
all patients. In most cases bicycle X-ECG was performed, either before discharge or 
during a cardiac rehabilitation program. In view of the potential adverse prognostic 
consequences of reocclusion, even in patients without recurrent ischemic symptoms, 
and the widespread use of X-ECG in these patients, we assessed the value of this 
test in the prediction of reocclusion and long-term clinical outcome after successful 
fibrinolysis.
In summary, this thesis focuses on the long-term prognostic consequences of reocclusion 
in patients with successful reperfusion after fibrinolysis. After the acute phase 
reocclusion is associated with an increased risk of reinfarction and revascularization, 
but so far an effect on long-term survival has not been demonstrated. Although in 
many cases reocclusion occurs without recurrent ischemic events, it may still adversely 
affect recovery of left ventricular function. Even in these cases reocclusion may have a 
detrimental effect on long-term prognosis. Identification of patients at increased risk 
of reocclusion may therefore carry important clinical implications. In this thesis new 
non-invasive predictors of reocclusion are analyzed. In addition, we study whether 
patients at increased risk of reocclusion are also at increased risk of adverse long-term 
outcome. If there is a causal relationship between reocclusion and long-term prognosis, 
prevention of reocclusion may translate in improved long-term outcome. However, 
reocclusion could only be a marker of poor prognosis. To further clarify this important 
issue we assess whether a reduction in reocclusion with intensive antithrombotic 
therapy confers a beneficial effect on long-term clinical outcome. 
In view of the above, this thesis aims to gain mechanistic insights in the intriguing 
relationship between reocclusion, long-term clinical outcome, and predictors of 
these events. These insights may potentially influence the design of future trials on 
both mechanical and pharmacological reperfusion therapy after STEMI, as well as the 
development of improved treatment strategies.
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Outline of the thesis
After successful fibrinolysis reocclusion is associated with adverse clinical outcome. 
However, most reocclusions occur without clinical signs of reinfarction. A high-grade 
stenosis is a strong predictor of reocclusion. The issue whether the increased risk of 
reocclusion associated with a high-grade residual stenosis translates into a higher risk 
of reinfarction is addressed in Chapter 2. 
Chapter 3 studies the long-term prognostic impact of sustained patency of the infarct 
artery in patients surviving the acute phase of STEMI. The consequences of both 
symptomatic reocclusion and reocclusion occurring without recurrent ischemic events 
on 10-year cardiac survival are assessed.
Knowing that stenosis severity predicts reocclusion, and if reocclusion is indeed 
predictive of long-term cardiac mortality, stenosis severity may also be associated with 
impaired long-term prognosis. This question is addressed in Chapter 4.
In APRICOT-2 a three-month regimen of aspirin and moderate intensity anticoagulation 
resulted in a more than 40% relative reduction in reocclusion and lower rates of recurrent 
events. In Chapter 5 we studied whether this combined regimen would reduce the 
risk of long-term death and reinfarction, and if so, whether this beneficial effect was 
attributed to the early reduction in reocclusion. 
About half of all reocclusions occur in patients without recurrent ischemic events in the 
first months after the index event, but may still portend adverse long-term prognostic 
consequences. Exercise electrocardiography is routinely performed in patients with 
stable or no angina early after fibrinolysis. The value of this test as a non-invasive 
predictor of reocclusion and long-term clinical outcome in these patients is described 
in Chapter 6.
Although in the general population smokers are at increased risk of cardiovascular 
events, a paradoxical beneficial outcome has been reported in smokers after myocardial 
infarction. This was attributed to favorable clinical and angiographic baseline 
characteristics in smokers and a better response to fibrinolysis. After successful 
fibrinolysis outcome is strongly related to reocclusion of the infarct artery. The effects 
of smoking on reocclusion and long-term cardiac outcome in the combined APRICOT-1 
and -2 population are analyzed in Chapter 7.
In Chapter 8 the results and conclusions of all presented studies are summarized. The 
thesis is concluded with an epilogue, in which the findings are put in perspective and 
their potential implications are discussed. Finally, Chapter 9 contains a Dutch translation 
of the summary and epilogue. 
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Abstract
Background  After successful fibrinolysis, a high-grade stenosis at 24-hour angiography 
is strongly predictive of reocclusion and is often believed to result in high reinfarction 
rates. However, routine angioplasty did not reduce death or reinfarction in past trials. 
Systematic angiographic follow-up shows that reocclusion often occurs without clinical 
reinfarction. This study investigates whether the increased risk of reocclusion associated 
with a high-grade lesion translates into impaired clinical outcome.
Methods  In the ischemia-guided Antithrombotics in the Prevention of Reocclusion 
In COronary Thrombolysis (APRICOT-1) trial, 240 patients with ST-elevation myocardial 
infarction who had an open infarct artery 24 hours after fibrinolysis had 3-month repeat 
angiography to assess reocclusion, with clinical follow-up at 3 months and 3 years. 
Results  On the basis of the optimal discriminative stenosis severity, the reocclusion 
rate was 40% (47/118) in patients with a high-grade residual stenosis and 16% (20/122) 
in patients with a low-medium-grade lesion (risk ratio [RR] 2.43, 95%CI 1.54-3.84, p<0.01). 
Three-month death and reinfarction rates did not differ: 6% (7/118) versus 9% (11/122; 
RR 0.66, 95%CI 0.26-1.64, p=ns). Systematic angiographic follow-up revealed that 
reocclusion of a high-grade lesion occurred in the absence of clinical reinfarction in 
85% (40/47) of patients, as compared with 45% (9/20) in patients with a low-medium-
grade stenosis (RR 1.89, 95%CI 1.15-3.12, p<0.01). Despite an independent association with 
reocclusion, a high-grade stenosis was not predictive of either short- or long-term death 
and reinfarction.
Conclusions After successful fibrinolysis and adopting an ischemia-guided revas-
cularization strategy, patients with a high-grade stenosis experience death and 
reinfarction rates similar to those of patients with a low-medium-grade lesion. This is 
true, despite a 2- to 3-fold higher risk of reocclusion. The finding that reocclusion of a 
high-grade lesion often occurs without clinical reinfarction explains the absence of a 
relationship between a severe stenosis and death or reinfarction. Appreciation of these 
observations may contribute to an optimal design of a future randomized trial to re-
evaluate the impact of a routine invasive strategy.
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Introduction
Despite the undisputed benefits on early infarct artery patency and clinical outcome 1, 
the initial success of fibrinolytic therapy is often partly offset by reocclusion. Reocclusion 
occurs in approximately 30% of patients within the first year after acute myocardial 
infarction 2-4, and portends adverse short- and long-term outcome 5-7.
Past observations suggested a relationship between a high-grade residual stenosis 
and reocclusion after successful fibrinolysis 8-11. It was assumed that reocclusion of a 
high-grade stenosis leads to a high incidence of death, reinfarction and recurrent 
ischemia 8-12. Unexpectedly, a meta-analysis on routine angioplasty did not show reduced 
death and reinfarction rates as compared with an ischemia-guided revascularization 
strategy, which was attributed to high periprocedural event rates 13. Unfortunately, 
angiographic reocclusion was not addressed in those trials. Later studies demonstrated 
that reocclusion occurs asymptomatically in as many as two-thirds of patients, that is 
without death or clinical reinfarction 3,5,6; collateral supply to the infarct area has been 
suggested as a potential mechanism 14. 
Because of the absence of a 1-to-1 relationship between reocclusion and these events, 
the attainable benefit from angioplasty to reduce death or reinfarction depends on the 
proportion of symptomatic reocclusions occurring in patients with a severe stenosis. 
The Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis 
(APRICOT-1) trial 2 was performed in the same era as the trials in the meta-analysis. 
In this angiographic and clinical follow-up trial, an ischemia-guided revascularization 
strategy was followed, irrespective of the presence of a high-grade stenosis. In this 
setting, we previously demonstrated that stenosis severity 24 hours after successful 
fibrinolysis was the only independent predictor of reocclusion 15. 
In this analysis we dichotomized our study population according to the optimal 
quantitative stenosis severity cut-point to predict reocclusion. Subsequently, we sought 
to assess whether the increased risk of reocclusion in patients with a high-grade stenosis 
at 24-hour angiography translates in impaired clinical outcome in both the short- and 
the long-term. 
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Methods
Protocol
The APRICOT-1 study protocol has been reported in detail previously 2. In brief, 300 
patients <71 years old with chest pain lasting >30 minutes and <4 hours and 0.2 mV ST-
segment elevation in at least two contiguous leads on the electrocardiogram (ECG) 
received fibrinolysis for suspected myocardial infarction, followed by 20,000 units 
of intravenous heparin every 24 hours. In the case of clinical signs of reperfusion, 
electrocardiographic signs of reperfusion, or both, clinically stable patients were asked 
to give informed consent to undergo coronary angiography within 48 hours after 
fibrinolysis. The infarct-related artery was identified with previously described methods, 
and in the case of a patent artery, grade 1 to 3 stenosis according to the European 
Cooperative Study Group (ECSG) criteria (Table 1), patients were eligible for the study 2. 
Sixteen patients were retrospectively excluded for not having a patent infarct artery at 
baseline angiography according to the blinded angiography committee.
Table 1  Stenosis grades
Stenosis grade
0
1
2
3
4
5
Normal
<50% diameter stenosis
50% to 90% diameter stenosis
91% to 99% diameter stenosis, complete filling within 3 cycles
91% to 99% diameter stenosis, no complete filling within 3 cycles
Total occlusion with or without collateral filling
The 284 patients with a patent infarct artery were randomly allocated to 1 of 3 arms: 
blinded treatment with either 325 mg of aspirin or placebo, or open-label coumadin 
including continued heparinization until the target INR (2.8-4.0) was reached. According 
to protocol, revascularization was only to be performed for recurrent ischemia refractory 
to maximal anti-ischemic medication. To assess reocclusion, follow-up angiography was 
scheduled at 3 months. When coronary angioplasty (PTCA) was performed before the 
planned repeat angiography, the patency status of the infarct artery before dilatation 
was scored as the follow-up end point.
At baseline angiography, quantitative coronary angiography (QCA) of the culprit 
lesion was performed, providing a precise estimation of the diameter stenosis with 
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low intraobserver and interobserver variability 16. For this analysis, the optimal single 
projection with the most severe measured stenosis was used. Morphology of the culprit 
lesion was scored according to Ambrose et al 17. 
Collateral filling of the infarct artery was assessed at both angiograms according to the 
Rentrop grading system 18.
Three-month clinical follow-up data included the rates of survival, reinfarctions, 
revascularizations, and recurrent ischemia. Follow-up on survival and reinfarction was 
extended to a 3-year period. Information was derived from medical charts, municipal 
registries, or telephone contact with the patient, relatives or the general practitioner.
Definition of patient groups and endpoints 
On the basis of the optimal stenosis severity cut-point to predict reocclusion, the study 
population was dichotomized in patients with a high-grade stenosis or patients with 
a low-medium-grade stenosis. Patients were observed for death and reinfarction until 
the day of the 3-month repeat angiography. A patient with a reoccluded infarct artery at 
urgent repeat angiography performed for clinical reinfarction was considered to have a 
so called ‘symptomatic’ reocclusion. 
The definition of reocclusion was ECSG grade 4 or 5 2. Clinical reinfarction was defined as 
recurrent ischemic symptoms lasting >30 minutes, accompanied by transmural ischemia 
in the same ECG area as the index infarction, with elevated creatine kinase levels. At 
follow-up visits, a careful patient history was taken and the ECG was screened for new 
Q-waves to detect possible silent reinfarctions.
In addition to death and reinfarction, revascularizations were scored, as was the incidence 
of recurrent ischemia until the day of follow-up angiography. Recurrent ischemia 
was defined as recurrent chest pain during stress testing or at rest, accompanied by 
electrocardiographic signs of ischemia. 
To study the prognostic impact of stenosis severity in the long-term, infarct-free survival 
at 3-year follow-up was assessed.
Statistics
Statistical analysis was performed with SPSS software version 9.0 (SPSS, Chicago, Ill). 
Receiver operating characteristics (ROC) analysis was performed on QCA stenosis as 
a predictor of reocclusion. The optimal cutoff level for stenosis severity was obtained 
with Fisher linear discriminant analysis.
To test differences between groups, the Student-t-test, Mann-Whitney-U-test or χ2-test were 
used when appropriate. Statistical significance was defined as a 2-sided p-value <0.05. 
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Multivariable logistic regression analysis was used to determine the association 
between a high-grade stenosis and reocclusion, short-term death, and reinfarction. 
Variables included in the multivariable model were those causing imbalances in baseline 
characteristics (see Results) combined with univariate predictors of reocclusion 15 and 
Thrombolysis in Myocardial Infarction (TIMI)-risk score variables associated with clinical 
outcome 19. Long-term event-free survival analysis was performed according to Kaplan 
and Meier, with the log-rank test for comparison between groups. Cox-regression 
analysis was used to assess a possible independent relationship between stenosis 
severity and the long-term infarct-free survival rate. 
Results
Of the 284 patients participating in the APRICOT-1 trial, this study group consisted of 
the 240 patients with 2 angiograms and complete QCA-analysis. Thirty-six patients did 
not undergo follow-up angiography because of refusal (n=28), coronary artery bypass 
grafting (n=6), or death (n=2). In 8 patients, QCA-analysis was technically not possible. 
These 44 patients did not differ from the study group, except for a tendency toward 
older age (59 ± 9 years versus 56 ± 9 years, p=0.06). 
Figure 1 shows the distribution of the quantitatively assessed severity of infarct-related 
stenoses. Baseline angiography was performed at a mean of 24 ± 14 hours. Stenosis 
severity was not related to the timing of the first angiogram. Follow-up angiography 
was performed after a mean of 75 ± 31 days.
Optimal diameter stenosis cutoff level for reocclusion
ROC analysis to determine the optimal QCA stenosis severity for predicting reocclusion 
is shown in Figure 2. Diagnostic accuracy of QCA stenosis for predicting reocclusion was 
moderate. The Fisher linear discriminant analysis identified a 62.7% residual diameter 
stenosis at baseline as the optimal cutoff level for reocclusion. The sensitivity rate was 
70%, with a negative predictive value of 84%. 
This cutoff level dichotomized the study population in 2 groups,
–	 a group of 118 patients with a high-grade stenosis (QCA >62.7%) who were at high 
risk of reocclusion (40%; 47/118) and 
–	 a group of 122 patients with a low-medium-grade stenosis (QCA <62.7%) who were 
at lower risk of reocclusion (16%; 20/122)
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Figure 1  Distribution of the quantitatively assessed severity of the infarct-related stenoses at 
24-hour angiography
Figure 2  ROC analysis for QCA stenosis as predictor of reocclusion (area under the curve 0.680, 
95% CI 0.605-0.754, p<0.01)
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This difference (40% versus 16%) represents an unadjusted relative risk of reocclusion 
of 2.43 (95%CI 1.54-3.84, p<0.01) for patients with a high-grade stenosis at baseline.  
Baseline characteristics are shown in Table 2. The rates of smoking (70%), hyper-
cholesterolemia (57%), diabetes (6%) and hypertension (26%) did not differ in the 
groups. In patients with a high-grade stenosis, a higher occurrence of smooth culprit 
lesions and a tendency toward more previous angina were observed. 
Table 2  Baseline characteristics
High-grade  
stenosis
(n = 118)
Low-medium-grade 
stenosis
(n = 122)
Men (%)  99  (84)  100  (82)
Age (y)  56 ± 9  56 ± 9
Previous angina   
 <4 weeks 
 >4 weeks
 41  (35)
 25  (21)
 31  (25)†
 23  (19)
Previous myocardial infarction  7  (6)  8  (7)
Time symptoms – fibrinolysis (h)  2.1 ± 1.0  2.0 ± 1.0
Fibrinolytic 
 Streptokinase 
 Anistreplase
 101  (86)
 17  (14)
 109  (89)
 13  (11)
Peak creatine kinase (units/L)*  1086  (454-1941)  1100  (624-2211)
Time fibrinolysis – first angiography (h)*  22  (13-31)  22  (14-33)
Anterior infarction  44  (37)  55  (45)
Single vessel disease  62  (53)  73  (60)
% stenosis QCA  70.5 ± 5.5  52.3 ± 9.1‡
Lesion type 
 Smooth 
 Complex
 74  (63)
 44  (37)
 61  (50)§
 61  (50)
Antithrombotic regimen 
 Coumadin 
 Aspirin 
 Placebo
 37  (31)
 49  (42)
 32  (27)
 42  (34)
 41  (34)
 39  (32)
Data are presented as the number (%) of subjects for discrete variables, and as mean ± standard deviation for continuous 
variables unless indicated otherwise
* median (25th-75th percentile); † p=0.07 for previous angina versus no previous angina; ‡ p<0.01; § p<0.05
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High-grade stenosis and death / reinfarction
Figure 3 shows the incidence of reocclusion and the incidence of death or reinfarction. 
Despite the 2- to 3-fold increased risk of reocclusion in patients with a high-grade 
stenosis, the incidence of death or reinfarction did not differ from that of patients with 
a low-medium-grade lesion: 6% (7/118) and 9% (11/122), respectively (RR 0.66, 95%CI 
0.26-1.64, p=ns). 
Systematic angiographic follow-up revealed that overall 73% (49/67) of reocclusions 
occurred in the absence of clinical reinfarction. Proportionally, reocclusion occurred 
more often without clinical reinfarction in patients with a high-grade stenosis than in 
patients with a low-medium-grade lesion: 85% (40/47) versus 45% (9/20), respectively 
(RR 1.89, 95%CI 1.15-3.12, p<0.01).
Figure 3 Incidence of reocclusion in patients with a high-grade stenosis (n=118) and a low-
medium-grade stenosis (n=122). Death and reinfarction rates grey.
Recurrent ischemia and revascularization
Recurrent ischemia was seen in 32% (38/118) of patients with a high-grade stenosis and 
27% (33/122) of patients with a low-medium-grade lesion (RR 1.19, 95% CI 0.80-1.76, p=ns). 
In aggregate, the revascularization rate was 11% (26/240): 14% (16/118) in patients with 
a high-grade stenosis and 8% (10/122) in patients with a low-medium-grade lesion (RR 
1.65, 95%CI 0.78-3.50, p=ns). 
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Of all patients who were conservatively treated for recurrent ischemia, only 1 patient 
sustained a reinfarction, which occurred after hospital discharge. This patient had a 
<50% stenosis at the 24-hour angiography. 
Collaterals
Of the 67 patients with reocclusion, the presence and quality of the collateral filling of 
the infarct artery could be assessed in 63 (94%). At baseline angiography, none of these 
patients had good collaterals. 
At follow-up angiography good collaterals were seen in 61% (27/44) of patients with 
a high-grade baseline stenosis and 42% (8/19) of patients with a low-medium-grade 
baseline lesion: RR 1.46, 95% CI 0.82-2.60, p=0.15.
Multivariable analysis
Multivariable analysis identified a high-grade QCA-stenosis as an independent predictor 
of reocclusion: OR 3.36, 95% CI 1.81-6.26, p<0.01. During the time period from baseline 
angiography until the day of repeat catheterization, a high-grade stenosis was not a 
predictor of death or reinfarction: OR 0.61, 95% CI 0.22-1.67, p=ns. Morphology of the 
culprit lesion was not predictive of reocclusion or clinical outcome.
Long-term follow-up
Median long-term clinical follow-up from the time of randomization was 858 days 
(25th-75th percentile: 565-1293). At the 3-year follow-up, the rate of survival free from 
reinfarction was 81% in patients with a high-grade stenosis, as compared with 82% in 
patients with a low-medium-grade stenosis (Figure 4, p=ns). A high-grade stenosis at 
baseline was not a predictor of long-term death and reinfarction: HR 0.99, 95% CI 0.53-
1.85, Cox-regression, p=ns. 
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Figure 4  Event-free survival, defined as a clinical course without death or reinfarction 
Discussion
This analysis of 240 patients who underwent successful fibrinolysis, in whom an ischemia-
guided revascularization strategy was followed, is the largest observation to date on 
the relationship among residual stenosis severity, reocclusion, death and reinfarction. 
In contrast to what is generally believed, patients with a high-grade residual stenosis 
– optimized to predict reocclusion – did not experience adverse clinical outcome 
when compared with patients with a low-medium-grade lesion; this is true despite a 
2- to 3-fold higher risk of reocclusion. Although the absence of an association between 
stenosis severity and clinical outcome has been reported before 20, these data provide 
insight into a potentially underlying mechanism. Moreover, an additional explanation 
is postulated for the lack of benefit observed in past trials on routine angioplasty after 
successful fibrinolysis.
Rationale of past angioplasty trials
These observations are in contrast to the hypothesis that formed the basis of previous 
trials studying routine angioplasty after successful fibrinolysis. These trials were based 
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on 2 premises: a suggested relationship between a high-grade residual stenosis and 
reocclusion, and the assumption that, with this increased risk of reocclusion, the subset 
of patients with a high-grade lesion could be identified as a high-risk group for death and 
reinfarction 8-12. Consequently, a reduction of the residual lumen narrowing was thought 
to reduce the incidence of reocclusion and subsequently to lead to improved clinical 
outcome 8,9. However, a meta-analysis of the randomized trials did not show a benefit 
in death and reinfarction rates for routine angioplasty after successful fibrinolysis when 
compared with an ischemia-guided strategy 13. This was attributed to high periprocedural 
event rates. 
The premises on which these trials were based have never been questioned, although 
at the time of initiation they were derived from small observational studies involving 
selected patients 8-12. Later reports from large angiographic trials consistently showed 
an association between stenosis severity and reocclusion, although an independent 
relationship has only been demonstrated in patients undergoing delayed angiography 
who have survived the first 24 to 48 hours or more 5,15,21-23. 
Stenosis severity, reocclusion and recurrent events
It has also been demonstrated that reocclusion is associated with an adverse clinical 
outcome 5-7,24. Because of the markedly increased risk of reocclusion in patients with a 
high-grade stenosis, it is tempting to consider these patients to be at a higher risk of 
death or reinfarction than patients with a low-medium-grade lesion. Trials on routine 
angioplasty after successful fibrinolysis were already ongoing, when it was shown that 
reocclusion occurs without death or clinical reinfarction in as many as two thirds of 
patients 3,5,6. Inherently, the degree of clinical benefit attainable with routine angioplasty 
largely depends on how often reocclusion of a high-grade stenosis occurs with these 
events. The unique design of the APRICOT-1 trial allowed us to study this question. 
Clinical and angiographic follow-up were assessed simultaneously at the day of repeat 
angiography, and the analysis included patients undergoing early angiography for 
recurrent ischemia. The rather conservative revascularization strategy in this trial 
(overall revascularization rate 11%) offers unique insight into the ‘natural clinical course’ 
after successful fibrinolysis. 
It was found that, despite a 2- to 3-fold increased risk of reocclusion, patients with a 
high-grade residual stenosis experienced similar short- and long-term clinical outcome 
when compared with patients with a low-medium grade stenosis (Figures 3 and 4). At 
first glance, this may seem unexpected; however, whereas only 1 of 6 patients with a 
reocclusion of a high-grade stenosis had a clinical reinfarction, this was the case in 
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approximately 1 of every 2 patients with a reocclusion of a low-medium-grade lesion. 
The clinical presentation of reocclusion may also be affected by the presence and quality 
of collateral supply to the reoccluded infarct artery and factors such as the viability of 
the myocardium distal to the culprit lesion and the presence of diabetes mellitus (less 
pain perception).
Our finding that stenosis severity after successful fibrinolysis is not related to clinical 
outcome not only complements observations from a previous study with 90-minute 
angiography 20, but also extends into the long-term. Patients with a high-grade stenosis 
were somewhat more likely to undergo revascularization in case of recurrent ischemia, 
which does not seem to have affected death and reinfarction rates; of all patients with 
recurrent ischemia who did not undergo revascularization, only 1 patient (stenosis <50% 
at baseline) sustained a reinfarction. 
Thus, even in the setting of a rather conservative, ischemia-guided strategy, a high-
grade stenosis was not predictive of clinical reinfarction, despite the associated high-
risk of reocclusion. Also with stenosis severity as a continuous variable, ROC-analysis 
was unable to detect a predictive cutoff level for reinfarction (data not shown). 
Study limitations
Our findings refer to a rather selected study population of clinically stable patients 
<71 years old, who received fibrinolysis within 4 hours of symptom-onset and showed 
clinical signs of reperfusion, electrocardiographic signs of reperfusion, or both, with 
angiographically proven patency at 24-hour angiography. This explains the low event 
rates in our study. However, the substantial reocclusion rates confidently allow 
comparison of the proportion of asymptomatic reocclusions between patients with a 
high-grade stenosis and patients with a low-medium-grade residual stenosis.
Despite careful identification of the culprit lesions by the angiographic committee, we 
cannot exclude that misinterpretations may have occurred, especially in patients with 
multivessel disease and multiple lesions.
Although patients were screened for history and underwent an ECG to detect silent 
reinfarction, it cannot be excluded that patients with a high-grade lesion experienced 
more silent reinfarctions.
Although currently the use of the TIMI criteria 22 is standard in angiographic studies, the 
APRICOT-1 trial used the ECSG criteria 2. If only anatomical reocclusions – ECSG grade 5 
stenoses 2 - are considered, the outcome of this analysis would not change.
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Implications and conclusions
Although these observations should be considered as hypothesis-generating, they 
may carry important considerations for a future prospective re-evaluation of a routine 
invasive strategy after successful fibrinolysis.
With the improved interventional techniques over the years and the use of glycoprotein 
IIb/IIIa receptor blockers, procedure-related events can certainly be reduced 25. After 
balloon angioplasty after successful fibrinolysis, reocclusion is still frequent (~17%) 24, 
with an incorporated risk of reinfarction. This underscores the need for stenting. The 
use of intravascular ultrasound scanning may further improve procedural outcome and 
provide more detailed information for identification and characterization of the culprit 
lesion 26. Although this was not confirmed in our study, previous angiographic studies 
showed an association between complex morphology of the culprit lesion and impaired 
outcome in patients with unstable angina 27.
Furthermore, the routine invasive arm of a future trial should not prescribe a certain 
cutoff point for severity of the culprit lesion to perform angioplasty. Many of the past 
randomized trials used a visually assessed stenosis severity of 60% or 70% as a cutoff 13. 
Our findings show that reocclusion of a less severe residual lesion is a frequent cause 
of clinical reinfarction.
Recently, the randomized Grupo de Análisis de la Cardiopatia Isquémica Aguda 
(GRACIA) trial showed that routine revascularization after fibrinolysis is safe and 
feasible 28. Because of the a priori low event rates after successful fibrinolysis, large 
patient numbers and long-term follow-up are required for a conclusive clinical efficacy 
study. However, in the case of stunned or hibernating myocardium, improving infarct 
artery patency, maintaining infarct artery patency, or both, could result in improved left 
ventricular recovery 29. To reduce the number of patients required for a conclusive study, 
a primary angiographic endpoint could therefore also be considered (i.e., the incidence 
of reocclusion or improvement in left ventricular ejection fraction).
In conclusion, our observations challenge the often-alleged association between a 
high-grade stenosis and clinical reinfarction in patients with an open infarct artery 
after thrombolytic therapy. This was observed in the setting of a rather conservative, 
ischemia-guided revascularization strategy. In addition to periprocedural events, past 
trials of routine angioplasty were mainly focused on severe residual lesions, which may 
also explain their lack of clinical benefit. Our findings indicate that reocclusion of a 
lower grade lesion is more likely to result in clinical reinfarction.
On the basis of these findings, a future randomized re-evaluation of a routine invasive 
strategy should target all amenable lesions, using glycoprotein IIb/IIIa blockers and 
stents to reduce periprocedural events and reocclusion.
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Abstract
Background  Whether late coronary patency after myocardial infarction has prognostic 
impact independent of left ventricular function remains a matter of debate. Reocclusion 
rates in the first year after fibrinolysis vary between 20% and 30%. Of all reocclusions, 
about 30% present as clinical reinfarction, associated with a 2-fold increased risk of 
mortality. The clinical impact of reocclusion that presents without reinfarction has not 
been studied; but an association has been demonstrated with impaired contractile 
recovery of left ventricular function, the strongest prognosticator of long-term 
outcome. We therefore studied the impact of 3-month coronary patency after successful 
fibrinolysis on 10-year cardiac survival.
Methods  In the APRICOT-1 trial, 248 ST-elevation myocardial infarction patients with 
an open infarct artery 24 hours after fibrinolysis had 3-month repeat angiography. Ten-
year clinical follow-up was complete in 99.6%.
Results  The reocclusion rate was 29% (71/248). Of these reocclusions, 24% presented 
as clinical reinfarction (17/71). Cardiac survival at 10 years was 73% in patients with a 
reoccluded infarct artery and 88% for patients with sustained patency (p<0.01). This 
difference was also present in patients in whom reocclusion was only detected as a result 
of systematic repeat angiography, that is, in the absence of reinfarction or ischemic 
symptoms between angiograms (70% versus 86%; p<0.03). Multivariable analysis 
identified sustained patency at 3-month angiography as independent predictor of 10-
year cardiac survival (hazard ratio 2.10; 95%CI 1.10-4.02) together with left ventricular 
ejection fraction.
Conclusions  Sustained infarct artery patency in the first 3 months after successful 
fibrinolysis is a strong predictor of 10-year cardiac survival, independent of left ventricular 
function. Notably, this also holds true when reocclusion occurs without signs of clinical 
reinfarction or recurrent ischemia. Therefore, future preventive strategies should also 
focus on ‘clinically silent’ reocclusions. Additional studies on better antithrombotic 
regimens and the combination with a routine invasive strategy early after successful 
fibrinolysis are warranted.
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Introduction
Late coronary patency after myocardial infarction, and its potential prognostic impact 
independent of left ventricular (LV) function, remains an issue of ongoing debate. After 
primary percutaneous coronary intervention reocclusion is infrequent, especially after 
the introduction of stenting 1. However, many patients with ST-elevation myocardial 
infarction are treated with fibrinolytic therapy; and reocclusion rates vary from 5% to 
10% before hospital discharge 2-4 to 20% to 30% in the subsequent year when adopting 
a conservative revascularization strategy 5-7. About 30% of these reocclusions result in 
clinical reinfarction. The incidence of clinical reinfarction is about 5% at 30 days, of which 
half occur within 48 hours after fibrinolysis 8. These early symptomatic reocclusions 
are associated with a 2-fold increase in mortality 4,8,9. Notably, systematic angiographic 
follow-up has revealed that about half of reocclusions occur without overt ischemic 
symptoms 10,11. When reocclusion occurs in the absence of clinical reinfarction, impaired 
LV contractile recovery has been demonstrated 12. In contrast, patients with sustained 
patency showed improvement in LV function, a key correlate of both short- and long-
term outcomes 13.
To date, only one study after fibrinolysis demonstrated the adverse prognostic 
consequences of late reocclusion over a 6-year follow-up period, independent of LV 
function. Reocclusion was assessed 6 months after routine angioplasty, performed 10 
days after fibrinolysis 11. Other studies on the impact of an open infarct artery reported 
contradicting findings, and included a heterogeneous population of patients with 
persistently occluded and reoccluded infarct arteries, both with and without prior 
reperfusion therapy 14. 
In light of the continuing interest in the concept of late coronary patency 14,15, we sought 
to assess its impact on 10-year cardiac survival in a well-defined population of myocardial 
infarction patients with a patent infarct artery 24 hours after fibrinolysis in whom a 
conservative ischemia-guided revascularization strategy was adopted.
Methods
Protocol
The APRICOT-1 study protocol has been reported in detail previously 5. In brief, 300 patients 
<71 years old with chest pain lasting >30 minutes and <4 hours, and with 0.2 mV ST-segment 
elevation in at least 2 contiguous leads on the electrocardiogram, received fibrinolysis for 
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suspected acute myocardial infarction followed by 20,000 U of intravenous heparin per 
24 hours. In the case of clinical and/or electrocardiographic signs of reperfusion, clinically 
stable patients were asked informed consent to undergo coronary angiography within 
48 hours after fibrinolysis. Patients with a patent infarct artery, defined as grade 1 to 3 
stenosis according to the European Cooperative Study Group (ECSG) criteria (Table 1), 
were eligible for the study. Sixteen patients were retrospectively excluded for not having 
a patent infarct artery at baseline angiography according to the blinded angiography 
committee.
The 284 patients with a patent infarct artery were randomly allocated to one of 3 arms: 
blinded treatment with either 325 mg of aspirin or placebo, or open-label coumadin 
including continued heparinization until the target International Normalized Ratio (2.8-
4.0) was reached. 
Table 1  Classification of coronary artery patency according to the European Cooperative 
Study Group
Stenosis grade
0
1
2
3
4
5
Normal
<50% diameter stenosis
50% to 90% diameter stenosis
91% to 99% diameter stenosis, complete filling within 3 cycles
91% to 99% diameter stenosis, no complete filling within 3 cycles
100% diameter stenosis
By protocol, revascularization was only to be performed in case of spontaneous or 
inducible recurrent ischemia refractory to maximal anti-ischemic medication. The 
protocol recommended a predischarge stress test. 
After follow-up angiography the study medication was discontinued; and all patients 
received aspirin based on the ISIS-2 results 16, which became available shortly after 
initiation of the trial. 
At the time of completion of the angiographic main trial the investigators decided to 
perform 3-year clinical follow-up to study the long-term impact of reocclusion 10. In view 
of the low 3-year mortality rates follow-up was extended to 10 years to study the impact 
of reocclusion on long-term survival.
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Cardiac catheterization
The primary endpoint of the APRICOT study was reocclusion of the infarct artery, defined 
as ECSG grade 4 or 5 stenosis (Table 1), at follow-up angiography scheduled at 3 months. 
If coronary angioplasty was performed before this planned follow-up angiography, the 
patency status of the infarct artery before dilatation was scored as study endpoint. 
Left ventricular ejection fraction was calculated from the 300 right anterior oblique 
ventriculogram by the area-length method. One of the participating centers did not 
routinely perform ventriculography. In 36 cases ejection fractions at angiographic follow-
up were not available. In 15 of these, data were retrieved and/or retrospectively assessed 
(M.B./F.W.A.V.); information from the medical chart and ejection fractions determined 
otherwise (echocardiography, nuclear imaging) were used in the case angiographic data 
could not be retrieved. 
Clinical follow-up
Ten-year survival data were collected from medical charts, from municipal registries, or 
by telephone contact with the patient relatives or general practitioner. Cardiac mortality 
was defined based on the information of the treating physician, and only in the case of a 
confirmed cardiac diagnosis. An instantaneous death, for which the cause could not be 
determined with certainty, was scored as a death of cardiac origin. 
Confirmed vascular deaths (strokes, aneurysms, dissections, pulmonary embolisms) 
were not considered as cardiac death. If the cause was unknown/uncertain and death 
did not occur instantaneously it was classified as ‘cause undetermined’.
Statistics
Statistical analysis was performed with SPSS 11.0 (SPSS Inc. 2001, Chicago, USA). 
Differences between continuous variables were compared using the Student t-test and 
Mann-Whitney-U-test whenever appropriate. Comparisons of proportions between groups 
were performed with the χ2-test. Long-term survival analysis was performed according to 
Kaplan and Meier, using the log-rank test for a univariable comparison between patients 
with coronary patency at follow-up angiography and those with a reoccluded infarct artery. 
Statistical significance was defined as a 2-sided p-value <0.05.
Multivariable Cox-regression analysis using forward logistic regression was used to 
determine the association between infarct artery patency at follow-up angiography 
and 10-year cardiac survival. Variables studied were baseline characteristics that were 
imbalanced between the study groups (p<0.10, Results) and variables with a univariable 
association with 10-year cardiac survival (p<0.10, Results). Infarct artery, LV function and 
age were prospectively chosen to be included, irrespective of the corresponding p-value.
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Results
Of the 284 patients who had a patent infarct artery 24 ± 14 hours after fibrinolytic therapy, 
248 (87%) underwent follow-up angiography performed 75 ± 31 days later. Refusal to 
undergo the second angiography was reported in 28 of 36 cases; 2 patients died and the 
other 6 patients had coronary bypass surgery. Patients without follow-up angiography 
were more often female (31% vs. 17%, p<0.05), and older (60 ± 7 vs. 56 ± 9 years, p<0.01) 
and more often had a history of myocardial infarction (17% vs. 6%, p<0.03). 
Reocclusion was observed in 29% of patients, dividing the present study population 
into 177 patients with sustained infarct artery patency and 71 patients with reocclusion 
at follow-up angiography. Patients’ characteristics at the time of follow-up angiography 
are listed in Table 2. 
Table 2  Clinical and angiographic characteristics at follow-up angiography
Sustained patency
(n = 177)
Reocclusion
(n = 71)
Men  144  (81)  62  (87)
Age (years)  56 ± 9  57 ± 9
History of MI#  11  (6)  4  (6)
Anterior MI  70  (40)  34 (48)
Peak CK, median (IQR)  1065 (561-1983)  1143 (515-2150)
Antithrombotic therapy
 Aspirin
 Coumadin
 Placebo
 70 (40)
 57 (32)
 50 (28)
 23 (32)
 24 (34)
 24 (34)
Clinical status:
 Symptomatic*
 Asymptomatic
 32 (18)
 145 (82)
 38 (53)
 33 (47)
Infarct-related artery:
 LAD
 LCX
 RCA
 71 (40)
 28 (16)
 78 (44)
 34 (48)
 11 (15)
 26 (37)
Single vessel disease  106 (60)  36 (51)
Ejection fraction %*
 
 ≤40%
 ≤45%
 ≤50%
 55 ± 11   
    (n=158)
 17 (11)
 31 (20)
 51 (32)
 51 ± 12   
     (n=69) 
 14 (20)
 20 (29)
 31 (45)
Data are presented as the number (%) of subjects for discrete variables, and as mean ± SD for continuous variables. MI = 
myocardial infarction ; CK = creatine kinase ; IQR = interquartile range ; LAD = left anterior descending artery ; LCX = left 
circumflex coronary artery ; RCA = right coronary artery ; # prior to inclusion in the APRICOT-1 trial ;* p<0.10
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As a consequence of recurrent ischemic symptoms and/or reinfarction, second 
angiography was performed earlier than scheduled in 26 patients (10%) with subsequent 
revascularization. Fourteen patients had a reoccluded infarct artery: all underwent 
successful recanalization. At the time of elective follow-up angiography none of the 
patients was revascularized. 
Long-term survival
During follow-up a total number of 59 deaths were observed, 40 of which were cardiac, 
18 were non-cardiac and 1 was unclassifiable (sustained patency). In all but one of the 
surviving patients >10-year follow-up was available (99.6%). Median survival follow-up 
was 10.8 years.
Late infarct artery patency and long-term cardiac survival
Overall, 21 deaths were observed in the group with reocclusion, and 38 in the sustained 
patency group. Overall 10-year survival did not differ significantly: 70% versus 79% 
(p=0.16). In the 71 patients with reocclusion 19 cardiac deaths were observed as compared 
to 21 cardiac deaths in the 177 patients with sustained patency. Cardiac 10-year survival 
rates were lower in patients with reocclusion: 73% versus 88%, respectively (Figure 1) 
(log-rank p<0.01). 
Figure 1  Ten-year cardiac survival and the impact of sustained coronary patency versus 
reocclusion
Patent (n) 177 172 168 157 149 138
Reocclusion (n) 71 66 64 61 55 52
P atients at risk
Log-rank: p<0.01
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Cardiac survival in the 14 patients with reocclusion who were successfully recanalized 
(see above) did not differ from patients without reopening of the reoccluded infarct 
artery: 64% vs. 75% (p=ns). If these 14 patients were classified as having a patent infarct-
related artery (instead of having reocclusion), the 10-year cardiac survival rate was 73% 
for patients with a reoccluded infarct artery as compared with 86% for patients with a 
patent infarct artery after the second angiography (log-rank p=0.02).
Of the 71 patients with reocclusion 38 (53%) were classified as symptomatic between 
the two angiograms: 17 (24%) had reinfarction, 19 (27%) had unstable angina, and 2 
(3%) had angina with positive stress testing. The remaining 33 (47%) were classified 
as asymptomatic. The 10-year cardiac survival in both patients with symptomatic 
reocclusion and patients with asymptomatic reocclusion is depicted in Figure 2. 
Figure 2  Ten-year cardiac survival
Patients with sustained coronary patency (SP) versus those with symptomatic reocclusion 
(SR; reinfarction, recurrent ischemia or angina with positive stress testing) and those with 
asymptomatic reocclusion (AS). SP versus SR: p=0.05; SP versus AR: p<0.03; SR versus AR: p=0.6
SP (n) 177 172 168 157 149 138
AR (n) 33 31 30 28 26 25
SR (n) 38 35 34 33 29 27
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The 10-year cardiac survival was 70% in patients with asymptomatic reocclusion as 
compared with 86% in patients with sustained patency (Figure 2, log-rank p<0.03). There 
were no differences in the nature of death between patients with an open or reoccluded 
infarct artery: sudden death accounted for half of all cardiac causes in both groups. 
Revascularization
During long-term follow-up after the repeated angiography 28% (69/248) of patients 
underwent revascularization of the infarct artery. Revascularization rates did not differ 
between patients with sustained patency and patients with reocclusion: 27% (47/177) 
versus 31% (22/71), p=ns.
Prognostic impact of infarct artery patency and left ventricular function
By univariable comparison age, previous myocardial infarction, multivessel disease 
and LV ejection fraction were associated (p<0.10) with lower 10-year cardiac survival 
(Table 3). To assess the potential independent prognostic impact of late infarct artery 
patency, these variables were included in a multivariable Cox-regression model. On 
clinical grounds, the infarct-related artery was included as well, although not meeting 
the prespecified p-value (p=0.13, Table 3). The clinical status at the time of repeated 
angiography (symptomatic versus asymptomatic) was also part of the model, given its 
association with reocclusion (Table 2).
Reocclusion predicted 10-year cardiac death (hazard ratio [HR] 2.10; 95% CI 1.10-4.02), 
independent of LV function, which turned out to be the only other independent 
prognostic variable (Table 4). When including ejection fraction as dichotomous variable, 
the corresponding hazard ratios for 10-year cardiac death were 2.21 (95% CI 1.14-4.30) for 
ejection fraction ≤45% and 2.24 (95% CI 1.18-4.28) for reocclusion.
The relation between coronary patency and cardiac survival was studied in several 
subgroups (Table 5). No significant interaction was observed between the various 
subgroups.
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Table 3  Univariable associations with 10-year cardiac death
Cardiac death  
(n = 40)
No cardiac death  
(n = 208) p
Age (years)  58 ± 9  56 ± 9 0.09
History of MI*  13% 5% 0.02
Multivessel disease  55%  40% 0.06
Infarct artery
 LAD
 Left
 53%
 68%
 40%
 56%
0.13
0.16
Reocclusion  48%  25% <0.01
Ejection Fraction (%)
 ≤40%
 ≤45%
 ≤50%
 50 ± 14  (n = 37)
 24%  (n = 9)
 38%  (n = 14)
 49%  (n = 18)
55 ± 11  (n = 190) 
 12%  (n = 22)
 20%  (n = 37)
 34%  (n = 64)
0.05
0.08
0.02
0.10
LAD = left anterior descending artery ; Left = LAD and left circumflex coronary artery;  
MI = myocardial infarction; * prior to inclusion in the APRICOT-1 trial.
Table 4  Independent predictors of 10-year cardiac death (multivariable analysis)
 Hazard ratio 95% CI p
Age per yr 1.04 0.99-1.08 0.06
Ejection fraction % (continuous) 0.97 0.94-0.99 0.03
Reocclusion 2.10 1.10-4.02 0.03
Table 5  Prognostic impact of late coronary patency for infarct site and left ventricular function:
coronary patency and 10-year cardiac survival in subgroups
Variable
Patency 
(n = 177)
Reocclusion 
(n = 71) p Interaction-p
Infarct Artery
 LAD  (n = 105)
 nonLAD (n = 143)
 Left (n = 144)
 Right (n = 104)
85%
89%
85%
91%
68%
78%
71%
77%
0.03
0.09
0.04
0.06
ns
ns
Ejection fraction
 ≤45% (n = 51)
 ≥45% (n = 176)
83%
89%
55%
81%
0.01
0.27
ns
Survival percentages as determined by Kaplan-Meier analysis, compared by log-rank.
LAD = left anterior descending artery ; Left = LAD and left circumflex coronary artery ; 
Right = right coronary artery
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Discussion
This 10-year clinical follow-up report shows that sustained coronary patency in the 
subsequent 3 months after fibrinolysis for ST-elevation myocardial infarction is an 
important predictor of long-term cardiac survival, independent of LV function, even 
in a rather low-risk population of patients. Notably, we demonstrated the impact of 
reocclusions that occur without signs of recurrent ischemia and clinical reinfarction: 
even these reocclusions, detected as a result of protocol-driven repeat angiography, 
proved to be associated with adverse long-term outcome.
Late infarct artery patency and long-term survival
Although the prognostic consequences of early infarct artery patency 2 and early 
reinfarction and reocclusion are undisputed 4,8,9 conflicting studies have been reported 
regarding the independent impact of late coronary patency after myocardial infarction 
14. When restricted to studies after reperfusion therapy, data corroborate, supporting the 
importance of late patency 10,11,17-19. Notably, these studies often had paired angiography and 
reflected the impact of sustained patency versus reocclusion 10,11,19.
The first study after fibrinolysis that addressed the independent predictive value 
of late coronary patency was a 6-year follow-up report on consecutive patients with 
routine angioplasty about 10 days after reperfusion therapy 11. The prognostic impact 
of infarct artery patency at routine 6-month angiography was found to be independent 
of LV function. Our findings are in line with these results and demonstrate that late 
reocclusion independently doubles the risk of long-term cardiac mortality, with the 
most pronounced effects in patients with anterior infarction and/or impaired LV 
function. With respect to the revascularization strategy after fibrinolysis, the studies 
differ. Instead of routine angioplasty, the APRICOT study adopted a rather conservative, 
ischemia-guided revascularization strategy, with an overall 3-month revascularization 
rate of only 10%. The present findings therefore merely reflect the ‘natural course’ after 
fibrinolysis.
After fibrinolysis, reocclusion occurs in up to 30% of patients within a year. The minority 
results in clinical reinfarction 9,11,12 of which the adverse impact has been demonstrated 
before 8,20. However, about 50% of reocclusions occur ‘clinically silent’, i.e. in the 
absence of clinical reinfarction or ischemic symptoms. The present report is the first 
to demonstrate the adverse clinical impact of these ‘silent reocclusions’. Previously we 
showed that reocclusion in the absence of clinical reinfarction has been associated with 
LV dilatation at 5-year follow-up echocardiography 21. The question remains whether 
Peter Kievit-boek.indb   52 12-02-2009   17:49:28
 Sustained coronary patency after fibrinolytic therapy as independent predictor of 10-year cardiac survival
53
other (yet unknown) factors may attribute to the observed independent relation of 
reocclusion with survival. 
Until now, new treatment regimens have primarily focused on the reduction of clinical 
events, that is, reinfarction and recurrent ischemic events. New antithrombotic 
therapies and revascularization in case of recurrent ischemia have reduced the incidence 
of reinfarction 22,23. Our findings suggest the need to expand our focus toward the 
prevention of reocclusion in the absence of overt ischemic symptoms; that is, preventive 
strategies targeted against the whole spectrum of reocclusion are warranted.
Prevention of reinfarction and (re)occlusion: antithrombotic strategies
Antithrombotic treatment plays a prominent role in the prevention of reocclusion. A 
meta-analysis on long-term combined antiplatelet and moderate intensity anticoagulant 
therapy reported a ~10% reduction in death or reinfarction 24. Administration of low-
molecular-weight-heparins until discharge also reduces recurrent events 25. Furthermore, 
promising short-term results have been reported with clopidogrel on top of aspirin 26. 
In view of the favorable short-term results with fondaparinux 27, trials on long-term 
treatment with new oral anticoagulants are eagerly awaited.
Prevention of reinfarction and reocclusion: revascularization strategies
Stenosis severity has been consistently reported to be associated with reocclusion 3,4,28. 
Yet, no reduction in death and/or reinfarction was observed with a strategy of routine 
revascularization in a review of trials from the 1990s, which was attributed to high 
periprocedural event rates 29. These studies do not represent modern cardiology with 
improved angioplasty techniques, stenting and glycoprotein IIb/IIIa receptor blockers. 
More recent 1-year data from the GRACIA-1 trial showed higher patency rates and improved 
LV function with a modern routine invasive strategy within 24 hours after fibrinolysis 30. In 
aggregate, the data of several feasibility trials conducted in the ‘stent era’ demonstrated a 
2-fold reduction in the rate of death or reinfarction with an early routine invasive strategy 
as compared with a delayed or ischemia-guided revascularization strategy 31. Importantly, 
in contrast to APRICOT, the above-mentioned trials on routine revascularization also 
included a substantial proportion of patients with occluded infarct arteries, which results 
in a population with a higher a priori risk of both mortality and (re)occlusion 2,9. This may 
have contributed to the observed results. Demonstration of an effect in a population like 
in APRICOT will require long-term follow-up or a large study population.
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Late opening of (re)occluded arteries
Potential mechanisms of the expected benefit of late recanalization include better 
electrical stability, the possibility of collateral supply to another coronary territory 
and assumed beneficial effects on LV function 14. The Occluded Artery Trial (OAT) is 
the first properly sized randomized trial to address the clinical implications of late 
recanalization, performed a median of 8 days after myocardial infarction 15,32. Although 
long-term patency was significantly higher, recovery of LV function was not better than 
after medical therapy; and 3-year clinical outcome was similar. A reduced risk of LV 
dilation was observed after routine intervention, achieved at the expense of an increased 
risk of reinfarction. Importantly, this trial mainly addressed patients with persistently 
occluded infarct arteries, without prior fibrinolysis. Whether these findings also hold 
true for patients with a reoccluded infarct artery after initially successful fibrinolysis 
is uncertain. In the 14 patients with reocclusion that underwent recanalization in our 
study, we did not observe a higher survival rate when compared to those without an 
intervention for reocclusion.
Limitations
Our findings refer to a well-defined but selected group of rather low-risk patients (all 
fibrinolysis, open infarct artery and angiographic follow-up) 5. In the present study, 
a conservative ischemia-guided revascularization strategy was adopted, whereas 
nowadays a more aggressive revascularization strategy is common.
In most patients ejection fraction was calculated from the right anterior oblique 
projection alone at ventriculography. Although the accuracy of this method to determine 
LV ejection fraction has its limitations, it was also used in other reports 19.
With regard to the clinical follow-up, the cardiovascular risk profile and medication 
were not routinely scored; and thus, differences between groups cannot be excluded. 
Furthermore, despite a strict definition of cardiac mortality, and detailed information 
about the circumstances of death in all deceased patients, the adjudication of mortality 
was sometimes limited by the recollection of patients’ relatives and general practitioners. 
Finally, notwithstanding the hypothetical advantages of prevention of reocclusion, it 
should be realized that reocclusion could only be a marker of poor prognosis, and not 
have a direct causal relationship with outcome.
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Conclusions and implications
The present report fuels the interest in the concept that late infarct artery patency is 
an important prognostic factor for long-term cardiac mortality after fibrinolysis for ST-
elevation myocardial infarction, independent of LV function. These findings refer to a 
well-defined population of patients with an initially open infarct artery after fibrinolysis. 
Most importantly, we demonstrated that outcome is also negatively affected in case 
reocclusion occurs in the absence of clinical reinfarction or recurrent ischemic symptoms. 
This calls for preventive strategies aimed at both symptomatic and asymptomatic 
reocclusions. Randomized clinical trials are warranted to determine whether optimized 
antithrombotic strategies and early routine revascularization will reduce the incidence 
of reocclusion and if this translates into improved long-term clinical outcome.
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Abstract
Background  Residual stenosis severity of the culprit lesion after successful fibrinolysis 
independently predicts reocclusion, which in turn is associated with increased cardiac 
mortality. Unexpectedly, past randomized trials on routine angioplasty of primarily 
severe lesions did not show clinical benefit in this setting. We studied the relationship 
between stenosis severity, reocclusion and 10-year cardiac outcome after successful 
fibrinolysis.
Methods  In the APRICOT trial 240 ST-elevation myocardial infarction patients with 
an open infarct artery 24 hours after fibrinolysis had 3-month repeat angiography to 
assess reocclusion. A rather conservative ischemia-guided revascularization strategy 
was followed (3-month revascularization rate 11%). Ten-year clinical follow-up was 
complete in 99.6% of patients. The study population was dichotomized based on the 
optimal discriminative stenosis severity (62.7%, QCA) for reocclusion.
Results  Reocclusion rates were 40% (47/118) in patients with a high-grade stenosis 
and 16% (20/122) in patients with a low-medium-grade lesion (RR 2.43, 95%CI 1.54-
3.84, p<0.01). Cardiac survival rates were 82% and 86%, respectively (p=ns). Infarct-free 
cardiac survival did not differ either: 70% versus 68% (p=ns). Reocclusion was associated 
with a two-fold higher risk of cardiac mortality (HR 2.28, 95%CI 1.19-4.35, p=0.01). This 
increased risk applied to both patients with a high-grade stenosis (HR 2.25, 95%CI 
0.94-5.64, p=0.07) and patients with a low-medium-grade stenosis (HR 2.31, 95%CI 0.79-
11.12, p=0.11). Ejection fraction (HR 0.96, 95%CI 0.93-0.99, p=0.01) and reocclusion (HR 
2.47, 95%CI 1.27-4.80, p<0.01) were the only independent predictors of 10-year cardiac 
mortality. Stenosis severity did not predict 10-year cardiac death or reinfarction.
Conclusion  Even with a rather conservative ischemia-guided revascularization strategy, 
a high-grade residual stenosis at 24-hour angiography after successful fibrinolysis does 
not predict 10-year cardiac death or reinfarction. The adverse impact of reocclusion on 
cardiac survival is similar in patients with a high-grade stenosis and patients with a 
low-medium-grade stenosis. These data suggest that in future randomized trials routine 
intervention should not be restricted to severe residual lesions, while the potential of 
optimized antithrombotic therapy to further improve outcome is underlined.
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Introduction
Despite improved outcomes with primary percutaneous coronary intervention 1, worldwide 
a large proportion of patients with ST-elevation myocardial infarction (STEMI) is still treated 
with fibrinolysis 2. Unfortunately, part of the initial success of fibrinolysis is often offset by 
reocclusion of the infarct artery 3. Reocclusion occurs in up to 30% of patients in the first 
3-12 months after successful reperfusion 4-6. Early reocclusion is associated with a two-fold 
higher risk of in-hospital mortality 7. In patients surviving the acute phase, reocclusion 
results in higher 3-year reinfarction and revascularization rates 8. From trials with protocol 
driven repeat angiography we learned that the majority of reocclusions occurs without 
signs or symptoms of myocardial infarction 3,5,7,8. Even in the absence of clinical reinfarction 
reocclusion has been shown to adversely affect left ventricular contractile recovery 9.
Stenosis severity of the infarct artery has been shown to be the only independent 
predictor of reocclusion after successful fibrinolysis 10-12. However, in a meta-analysis 
of randomized trials from the last decades of the past century routine angioplasty did 
not reduce death and reinfarction, which was attributed to high peri-procedural event 
rates 13. More recent data from the ‘stent era’ suggest a favorable impact of routine 
revascularization after fibrinolysis on death and reinfarction 14.
Earlier we reported that reocclusion also adversely affects long-term cardiac mortality, 
even when it occurs without signs and symptoms of reinfarction or recurrent ischemia 15. 
This observation fueled the hypothesis that stenosis severity, as independent predictor 
of reocclusion, may also be predictive of long-term cardiac mortality.
We therefore investigated whether stenosis severity was predictive of 10-year cardiac 
outcome in patients from the APRICOT-trial, in whom a rather conservative ischemia-
guided revascularization strategy was followed during the first months after successful 
fibrinolysis.
Methods
Protocol
The APRICOT study protocol has been described in detail previously 4. In brief, 300 
patients <71 years old with chest pain lasting >30 minutes and <4 hours, and 0.2 mV ST-
segment elevation in at least 2 contiguous leads on the electrocardiogram (ECG), received 
fibrinolysis for suspected myocardial infarction followed by 20,000 U of intravenous 
unfractionated heparin per 24 hours. In the case of clinical and/or electrocardiographic 
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signs of reperfusion, stable patients were asked informed consent to undergo coronary 
angiography within 48 hours after fibrinolysis. Patients with a patent infarct artery, 
defined as grade 1 to 3 stenosis according to the European Cooperative Study Group 
(ECSG) criteria 16, were eligible for the study. Sixteen patients were retrospectively 
excluded for not having a patent infarct artery at baseline angiography according to the 
blinded angiography committee.
Between 1987 and 1991 patients were randomly allocated to one of three arms: blinded 
treatment with either 325 mg of aspirin or placebo, or open-label coumadin including 
continued heparinization until the target INR (2.8-4.0) was reached. Symptom-limited 
exercise stress testing according to the local hospitals’ protocol was performed at 
discharge or before the first outpatient visit, planned at 4-6 weeks after admission. By 
protocol, revascularization was only to be performed for recurrent ischemia refractory 
to maximal anti-ischemic medication.
Follow-up angiography was scheduled at three months to assess reocclusion. When 
coronary angioplasty was clinically indicated and performed before the planned repeat 
angiography, the patency status of the infarct artery before wire crossing was scored as 
follow-up endpoint.
After follow-up angiography study medication was discontinued and, unless they had 
an indication for oral anticoagulation, all patients received aspirin based on the ISIS-2 
results 17, which became available shortly after initiation of the trial.
At baseline angiography quantitative coronary angiography (QCA) of the culprit lesion 
was performed, providing a precise estimation of the diameter stenosis with low intra- 
and interobserver variability 18. For this analysis the optimal single projection with the 
most severe measured stenosis was used. Morphology of the culprit lesion was scored 
according to the Ambrose criteria 19. 
At baseline angiography left ventricular ejection fraction was calculated from the 300 
right anterior oblique ventriculogram by the area-length method. Information from the 
medical chart and ejection fractions determined otherwise (echocardiography, nuclear 
imaging) were used in the case angiograms were not available and/or angiographic 
ejection fraction data were not reported. 
We collected ten-year clinical follow-up and survival data from medical charts, civil 
registries, and/or by written or telephone contact with the patient, relatives or the 
general practitioner.
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Definition of patient groups and endpoints
Reocclusion was defined as ECSG grade 4 or 5 stenosis 16. Receiver operating 
characteristics (ROC) analysis was performed on QCA stenosis as a predictor of 
reocclusion. The optimal stenosis severity cut-point to predict reocclusion was assessed 
using Fisher’s linear discriminant analysis. Based on this cut-point the study population 
was dichotomized in patients with a high-grade stenosis at high risk of reocclusion and 
patients with a low-medium-grade stenosis at lower risk of reocclusion.
Cardiac mortality was defined based on the information of the treating physician, and 
only in the case of a confirmed cardiac diagnosis. An instantaneous death, for which 
the cause could not be determined with certainty, was also scored as a death of cardiac 
origin. Confirmed vascular deaths (strokes, aneurysms, aortic dissections, pulmonary 
embolisms) were not considered as cardiac death. If the cause was unknown/uncertain 
and death did not occur instantaneously it was classified as ‘cause undetermined’. 
Reinfarction (infarct artery related) was defined as recurrent ischemic symptoms lasting 
>30 minutes accompanied by ischemic ECG changes in the same area as the index 
infarction or attributed to the same coronary artery as the index infarct artery at urgent 
repeat angiography, with elevation of creatine kinase levels. Reinfarctions not meeting 
these electrocardiographic or angiographic criteria were considered to be not infarct 
artery related.
Revascularization of the infarct artery was scored in the case of percutaneous coronary 
intervention (PCI) of the index infarct vessel or coronary artery bypass grafting 
(CABG).
Statistics
Statistical analysis was performed with SPSS 12.0 (SPSS Inc. 2003, Chicago, USA). 
For comparison of continuous variables the Student t-test and Mann-Whitney-U-test 
were used whenever appropriate. Comparisons of proportions between groups were 
performed with the χ2-test. Long-term survival analysis was performed according to 
Kaplan and Meier, using the log rank test for comparison between groups. Statistical 
significance was defined as a two-sided p-value <0.05.
Multivariable Cox-regression analysis using forward logistic regression was used to 
determine the association between stenosis severity at baseline angiography and 
10-year cardiac death. Variables included in the model were baseline characteristics 
that were imbalanced between the study groups (p<0.10, see Results), variables with a 
univariate association with 10-year cardiac death (p<0.10, see Results) and Thrombolysis 
in Myocardial Infarction (TIMI)-risk score variables 20. Antithrombotic regimen was 
prospectively chosen to be included.
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Results
Out of the 284 patients included in the APRICOT trial the current study group consists 
of the 240 patients with two angiograms and complete QCA-analysis. Thirty-six 
patients did not undergo follow-up angiography for reasons of refusal (n=28), CABG 
(n=6) or death (n=2). In 8 patients QCA-analysis was technically not possible. Baseline 
characteristics of these 44 patients did not differ from the study group except for a 
tendency towards older age (59 ± 9 versus 56 ± 9 years, p=0.06).
Figure 1 shows the distribution of the quantitatively assessed severity of infarct-related 
stenoses. Baseline angiography was performed at a mean of 24 ± 14 hours. Stenosis 
severity was not related to the timing of the first angiogram. Follow-up angiography 
was performed after a mean of 75 ± 31 days.
Figure 1  Distribution of the quantitatively assessed severity of the infarct-related stenoses at 
24-hour angiography
Cumulative % 
of patients
100%
50%
0%
0             10             20             30            40            50            60             70            80            90
median
62%
QCA stenosis (%)
Peter Kievit-boek.indb   65 12-02-2009   17:49:33
Chapter 4
66
Optimal diameter stenosis cut-point level for reocclusion
The study population was dichotomized based on the optimal QCA stenosis severity to 
predict reocclusion using previously described methods 12. 
ROC analysis is shown in Figure 2. Diagnostic accuracy of QCA stenosis to predict 
reocclusion was moderate. Fisher’s linear discriminant analysis identified a 62.7% residual 
diameter stenosis at baseline as the optimal cut-point level for reocclusion. Sensitivity 
of a ≥62.7% stenosis to predict reocclusion was 70%, with a negative predictive value 
of 84%.
Figure 2  ROC analysis for QCA stenosis as predictor of reocclusion (area under the curve 0.680, 
95% CI 0.605-0.754, p<0.01)
This cut-point level dichotomized the study population in the following groups:
– a group of 118 patients with a high-grade stenosis (QCA ≥ 62.7%) and a 40% (47/118) 
risk of reocclusion, and 
– a group of 122 patients with a low-medium-grade stenosis (QCA <62.7%) and a 16% 
(20/122) risk of reocclusion.
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This difference (40% versus 16%) represents an unadjusted relative risk of reocclusion 
of 2.43 (95% CI 1.54-3.84, p<0.01) for patients with a high-grade stenosis at baseline.
Baseline characteristics are shown in Table 1. Smoking (70%), hypercholesterolemia 
(57%), diabetes (6%) and hypertension (26%) did not differ between groups. In patients 
with a high-grade stenosis a higher occurrence of smooth culprit lesions and a tendency 
towards more previous angina were observed. 
Table 1  Baseline characteristics
High-grade stenosis
(n = 118)
Low-medium-grade stenosis
(n = 122)
Men (%)  99  (84)  100  (82)
Age (y)      56 ± 9      56 ± 9
Previous angina  66  (56)  54  (44)†
Previous myocardial infarction  7  (6)  8  (7)
Time symptoms – fibrinolysis (h)        2.1 ± 1.0        2.0 ± 1.0
Fibrinolytic
 Streptokinase
 Anistreplase
 101  (86)
 17  (14)
 109  (89)
 13  (11)
Peak creatine kinase (units/L)  1086  (454-1941)  1100  (624-2211)
Anterior infarction  44  (37)  55  (45)
Ejection fraction (%)      53 ± 12  (n = 111)       51 ± 11  (n = 109)
% stenosis QCA       70.5 ± 5.5      52.3 ± 9.1‡
Single vessel disease  62  (53)  73  (60)
Lesion type
 Smooth
 Complex
 74  (63)
 44  (37)
 61  (50)§
 61  (50)
Antithrombotic regimen
 Coumadin
 Aspirin
 Placebo
 37  (31)
 49  (42)
 32  (27)
 42  (34)
 41  (34)
 39  (32)
Data are presented as the number (%) of subjects for discrete variables, and as mean ± SD for continuous variables, 
except for peak creatine kinase which is presented as median (25th-75th percentile).
QCA = quantitative coronary angiography; † p=0.07; ‡ p<0.01; § p<0.05
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Clinical outcome
Ten-year clinical follow-up was complete in all but one patient (99.6%). In this patient 
8 years of follow-up were completed before he emigrated to Colombia. During follow-
up 56 deaths were observed, 37 of which were cardiac, 18 were non-cardiac and 1 was 
unclassifiable. 
Overall survival did not differ between patients with a high-grade stenosis and patients 
with a low-medium-grade stenosis: 74% versus 79% (p=ns). Cardiac survival was also 
similar: 82% versus 86% (Figure 3). Infarct-free cardiac survival did not differ either: 70% 
versus 68% (Figure 3, p=ns). Clinical event rates in both groups at follow-up are shown 
in Table 2. No differences between the two groups were observed in the rates of infarct 
artery related reinfarction. The overall revascularization rate was 34% with no difference 
between the two groups. The 3-month revascularization rate was 11%.
During follow-up 12 patients in the high-grade stenosis group (10%) and 13 patients in 
the low-medium-grade stenosis group (11%) had a reinfarction not related to the index 
infarct artery (p=ns).
Medication use was not systematically scored during the entire course of clinical follow-
up. Data on medication use at 10-year follow-up were retrieved in 92% (170/184) of 
survivors. There was no difference in guideline recommended therapies between the 
two groups: antiplatelet agents 74%, oral anticoagulants 15%, betablockers 52%, ACE-
inhibitors 32%, and statins 52%.
Table 2  Clinical outcome
High-grade 
stenosis
(n = 118)
Low-medium-grade 
stenosis
(n = 122)
p
(log rank)#
Death from all cause  31  (26)  25  (20) 0.29
Cardiac death  20  (17)  17  (14) 0.49
Reinfarction*  20  (17)  25  (20) 0.52
Cardiac death or reinfarction*  37  (31)  36  (30) 0.79
Revascularization*
 PCI
 CABG
 42  (36)
 25
 27
 39  (32)
 21
 23
0.35
Data are presented as number of subjects and proportions (%) per study group. 
Patients may have had events in more than one category.
PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting; * infarct artery related; # log-rank test 
on estimated 10-year event rates
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Figure 3  Estimated cardiac survival and cardiac survival without reinfarction in patients with a 
high-grade stenosis and patients with a low-medium-grade stenosis
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Stenosis severity, reocclusion and cardiac survival
The relationship between stenosis severity, reocclusion and cardiac survival is shown in 
Figure 4. In the overall population of 240 patients, cardiac survival was 88% in the 173 
patients with sustained patency versus 74% in the 67 patients with reocclusion at follow-
up angiography (hazard ratio (HR) 2.28, 95%CI 1.19-4.35, p=0.01). The more than two-fold 
higher risk of cardiac death in case of reocclusion was observed in both patients with 
a high-grade stenosis and patients with a low-medium-grade stenosis: HR 2.25, 95%CI 
0.94-5.64, p=0.07 and HR 2.31, 95%CI 0.79-11.12, p=0.11, respectively. The risk of cardiac 
death in case of reocclusion did not differ between patients with a high-grade stenosis 
and patients with a low-medium-grade lesion: RR 0.98, 95%CI 0.34-2.77, p=ns.
Successful recanalization of a reoccluded infarct artery was performed in 12 patients: 
7 with a high-grade baseline stenosis and 5 with a low-medium-grade lesion. All of 
these patients underwent follow-up angiography earlier than scheduled as a result of 
recurrent ischemic symptoms. Cardiac survival at 10-years in patients with a reopened 
infarct artery did not differ from patients with persistent reocclusion: 75% versus 74% 
(p=ns).
Figure 4  Estimated cardiac survival in patients with a high-grade stenosis and patients with a 
low-medium-grade stenosis in relation to the patency status of the infarct artery at follow-up 
angiography
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Multivariable analysis
Table 3 (top) summarizes the variables with an univariate association with 10-year 
cardiac mortality (p<0.10). Together with the variables that caused an imbalance in 
baseline characteristics (previous angina, lesion type), TIMI-risk score variables 20 and 
antithrombotic regimen (prespecified), these variables were entered in the multivariable 
model. 
Stenosis severity did not predict cardiac death, neither as dichotomous variable nor as 
continuous variable. Ejection fraction and reocclusion independently predicted 10-year 
cardiac mortality (Table 3, bottom).
The combined endpoint of 10-year cardiac death or reinfarction was not predicted by 
stenosis severity either: HR 0.73 (95%CI 0.43-1.26) and HR 0.99 (95%CI 0.97-1.01) for 
stenosis severity as dichotomous and continuous variable, respectively.
Table 3  Predictors of cardiac mortality 
Univariable analysis Hazard ratio (95% CI) p
High-grade vs low-medium-grade stenosis
Stenosis QCA (%, continuous)
 1.26  (0.66-2.40)
 1.00  (0.98-1.03)
0.49
0.81
Age (y)  1.04  (0.99-1.08) 0.08
Previous myocardial infarction  2.75  (1.07-7.06) 0.04
Ejection fraction (%, continuous)
Ejection fraction >40%
 0.96  (0.94-0.99)
 0.34  (0.17-0.69)
0.02
<0.01
Single vessel disease  0.57  (0.30-1.10) 0.10
Reocclusion  2.28  (1.19-4.35) 0.01
Multivariable analysis Hazard ratio (95% CI) p
High-grade vs low-medium-grade stenosis
Stenosis QCA (%, continuous)
 1.11  (0.54-2.28)
 1.00  (0.97-1.03)
0.77
0.98
Ejection fraction (%, continuous)
Ejection fraction >40%
 0.96  (0.93-0.99)
 0.33  (0.17-0.67)
0.04
<0.01
Reocclusion  2.47  (1.27-4.80) <0.01
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Discussion
In this study of 240 patients after successful fibrinolysis, a high-grade culprit stenosis 
at 24-hour angiography – optimized to predict reocclusion – does not predict 10-year 
cardiac outcome. This was found in the setting of a rather conservative ischemia-
guided revascularization strategy with a 3-month revascularization rate of only 11%. 
The observed lack of association between stenosis severity and cardiac outcome after 
fibrinolysis extends previous concordant findings regarding in-hospital and short-term 
events in the very long-term 12,21.
Stenosis severity, reocclusion and clinical outcome
The relationship between residual stenosis severity and reocclusion after successful 
fibrinolysis has been thoroughly addressed. Reports from large randomized trials 
consistently showed an association between stenosis severity and in-hospital reocclusion 
7,22,23. In patients surviving the acute phase of STEMI an independent relation between 
stenosis severity and late reocclusion has been observed 10-12.
Reocclusion increases the risk of recurrent ischemic events and death 3,7,8. When 
occurring early after successful fibrinolysis a two-fold higher risk of in-hospital mortality 
has been reported 7. Reocclusion after angioplasty performed 10 days after fibrinolysis 
has been shown to predict mortality in the long-term 24. Notably, most reocclusions 
occur without clinical events 3,5,7,8. Even if reocclusion occurs in the absence of clinical 
reinfarction, it has adverse impact on left ventricular function 9. Previously we have 
shown that reocclusion is a strong predictor of 10-year cardiac mortality, independent of 
left ventricular ejection fraction and even when occurring without signs of reinfarction 
or recurrent ischemia 15. 
Given the independent relationship between stenosis severity and reocclusion on the 
one hand and reocclusion and cardiac outcome on the other, it seems logical to assume 
an association between stenosis severity and clinical outcome. Unexpectedly, in a meta-
analysis of trials from the last decades of the past century routine angioplasty did not 
reduce death and reinfarction after successful fibrinolysis 13. This was attributed to high 
peri-procedural event rates. Importantly, a high-grade residual stenosis formed the 
criterion to perform angioplasty in most of these trials. An additional explanation for 
the observed lack of benefit was postulated based on data from the APRICOT-trial 12. In 
APRICOT a rather conservative, ischemia-guided, revascularization strategy was followed, 
which enabled us to study the ‘natural’ relationship between stenosis severity, reocclusion 
and recurrent events in the first 3 months after successful fibrinolysis. We showed that 
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reocclusion of a high-grade lesion results in clinical reinfarction in only one out of six 
cases, whereas reocclusion of a low-medium-grade lesion presents as clinical reinfarction 
in almost one out of two cases 12. This mechanism may be an additional reason for the 
lack of clinical benefit in the abovementioned revascularization trials, as in most cases 
only severe stenoses were targeted for dilatation. In the present study it is shown that 
long-term cardiac death or reinfarction can not be predicted based on stenosis severity 
at 24-hour angiography. More important, the risk of cardiac death in case of reocclusion 
was similar in patients with a high-grade stenosis and patients with a low-medium-grade 
lesion: irrespective of stenosis severity reocclusion incorporated a more than two-fold 
higher risk of cardiac death (Results, Figure 4). These findings suggest that future trials on 
routine intervention should not be restricted to patients with severe stenoses, as patients 
with less severe lesions may also benefit from revascularization.
Methodological considerations of the present study findings
Using the optimal stenosis severity cut-point for reocclusion the risk of reocclusion 
in patients with a high-grade stenosis was more than twice the risk of patients with 
a low-medium-grade lesion (40% versus 16%). Nevertheless, cardiac death rates did 
not differ between the two groups. Notably, despite being an independent predictor 
of reocclusion, the discriminative accuracy of stenosis severity to predict reocclusion 
is only moderate: almost a third of all reocclusions still occurred in patients with a low-
medium-grade lesion. This lack of optimal contrast (ideally a group with reocclusion 
versus a group without reocclusion) may partially explain that no difference in cardiac 
survival was observed.
Furthermore, cardiac mortality at 10 years in our study is remarkably low, reflecting 
the patients’ good a priori prognosis (patent infarct artery after fibrinolysis, survivors 
of the acute phase and mean ejection fraction >50%). Therefore, the sample size of our 
study was not sufficient to detect a difference in cardiac survival. Calculating from the 
observed absolute cardiac mortality rates (17% in patients with a high-grade stenosis 
versus 14% in patients with a low-medium-grade stenosis) a sample size of 4700 patients 
with complete 10-year follow-up would have been required to detect this 3% survival 
difference with 80% power. However, regarding the combined endpoint of cardiac 
death or reinfarction, with a considerable higher incidence, no difference between the 
two groups was observed either.
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Implications
Future strategies to improve long-term cardiac outcome after successful fibrinolysis 
should primarily focus on predictors of adverse events. Even in this rather low risk 
population baseline left ventricular ejection fraction is an independent predictor of 
long-term cardiac mortality. This once again underscores the need for early restoration of 
good antegrade flow. In addition, reocclusion proved to be an important prognosticator, 
independent of left ventricular ejection fraction 15. Therefore, sustaining patency of the 
infarct artery is a potential target for treatment. With stenosis severity as independent 
predictor of reocclusion 10-12 routine revascularization may be an attractive option to 
improve outcome. 
As mentioned before, previous studies on routine angioplasty showed no benefit, 
attributed to high peri-procedural event rates 13. These studies do not represent modern 
cardiology with improved angioplasty techniques, stenting and use of glycoprotein 
IIb/IIIa receptor blockers to reduce procedure-related events 25. More recent one-year 
data from the GRACIA-1 trial showed higher patency rates and improved left ventricular 
function with a modern routine invasive strategy within 24 hours after fibrinolysis 26. In 
aggregate, the data of several feasibility trials conducted in the ‘stent era’ demonstrated 
a two-fold reduction in the rate of death or reinfarction with an early routine invasive 
strategy as compared to a delayed or ischemia-guided revascularization strategy 14. The 
observed benefit was mainly driven by a reduction in reinfarction.
Importantly, most studies investigating the impact of routine angioplasty focused mainly 
on the prevention of reinfarction and did not address reocclusion in lack of systematic 
follow-up angiography. Therefore, it is uncertain how much of the observed benefit in 
the more recent trials is attributed to better patency, and how much is related to a 
reduction in procedure related events. Another difference with APRICOT is that these 
studies not only included patients with patent infarct arteries, but also studied patients 
with (re)occluded vessels.
Whether in the current era routine revascularization after successful fibrinolysis can 
reduce the rate of reocclusion, and thereby, improve outcome, remains to be determined 
in a properly sized randomized trial. With a risk of reocclusion of only 6% or less after 
routine stenting 27, this may not only lower the rate of symptomatic reocclusions, thereby 
reducing short-term death or reinfarction, but it will also affect the rate of reocclusion 
without clinical events. Sustained patency of the infarct artery after stenting may 
portend a beneficial effect on left ventricular recovery and potentially improve long-
term outcome. As reocclusion of a low-medium-grade lesion incorporates a high risk 
for reinfarction 12 and has a similar adverse impact on long-term cardiac survival as 
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reocclusion of a high-grade lesion (Figure 4), lesions of intermediate severity should 
also be considered for revascularization. Intravascular ultrasound and fractional flow 
reserve may be useful to guide therapy in these cases 28.
Antithrombotic treatment also plays a prominent role in the prevention of reocclusion 29. 
This applies to patients after stenting, in particular those receiving drug eluting stents 30, 
but it may be especially important in patients with lesions not amenable for intervention. 
Prolonged treatment with several antithrombotics in combination with aspirin has been 
proven to further improve outcome after myocardial infarction 29. 
In addition to antithrombotic treatment, optimal medical therapy including betablockers, 
ACE-inhibitors and statins is indicated 29. The rates of patients treated with these agents 
in survivors in our population underline the potential for further optimization of medical 
treatment.
Study limitations
The present study is a post-hoc analysis from a randomized trial performed more than a 
decade ago and should therefore be considered as hypothesis generating.
Our population consists of a well-defined (all fibrinolysis, open infarct artery, 
angiographic follow-up), but selected group of rather low-risk patients 4. 
The cardiovascular risk profile and medication were not routinely scored during follow-
up, and thus, over time differences between groups cannot be excluded. However, 10-
year medication use was similar in survivors in both groups. 
Whether there is a causal relationship between reocclusion and cardiac death or that 
reocclusion is merely a marker of poor prognosis remains unclear. Studies on the 
prognostic impact of prevention of reocclusion have to be awaited.
Conclusions
In the setting of a rather conservative ischemia-guided revascularization strategy after 
successful fibrinolysis, a high-grade residual stenosis at 24-hour angiography - optimized 
to predict reocclusion - does not predict 10-year cardiac outcome. Two potential 
explanations for this unexpected finding are postulated. First, although stenosis severity 
is an independent predictor of reocclusion, the discriminative accuracy is moderate, 
with a third of patients with reocclusion not being identified as high risk. Second, the 
adverse impact of reocclusion on cardiac survival is similar in patients with a high-grade 
stenosis and patients with a low-medium-grade stenosis. 
Although the question remains whether the absence of an association between 
stenosis severity and cardiac outcome was due to a lack of power, these findings 
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suggest that future randomized studies on the impact of routine revascularization 
should not be restricted to patients with a severe residual stenosis. In the prevention 
of reocclusion routine intervention may be beneficial in all patients with amenable 
lesions, irrespective of the severity of the culprit stenosis, with concomitant use of 
glycoprotein IIb/IIIa receptor blockers and stents. Furthermore, patients should receive 
prolonged intensive antithrombotic therapy, especially those with lesions not amenable 
for revascularization. Randomized clinical trials are warranted to determine whether 
prevention of reocclusion after successful fibrinolysis translates in improved long-term 
clinical outcome.
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Abstract
Background  Long-term addition of antithrombotics (clopidogrel, anticoagulants) to 
aspirin has improved outcome after acute coronary syndromes. Data on the impact 
after fibrinolysis are scarce. In APRICOT-2, adjunctive moderate-intensity coumarin 
(median international normalized ratio [INR] 2.6) conferred a marked reduction in 
3-month reocclusion and ischemic events. Given the association between reocclusion 
and long-term outcome, we performed long-term clinical follow-up.
Methods  Patients with TIMI 3 flow <48 hours after fibrinolysis for ST-elevation myocardial 
infarction were randomized to aspirin plus coumarin, with prolonged heparinization 
until the target INR (2-3) was reached, or aspirin with standard heparinization. Three-
month follow-up angiography (reocclusion rates 15% versus 28%) and long-term clinical 
follow-up (median 7.3 years, interquartile range 5.9-8.6 years) were performed.
Results Patients randomized to adjunctive anticoagulation (n=123) received coumarin 
for a median of 280 days (113-387 days). Survival was 94% versus 88% in patients on 
aspirin alone (n=128, p=0.12). Infarct-free survival was 86% versus 71% (p=0.01). TIMI 
bleeding was 4% in both groups. Patients with reocclusion had impaired survival: 80% 
versus 94% (p<0.01).
In a multivariable model without reocclusion, combination therapy independently 
predicted survival (hazard ratio [HR] 0.36, 95%CI 0.13-1.00) and infarct-free survival (HR 
0.51, 95%CI 0.28-0.95). When adjusted for reocclusion, combination therapy did not 
predict outcome. Reocclusion independently predicted death (HR 2.56, 95%CI 1.02-6.43) 
and reinfarction.
Conclusions  Moderate-intensity oral anticoagulation added to aspirin improved 8-year 
clinical outcome after successful fibrinolysis. The beneficial effect was largely attributed 
to a reduction in reocclusion, which independently predicted death and reinfarction. 
This study provides a mechanistic rationale for prolonged adjunctive anticoagulation 
after fibrinolysis.
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Introduction
Although aspirin is markedly effective in the secondary prevention after acute coronary 
syndromes (ACS) 1, a substantial risk of recurrent ischemic events remains. Aspirin 
resistance has been implicated as a potential mechanism for the failure of monotherapy 
2, and after non-ST-elevation ACS dual antiplatelet therapy with clopidogrel for 9 to 
12 months improved outcome 3. In patients with ST-elevation myocardial infarction 
(STEMI) who do not undergo primary percutaneous coronary intervention (PCI), dual 
antiplatelet therapy seems also promising, but studies are restricted to short-term use 
of clopidogrel 4,5. In these patients, the 6-month addition of a novel direct thrombin 
inhibitor to aspirin also conferred benefit 6. Although this agent was withdrawn because 
of adverse effects, several new anticoagulants are now under investigation, whereas 
traditional oral anticoagulation has gained renewed interest. A meta-analysis reported 
a reduction in recurrent events with long-term moderate-intensity anticoagulation (INR 
2-3) adjunctive to aspirin, at the expense of an increased bleeding risk 7.
In the Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis 
(APRICOT)-2 trial, a regimen of aspirin, prolonged heparinization, and moderate-
intensity coumarin (median INR 2.6) resulted in a 45% relative reduction in 3-month 
reocclusion in patients with a patent infarct artery after fibrinolysis for STEMI, with lower 
rates of reinfarction and revascularization 8. Early reocclusion has been shown to double 
the risk of in-hospital mortality 9, and in patients surviving the acute phase of STEMI, 
reocclusion is associated with an increased risk of long-term cardiac death, reinfarction 
and revascularization 10,11. The adverse prognostic impact of reocclusion even holds 
true when it occurs without reinfarction or recurrent ischemia, which is observed in 
about half of cases 10. It remains to be demonstrated whether the relationship between 
reocclusion and long-term outcome is indeed causal; it could also merely be a marker 
of poor prognosis.
In patients from APRICOT-2 who underwent follow-up angiography, we performed long-
term clinical follow-up to study whether the initial clinical benefit with the combined 
regimen was sustained in the long term, and, if so, whether the observed benefit would 
be explained by the reduced risk of reocclusion.
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Methods
Protocol
The study protocol of the APRICOT-2 trial has been described in detail previously 8. The 
ethics review committees of the participating hospitals approved of the trial, and all 
patients gave informed consent. 
Between 1994 and 2000, 308 patients younger than 76 years with chest pain refractory 
to nitrates lasting >30 minutes and <6 hours received fibrinolysis for suspected STEMI 
in combination with aspirin 80 mg and unfractionated heparin. Angiography was 
performed within 48 hours of fibrinolysis in clinically stable patients with clinical and/
or electrocardiographic signs of reperfusion. Patients with Thrombolysis in Myocardial 
Infarction (TIMI) 3 flow 12 as assessed by the local investigator were randomized to 2 
arms. In one arm, patients continued treatment with aspirin 80 mg with discontinuation 
of heparin after 48 hours. In the other arm, coumarin was added to aspirin 80 mg with 
continuation of heparin until moderate-intensity anticoagulation (target INR 2-3) was 
achieved. Thirty-four patients were excluded from analysis because flow in the infarct 
artery was not considered TIMI 3 flow by the angiographic core laboratory.
Follow-up angiography was scheduled at 3 months to assess reocclusion, which was 
defined as TIMI 2 flow or less. Revascularization was to be performed in case of recurrent 
ischemia, either spontaneous or inducible at stress testing, which was recommended in 
all patients. If PCI was performed before the planned follow-up angiography, the patency 
status of the infarct artery before wire crossing was scored as study endpoint.
After discharge, monitoring of oral anticoagulation was performed in specialized 
outpatient clinics (‘Thrombosediensten’). At the first outpatient visit after follow-
up angiography, patients randomized to aspirin plus coumarin were asked to 
continue adjunctive oral anticoagulation for 1 year. Patients who refused to continue 
anticoagulation and those who were already off study medication received aspirin 80 mg 
as standard antithrombotic treatment. In case of coronary stenting, oral anticoagulation 
was discontinued and patients received adjunctive ticlopidine or clopidogrel for 1 
month.
Coronary angiography
TIMI flow grading and quantitative coronary angiography of the culprit lesion were 
performed at a core laboratory (Heartcore Leiden B.V., Leiden, the Netherlands). For 
this analysis, the optimal single projection with the most severe measured stenosis was 
used. 
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Morphology of the culprit lesion was scored according to the Ambrose criteria 13. 
Left ventricular ejection fraction was calculated from the 300 right anterior oblique 
ventriculogram by the area-length method. In case ventriculography was not performed, 
ejection fraction was determined by echocardiography.
Clinical follow-up
Long-term clinical and survival data were collected from medical charts, civil registries, 
or by written or telephone contact with the patient, relatives or the general practitioner. 
All deaths were confirmed by civil registry data.
An event was qualified as reinfarction (infarct artery related) when at least 3 of the 
4 GUSTO-1 criteria 8 were met: 1) recurrent ischemic symptoms lasting >15 minutes 
after resolution of symptoms of the index infarction, 2) new ST-T wave changes or 
new Q-waves in the same area as the index infarction, 3) a second elevation in cardiac 
enzymes over the upper limit of normal (or by a further 20% if already elevated), and 4) 
reocclusion of the infarct artery.
Revascularization was scored in case of PCI of the index infarct vessel or coronary artery 
bypass grafting (CABG). Bleeding was reported according to the TIMI criteria 8.
Statistics
Statistical analysis was performed with SPSS 14.0 (SPSS Inc. 2005, Chicago, USA). 
For comparison of continuous variables the Student t-test and Mann-Whitney-U-test 
were used whenever appropriate. Comparisons of proportions between groups were 
performed with the χ2-test. Statistical significance was defined as a two-sided p-value 
less than 0.05.
Long-term survival analysis was performed according to Kaplan and Meier, using the 
log rank test for comparison between groups. Multivariable survival analyses were 
performed using Cox proportional hazard analyses. Left ventricular ejection fraction and 
TIMI risk score variables 14 were prospectively chosen to be included in the multivariable 
model.
Results
Of the 274 patients with a patent infarct artery after fibrinolysis included in the APRICOT-
2 trial, 251 (92%) underwent follow-up angiography. Reasons for not undergoing repeat 
angiography are shown in the study flow chart in Figure 1. Baseline characteristics of 
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patients with and without follow-up angiography did not differ. Table 1 lists the baseline 
characteristics of patients who underwent follow-up angiography. Between the 2 
antithrombotic treatment arms no significant differences were observed.
Figure 1  Study design of the APRICOT-2 trial showing all patients with repeat angiography and 
long-term clinical follow-up 
APRICOT-2
Acute ST-elevation myocardial infarction
Fibrinolytic therapy
Intravenous heparin
Aspirin
Coronary angiography <48 hours 
Infarct artery with TIMI 3 flow
Inclusion n = 274
Aspirin plus coumarin
n = 135
Aspirin 
n = 139
No 2nd angiogram: n = 12
 refusal n = 10
 death n = 1 
 CABG n = 1
No 2nd angiogram: n = 11
 refusal  n = 9
 CABG n = 2
Aspirin plus coumarin
n = 123
Aspirin 
n = 128
3-month follow-up angiography
long-term clinical follow-up
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Table 1  Baseline characteristics of patients who underwent follow-up angiography
Aspirin plus coumarin
(n = 123)
Aspirin
(n = 128) p
Clinical characteristics
Men  104  (85)  104  (81) 0.49
Age (y)    56 ± 10    57 ± 11 0.17
Previous angina  66  (54)  76 (59) 0.36
Previous myocardial infarction  13  (11)  15  (12) 0.77
Current smoker  77  (63)  71  (56) 0.25
Diabetes  3  (2)  7  (6) 0.22
Hypertension  27  (22)  38  (30) 0.16
Family history of CAD  61  (50)  51  (40) 0.12
Hypercholesterolemia  69  (56)  80  (63) 0.30
Time symptoms – fibrinolysis (h)      2.2 ± 1.2      2.5 ± 1.4 0.11
Previous aspirin use  21  (17)  20  (16) 0.76
Fibrinolytic
 Fibrin-specific
 Non fibrin-specific
 53  (43)
 70  (57)
 48  (38)
 80  (62)
0.36
Peak creatine kinase (units/L)  987  (388-2222)  869  (506-1827) 0.19
Angiographic characteristics
Infarct artery
 LAD
 LCX
 RCA
 52  (42)
 13  (11)
 58  (47)
 49  (38)
 25  (20)
 54  (42)
0.14
Culprit stenosis severity (%, QCA)
 >70 % stenosis
   56.3 ± 15
 17  (14)
   59.2 ± 13
 26  (20)
0.11
0.17
Culprit lesion morphology
 Smooth
 Complex
 78  (63)
 45  (37)
 80  (63)
 48  (37)
0.88
Single vessel disease  70  (57)  70  (55) 0.72
Left ventricular ejection fraction (%)    53.2 ± 10    53.4 ± 9 0.82
Data are presented as number (%) of subjects for discrete variables and mean ± standard deviation for continous 
variables, except for peak creatine kinase which is presented as median (interquartile range)
CAD = coronary artery disease; LAD = left anterior descending coronary artery; LCX = left circumflex coronary artery;  
RCA = right coronary artery; QCA = quantitative coronary angiography
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Medication
Of the 123 patients randomized to combination therapy, 114 (93%) were still on study 
medication at the time of follow-up angiography. Of these patients, 75 (66%) consented 
to continue anticoagulation after follow-up angiography. The proportional use of 
coumarin on top of aspirin over time in patients randomized to this strategy is shown in 
Figure 2. The median duration of adjunctive anticoagulation was 280 (interquartile range 
[IQR] 113-387) days. At the end of follow-up, only 4% (5/123) of patients was still using 
coumarin. The main reasons for discontinuation of oral anticoagulants were completion 
of study protocol (56%), PCI or CABG (15%), and bleeding or anemia (10%).
Overall medication use was assessed at follow-up angiography, at 1 year and at long-
term follow-up (median 7.0 years). At these time points, the use of aspirin (100%, 98%, 
93%), beta blockers (95%, 82%, 79%), ACE-inhibitors (41%, 43%, 48%) and statins (46%, 
64%, 80%) did not differ between the 2 groups.
Figure 2  Proportional use of coumarin on top of aspirin over time in patients randomized to 
combination therapy 
Long-term clinical outcome
Median clinical follow-up was 7.3 (IQR 5.9-8.6) years. Crude long-term clinical event 
rates in both groups are shown in Table 2. 
Long-term survival was 94% in patients in the aspirin plus coumarin group versus 88% 
in patients on aspirin alone (HR 0.50, 95% CI 0.20-1.22, p=0.12; Figure 3). Survival free 
from reinfarction was 86% in patients on combination therapy versus 71% in patients 
on aspirin alone (HR 0.49, 95% CI 0.27-0.88, p=0.01; Figure 3). Combination therapy also 
markedly improved survival free from reinfarction or revascularization: 57% versus 36%, 
p<0.01.
0 1 2 3 4 5
0
50
100
 years
%
Number of patients using aspirin plus coumarin
123 53 12  6 5
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One patient in the combination group had a reinfarction 3 days after discontinuation 
of coumarin for a dental procedure. All other patients in this group remained free from 
death or reinfarction for at least 2 months after discontinuation of coumarin.
Figure 3  Estimated long-term survival and long-term survival free from reinfarction in patients on 
aspirin plus coumarin and patients on aspirin alone
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Table 2  Long-term clinical outcome
Aspirin plus coumarin
(n = 123)
Aspirin
(n = 128)
p
(log rank)*
Death  7  (6)  15  (12) 0.12
Reinfarction  12  (10)  23  (18) 0.055
Revascularization
 PCI
 CABG
 45  (37)
 36  (29)
 11 (9)
 68  (53)
 58  (45)
 15  (12)
0.002
0.003
0.45
Death or reinfarction  17 (14)  34  (27) 0.014
Death, reinfarction or revascularization  51 (41)  78  (61) <0.001
Data are presented as number of subjects and crude proportions (%) per study group. Patients may have had events in 
more than one category. * log-rank test on estimated 8-year event rates. PCI = percutaneous coronary intervention;  
CABG = coronary artery bypass grafting
Bleeding
Bleeding rates are shown in Table 3. TIMI major and minor bleeding was infrequent with 
an incidence of 4% in both groups (p=ns). No intracranial bleeds were observed.
Table 3  Cumulative rates of bleeding during follow-up
Follow-up angiography 1 year follow-up Long-term follow-up
Aspirin plus 
coumarin Aspirin
Aspirin plus 
coumarin Aspirin
Aspirin plus 
coumarin Aspirin
Overall
 TIMI major 
 TIMI minor
 Access site*
 Other#
 21  (17)
 2  (2)
 2  (2)
 12  (10)
 5  (4)
 22  (17)
 2  (2)
 2  (2)
 15  (12)
 3  (2)
 24  (20)
 2  (2)
 3  (2)
 12  (10)
 7  (6)
 23  (18)
 2  (2)
 2  (2)
 15  (12)
 4  (3)
 28  (23)
 3  (2)
 3  (2)
 12  (10)
 10  (8)
 24  (19)
 3  (2)
 2  (2)
 15  (12)
 4  (3)
Data are presented as number of subjects and proportions (%) per treatment group (aspirin plus coumarin n=123, aspirin 
n=128). * groin hematomas and pseudoaneurysms (during the initial three-month study period); #  non-access site related 
bleeds not meeting the TIMI criteria
Reocclusion and long-term clinical outcome
Reocclusion of the infarct-related artery occurred in 15% (19/123) of patients on aspirin 
plus coumarin versus 28% (36/128) of patients on aspirin alone (RR 0.55; 95% CI 0.33-
0.90, p<0.02). 
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Between the 2 angiograms, recurrent ischemic events (reinfarction, unstable angina or 
angina with inducible ischemia at stress testing) occurred in 29% (35/123) of patients 
on combination therapy versus 47% (60/128) of patients on aspirin alone (p<0.01). 
Reocclusion rates in these patients were 23% (8/35) versus 37% (22/60), p=ns. Follow-
up angiography was performed earlier in patients with recurrent ischemic events: 59 ± 
44 days versus 98 ± 43 days after the initial angiogram (p<0.01). As a result, the time to 
follow-up angiography was markedly shorter in patients assigned to aspirin alone: 73 ± 
41 days versus 95 ± 31 days (p<0.01).
Long-term survival was 80% in the 55 patients with a reoccluded infarct artery versus 
94% in the 196 patients with sustained patency (HR 3.68, 95% CI 1.60-8.49, p<0.01; Figure 
4). Survival free from reinfarction was 57% in patients with reocclusion versus 84% in 
patients with sustained patency (HR 2.92, 95% CI 1.67-5.10, p<0.01, Figure 4). Survival free 
from reinfarction or revascularization (25% versus 53%, p<0.01) was also markedly lower 
in patients with reocclusion.
Multivariable analysis
Independent predictors of long-term outcome are shown in Table 4. In a model without 
reocclusion, combined treatment with aspirin plus coumarin independently predicted 
8-year survival and infarct-free survival. When reocclusion was included in the model, 
combination therapy was no longer significantly predictive of long-term outcome. 
Reocclusion, age and ejection fraction independently predicted long-term survival. 
Reocclusion and age were also independent predictors of long-term infarct-free survival.
Table 4  Cox-regression analysis: predictors of long-term death or reinfarction
Death
HR (95% CI)
Death or reinfarction
HR (95% CI)
Model without reocclusion
Aspirin plus coumarin versus aspirin alone
Age (per year)
Ejection fraction
 0.36  (0.13-1.00) †
 1.11  (1.05-1.17) *
 0.94  (0.90-0.98) *
 0.51  (0.28-0.95) #
 1.05  (1.02-1.09) *
 0.99  (0.96-1.03) ‡
Model including reocclusion
Aspirin plus coumarin versus aspirin alone
Age
Ejection fraction
Reocclusion
 0.46  (0.15-1.39) ‡
 1.10  (1.04-1.16) *
 0.95  (0.91-0.99) #
 2.56  (1.02-6.43) #
 0.62  (0.33-1.19) ‡
 1.05  (1.02-1.09) *
 1.00  (0.97-1.04) ‡
 2.43  (1.33-4.44) *
* p<0.01, # p<0.05, † p=0.05, ‡ p=ns
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Figure 4  Estimated long-term survival and long-term survival free from reinfarction in patients 
with sustained patency and patients with reocclusion
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Discussion
This 8-year follow-up study of the APRICOT-2 trial shows that the 3-month clinical 
benefit achieved with prolonged anticoagulation adjunctive to aspirin after successful 
fibrinolysis is sustained in the long term. Moderate-intensity coumarin (INR 2-3) 
continued for a median of 9 months reduced long-term death and reinfarction, with a 
sustained benefit after discontinuation of therapy.
To our knowledge, we provide the first evidence that a reduction in reocclusion with 
combination therapy is associated with a lower long-term risk of death or reinfarction, 
whereas the independent relationship between late reocclusion and long-term mortality is 
confirmed. The marked reduction in reocclusion seems one of the main mechanisms behind 
the improved clinical outcome with combined antithrombotic therapy. These observations 
provide a mechanistic rationale for prolonged moderate-intensity anticoagulation in the 
setting of an ischemia-guided revascularization strategy after fibrinolysis.
Reocclusion and clinical outcome
As reported previously 9-11, and also in this study, reocclusion was independently 
associated with adverse outcome. Importantly, the independent relationship between 
reocclusion and long-term survival, which was first observed in APRICOT-1 10, was also 
present in the current study. The unique design of the APRICOT-2 trial with mandatory 
follow-up angiography in all patients enabled us to demonstrate the beneficial effect of 
a reduction in reocclusion on long-term death and reinfarction. 
Aspirin alone has been shown effective in the prevention of early reocclusion in a meta-
analysis 15, and after the ISIS-2 trial, the early clinical benefit of aspirin after myocardial 
infarction is undisputed 16. Long-term clinical benefit has been demonstrated after 
myocardial infarction 1, but its efficacy is not as marked as in the first 30 days. This may 
explain why aspirin was not found to be superior to placebo in the prevention of late 
reocclusion in modestly sized randomized angiographic follow-up trials 17,18. 
The prolonged combined antithrombotic strategy resulted in reduced reocclusion rates 
and superior long-term outcome. A reduction in reocclusion with oral anticoagulation 
added to aspirin was also observed in a previous smaller study including patients with 
unstable angina or myocardial infarction 19. Interestingly, we found the combined 
antithrombotic regimen no longer to be predictive of outcome when reocclusion 
was entered in the multivariable model. This suggests that the marked reduction in 
reocclusion was the main mechanism behind the improved outcome with prolonged 
adjunctive moderate-intensity anticoagulation after successful fibrinolysis.
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Heparin and oral anticoagulation adjunctive to aspirin
Our observations with regard to clinical outcome corroborate with other studies on 
moderate-intensity oral anticoagulation (INR 2-3) added to aspirin after ACS 7. The 
combined regimen included prolonged heparinization for an additional 2 1/2 days when 
compared with the standard 48 hours in the aspirin-alone arm 8. Most of the in-hospital 
reinfarctions in the aspirin group occurred within 24 hours after discontinuation of 
heparin, suggesting a rebound phenomenon 20. Notably, more than half of the observed 
difference in reinfarctions in the first 3 months occurred after discharge 8. This suggests 
that besides prolonged heparinization, the continued use of oral anticoagulation after 
discharge also contributed to the early clinical benefit. 
In the combination group, oral anticoagulation was continued for a median duration 
of 9 months. After that time, the achieved reduction in reinfarction was sustained 
with no signs of convergence of the Kaplan-Meier curves (Figure 3). Only one patient 
had a reinfarction shortly after discontinuation of coumarin. The clinical benefit in the 
first year was primarily driven by a reduction in reinfarction, with most of the benefit 
achieved within the first 3 months, associated with the reduction in reocclusion. After 
8 years of follow-up, mortality in patients treated with combination therapy was 6% as 
compared with 12% in those allocated to aspirin alone. Given the modest study size 
and mortality rates in our study, this may be the play of chance. However, given the 
independent association between reocclusion and long-term mortality, and the lower 
risk of reocclusion in patients receiving prolonged combined antithrombotic therapy, 
this may also be a first indication that a reduction in reocclusion may indeed have a 
beneficial effect on long-term survival.
Compliance to anticoagulation was high, with 93% of patients treated according to 
protocol in the first 3 months. In this early period, bleeding rates were low and did not 
differ between groups (Table 3). With respect to long-term safety, our ability to draw firm 
conclusions is limited by the small number of patients on combination therapy for more 
than one year. The observed low risk of bleeding may be related to the rather low-risk 
patients (not older than 75 years, clinically stable) and the monitoring of anticoagulation 
in specialized outpatient clinics. Given the interindividual and intraindividual variability, 
optimal oral anticoagulation therapy has been shown to require dose-adjusted, 
frequently monitored, and individually tailored therapy in a high compliance setting 21.
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Alternative strategies to prevent recurrent events
Although self-assessed dose-adjusted anticoagulation may be an option in selected 
patients 22, several new agents have been tested in search for less cumbersome alternatives 
with a more predictable treatment effect than heparin and coumarin. When compared 
with a standard 48-hour infusion of intravenous heparin, low-molecular-weight-heparins 
administered until discharge have been shown to reduce recurrent events 23-25. Favorable 
short-term results have also been reported with the direct thrombin inhibitor bivalirudin 26 
and the indirect Xa blocker fondaparinux 27. In 2 trials with low molecular weight heparins, a 
catch-up phenomenon has been observed after discontinuation with comparable outcome 
at 30 days to 1 year 28. Recent follow-up data from the EXTRACT TIMI-25 trial showed that 
half of the initial reduction in reinfarction was lost at 1 year 29. Together with the benefit 
observed with the 6-month addition of a direct oral thrombin inhibitor to aspirin after 
myocardial infarction 6, these observations suggest a role for prolonged anticoagulation 
after discharge. Although the studied agent (ximelagatran) was withdrawn because of 
adverse effects, currently, several new anticoagulants are investigated in large-scale 
clinical trials. The optimal duration of prolonged anticoagulation adjunctive to aspirin 
after acute myocardial infarction is unknown. Beneficial effects have been observed with 
3 months to 4 years of treatment 7. Analogous to the duration of adjunctive clopidogrel 
after non-ST-elevation ACS 3, a period of 9 to 12 months may be considered. Although the 
APRICOT-2 data support a benefit from a 3-month regimen of combined antithrombotic 
treatment, conclusions on the effects of prolonging adjunctive anticoagulation beyond 
that period are limited by the modest sample size and the limited absolute number of 
patients that continued combination therapy after follow-up angiography (Figure 2).
After STEMI, prolonged dual antiplatelet therapy may also be an option, given the 
beneficial effect of clopidogrel on short-term infarct artery patency and clinical 
outcome 4,5. An indirect meta-analysis of clopidogrel versus moderate-intensity warfarin 
adjunctive to aspirin after ACS suggests a comparable efficacy of both strategies, with 
a small increase in major bleeding with the latter 30.
With stenosis severity as one of the few variables consistently reported to be associated 
with reocclusion 31, routine revascularization also appears to be an attractive option 
to improve outcome. The lack of benefit from routine angioplasty after successful 
fibrinolysis in past trials was attributed to procedure-related events 32. Recent combined 
data of feasibility trials conducted in the modern era of stents and glycoprotein IIb/
IIIa inhibitors showed a 2-fold reduction in death or reinfarction with an early routine 
invasive strategy when compared to delayed or ischemia-guided revascularization 33.
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Limitations
The APRICOT-2 trial was a relatively small open label study in a selected low-risk 
population of patients with a patent infarct artery after fibrinolysis, which was primarily 
designed to study the impact of a 3-month adjunctive anticoagulation regimen on 
reocclusion. With clinical outcome as secondary endpoint, it should be considered a 
conceptual study to provide insight into the mechanism underlying a potential clinical 
benefit. Extrapolation of our data to the more general population of patients after 
fibrinolysis should therefore be done with caution. The presented data on prolonged 
adjunctive anticoagulation beyond the initial 3-month randomized study period ought 
to be considered as observational and only apply to a limited number of patients on 
combination therapy. However, despite these limitations, our data corroborate well 
with the results of the larger clinical trials on long-term moderate-intensity oral 
anticoagulation adjunctive to aspirin after myocardial infarction 7. 
Whereas the APRICOT-2 protocol mandated an ischemia-guided revascularization 
strategy, irrespective of the severity of the residual stenosis, current guidelines for 
PCI advocate a more aggressive revascularization strategy after fibrinolysis 34,35. The 
potential of prolonged anticoagulation to improve outcome when such a strategy is 
followed remains to be determined.
Conclusions
Prolonged moderate-intensity anticoagulation (INR 2-3) adjunctive to aspirin after 
successful fibrinolysis conferred an early clinical benefit, which was sustained on the 
long-term after discontinuation of therapy. This was achieved with an acceptable risk 
of bleeding in a high-compliance setting with anticoagulation monitored in specialized 
clinics. The clinical benefit was largely attributed to a reduced risk of reocclusion, which 
independently predicted long-term death and reinfarction. Our observations provide 
mechanistic proof of the concept that a reduction in reocclusion leads to improved 
long-term outcome and support a role for prolonged adjunctive anticoagulation in the 
setting of an ischemia-guided revascularization strategy after successful fibrinolysis.
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Abstract
Background  Reocclusion of the infarct-related artery (IRA) strongly predicts outcome 
after successful fibrinolysis. However, angiographic studies show that most reocclusions 
occur without recurrent ischemic events. Although culprit stenosis severity independently 
predicts reocclusion, no clinically useful cut-point has been established. We studied the 
value of exercise ECG as a non-invasive predictor of reocclusion and long-term clinical 
outcome.
Methods  In the APRICOT-2 trial 251 STEMI patients with an open IRA <48 hrs after 
fibrinolysis had 3-month repeat angiography. The protocol recommended postinfarction 
exercise ECG. Five-year clinical follow-up was complete.
Results  Of the 251 patients 195 (78%) had stable or no recurrent angina (NYHA I-II). 
At a median of 30 days 140 (74%) patients performed bicycle exercise ECG. Repeat 
angiography revealed reocclusion in 27% (14/52) of patients with a positive or 
inconclusive (abnormal) exercise ECG and in 11% (10/88) of patients with a negative test 
(p=0.02). 
In a multivariable model, without culprit stenosis severity, an abnormal exercise ECG 
independently predicted reocclusion (OR 3.04, 95%CI 1.17-7.86, p=0.02). When culprit 
stenosis severity was added to the model exercise ECG was no longer predictive (OR 
2.24, 95%CI 0.74-6.82).
Patients with an abnormal exercise ECG had impaired 5-year infarct-free survival: 85% 
versus 95%, p=0.02.
Conclusions  In clinically stable patients after successful fibrinolysis, a positive or 
inconclusive exercise ECG was associated with a 2-fold increased risk of reocclusion and 
impaired long-term clinical outcome. The value of exercise ECG to predict reocclusion 
was attributed to culprit stenosis severity. The binary result of this non-invasive test may 
therefore be used as a surrogate for stenosis severity in the prediction of reocclusion.
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Introduction
Although an increasing number of ST-elevation myocardial infarction (STEMI) patients 
is treated with primary percutaneous intervention, a large proportion still receives 
fibrinolytic therapy 1. Unfortunately, part of the initial success of pharmacological 
reperfusion is often offset by reocclusion of the infarct artery 2. Reocclusion occurs in 
up to 30% of patients in the first year after successful fibrinolysis 2-5 and is associated 
with an increased risk of death, reinfarction and revascularization 6,7. 
Importantly, the majority of reocclusions occur in patients without overt clinical 
symptoms 2,4,6,7. Notably, reocclusion occurring without clinical reinfarction precludes 
recovery of left ventricular function 8. In patients without symptoms or signs of recurrent 
ischemia reocclusion independently predicts 10-year cardiac mortality 9. Therefore, 
identification of patients who appear to be clinically stable but are at increased risk of 
(silent) reocclusion may have important prognostic consequences.
The strongest independent predictor of reocclusion after successful fibrinolysis is 
residual stenosis severity of the culprit lesion 10-12. However, a clinically useful cut-point 
level for this invasive variable has not been established. Moreover, stenosis severity has 
not been shown predictive of clinical outcome 12,13. For clinical use a widely available non-
invasive test, which discriminates between patients at high or low risk of reocclusion 
and associated events, would be ideal.
Exercise testing is a class 1 ACC/AHA guideline recommendation after STEMI 14, and is 
widely used for detection of residual ischemia, prognostic stratification and assessment 
of exercise capacity 15-17. To our knowledge there are no data on the prediction of 
reocclusion with the use of exercise testing.
For this analysis we assessed the value of bicycle exercise electrocardiography (X-ECG) 
as a non-invasive tool in the prediction of reocclusion and long-term clinical outcome in 
patients from the APRICOT-2 trial 5 with a stable clinical course in the first month after 
successful fibrinolysis.
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Methods
Protocol
The study protocol of the APRICOT-2 trial has been described in detail previously 5. The 
trial was approved by the ethics review committees of the participating hospitals and all 
patients gave informed consent. Figure 1 depicts the study design.
Figure 1  Study design of the APRICOT-2 trial
In the APRICOT-2 study, 308 patients <76 years with chest pain refractory to nitrates 
lasting >30 minutes and <6 hours received fibrinolysis for suspected ST-elevation 
myocardial infarction in combination with aspirin 80 mg and unfractionated heparin. 
Angiography was performed within 48 hours of fibrinolysis in clinically stable patients 
with clinical and/or electrocardiographic signs of reperfusion. Patients with TIMI 3 
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flow 18 as assessed by the local investigator were randomized to two arms. In one arm 
patients continued treatment with aspirin 80 mg with discontinuation of heparin at 
48 hours. In the other arm coumarin was added to aspirin 80 mg with continuation of 
heparin until moderate-intensity anticoagulation (target INR 2-3) was achieved. The 34 
patients without TIMI 3 flow in the infarct artery according to the angiographic core 
laboratory were excluded from analysis.
Follow-up angiography was scheduled at three months to assess reocclusion, which 
was defined as TIMI 2 flow or less 18. Revascularization was to be performed in case 
of recurrent ischemia, either spontaneous or inducible at stress testing, which was 
recommended in all patients. When coronary angioplasty was clinically indicated and 
performed before the planned repeat angiography, the patency status of the infarct 
artery before wire crossing was scored as follow-up endpoint.
Angiography
At baseline angiography quantitative coronary angiography (QCA) of the culprit lesion 
was performed at a core laboratory (Heartcore Leiden B.V., Leiden, the Netherlands), 
providing a precise estimation of the diameter stenosis with low interobserver and 
intraobserver variability 19. For this analysis the optimal single projection with the 
most severe measured stenosis was used. Morphology of the culprit lesion was scored 
according to the Ambrose criteria 20.
Exercise testing
Symptom limited exercise electrocardiography (X-ECG) was planned in all clinically 
stable patients and performed predischarge or during outpatient cardiac rehabilitation, 
which started within a month after hospital discharge. In case more than one X-ECG 
was performed results of the first symptom limited X-ECG were used. All participating 
centers routinely performed bicycle exercise testing, except for one in which patients 
routinely underwent treadmill testing. In view of the differences in exercise physiology 
and protocol between treadmill testing and bicycle testing these patients were excluded 
from analysis. 
Bicycle X-ECG was performed using a standard protocol. At rest blood pressure, heart 
rate and 12-lead ECG were recorded in sitting position. Workload at test onset was 25-50 
Watts (W) and increased by 10 W every minute at a pedaling frequency of 60 rounds per 
minute. During X-ECG symptoms, ST-segment changes and arrhythmias were recorded. 
Patients were encouraged to continue exercise until limiting symptoms or signs were 
experienced.
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All X-ECGs were evaluated by a single reviewer (PK), who was blinded to the angiographic 
outcome of the patients. The following variables were registered: use of beta-blockers 
at the time of the exercise test, heart rate and blood pressure at rest and at maximal 
exercise, angina, ST-elevation in relation to the presence and location of Q-waves, ST-
depression, T-wave changes, arrhythmias, conduction abnormalities and reasons for 
discontinuation of exercise.
Exercise capacity as measured in Watts was converted to maximal oxygen consumption 
calculated as metabolic equivalents (METS) using the following formula 21: METS = [13 x 
workload (W) / weight (kg) + 3.5] / 3.5.
Increase of the pressure-rate-product (dPRP) was calculated as the difference from rest 
to maximal exercise.
The X-ECG was considered positive when ischemic ST-segment changes occurred. These 
were defined as horizontal or downsloping ST-depression of more than 1.0 mm 0.08 s after 
the J-point in three consecutive beats in lead V4, V5 or V6, or ST-elevation of more than 
2.0 mm in three consecutive beats in any lead without Q-waves. Q-waves were defined as 
Q-wave amplitude >1/3 of the R-wave and/or duration of more than 0.04 s. In case of ST-
segment abnormalities at rest deviation was measured as changes from rest.
The X-ECG was recorded as inconclusive, if maximal heart rate was less than 70% of 
expected (220 beats per minute minus age) without ischemic ST-segment changes 22.
Clinical follow-up
Five-year clinical and survival data were collected from medical charts, civil registries, or 
by written or telephone contact with the patient, relatives or the general practitioner.
An event was qualified as reinfarction (infarct artery related) when at least 3 of the 
4 GUSTO-1 criteria were met 23: 1) recurrent ischemic symptoms lasting >15 minutes 
after resolution of symptoms of the index infarction, 2) new ST-T wave changes or 
new Q-waves in the same area as the index infarction, 3) a second elevation in cardiac 
enzymes over the upper limit of normal (or by a further 20% if already elevated), and 4) 
reocclusion of the infarct artery.
Revascularization was scored in case of percutaneous coronary intervention (PCI) of the 
index infarct vessel or coronary artery bypass grafting (CABG).
Statistics
Statistical analysis was performed with SPSS 14.0 (SPSS Inc. 2005, Chicago, USA). 
For comparison of continuous variables the Student t-test and Mann-Whitney-U-test 
were used whenever appropriate. Comparisons of proportions between groups were 
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performed with the χ2-test. Statistical significance was defined as a two-sided p-value 
<0.05.
Logistic regression analysis was used to determine the association between exercise 
test variables and reocclusion. Antithrombotic regimen and the known predictors of 
reocclusion, i.e. stenosis severity 10-12 and smoking status 24, were prospectively chosen 
to be included in the multivariable model. Baseline characteristics that were imbalanced 
between groups (p<0.10) were also included.
Long-term survival analysis was performed according to Kaplan and Meier, using the 
log rank test for comparison between groups. Multivariable survival analyses were 
performed using Cox proportional hazard analyses. 
Results
Of the 274 patients with a patent infarct artery after fibrinolysis who were included in 
the APRICOT-2 trial 251 (92%) underwent follow-up angiography (Figure 2). Of these 
patients 56 (22%) experienced early recurrent ischemic events. In-hospital reinfarction 
(n=7) and postinfarction angina (n=26) occurred in 13% of patients. After discharge and 
before exercise testing was performed, 23 patients (9%) were readmitted, either for 
reinfarction (n=5) or unstable angina (n=18). Patients with recurrent ischemic events 
underwent early repeat angiography (a median of 27 days after randomization), which 
was followed by revascularization in 66% of cases.
Of the 195 patients with stable angina (NYHA class I-II) 30 were included in the one 
participating center that routinely performed treadmill testing instead of bicycle X-ECG. 
These patients were excluded from analysis. Of the remaining 165 patients 140 (85%) 
performed bicycle exercise testing. Reasons for not performing bicycle X-ECG are listed 
in Figure 2. Baseline characteristics of patients undergoing bicycle X-ECG did not differ 
significantly from patients who did not.
Bicycle X-ECG
Bicycle X-ECG was performed a median of 32 (10-42) days after randomization and 
a median of 62 (47-83) days prior to repeat angiography. In one patient the test was 
prematurely discontinued for ST-segment elevation with concomitant angina. In all 
other patients general fatigue or shortness of breath was the reason to discontinue the 
test. Table 1 lists the X-ECG variables in our study population.
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Figure 2  Flow chart showing number of patients from APRICOT-2 randomized and number with 
angiographic follow-up undergoing bicycle X-ECG
APRICOT-2
Patients randomized 
n = 308
Included
n = 274
2nd angiography
n = 251
Stable or no recurrent angina (NYHA class I-II)
n = 195
Bicycle exercise test performed 
n = 140
Exclusion: n = 34
No TIMI 3 flow
(core lab)
No 2nd angiogram n = 23
 refusal n = 19
 death n = 1
 CABG n = 3
Early clinical instability n = 56
 Reinfarction  n = 12
 Unstable angina* n = 44
No bicycle exercise test performed n = 55
 Inclusion in hospital performing treadmill X-ECG n = 30
 Transfer to hospital performing MPI or DSE# n = 9
 Non-cardiac conditions  n = 9
 Miscellaneous n = 7
* = post-infarction angina or readmission for unstable angina
# = myocardial perfusion imaging (MPI) or dobutamine stress echocardiography (DSE)
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Table 1  Variables recorded at bicycle exercise testing 
Clinically stable patients
undergoing X-ECG
(n = 140)
Resting variables
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Heart rate (beats per minute)
Beta-blocker use
 128  ±  24
 77  ±  14
 64  ± 11
 131 (94%)
Exercise variables
Maximal workload (Watt)
Proportion of age-predicted maximal workload achieved, %
METS
Maximal heart rate (beats per minute)*
Proportion of age-predicted maximal heart rate achieved, %*
Maximal systolic blood pressure (mmHg)
Maximal diastolic blood pressure (mmHg)
Pressure Rate Product*
Increase of Pressure Rate product*
Angina
ST segment depression
ST segment elevation
Non significant ECG changes
No ECG changes
Positive test result 
Inconclusive test result
Negative test result 
 138  ±  37
 91  ±  17
      7.5  ±  1.7
 126  (110-142)
 77  (67-88)
 182  ±  31
 81 ±  13
 22753  (18614-27285)
 14762  (10609-19189)
 12  (9%)
 15  (11%)
 1  (1%)
 45  (32%)
 79  (56%)
 16  (11%)
 36  (26%)
 88  (63%)
Data are presented as number of subjects (%), values as mean ± standard deviation unless indicated otherwise; * median 
(25th-75th percentile). METS = metabolic equivalents
Reocclusion
The overall reocclusion rate in APRICOT-2 was 22% (55/251). Of these reocclusions 56% 
(31/55) occurred in the 195 patients with a stable clinical course early after fibrinolysis. 
In the 140 patients who performed bicycle X-ECG the reocclusion rate was 17% (24/140). 
Exploratory analysis showed that in this study population the strongest X-ECG variable 
to predict reocclusion was the exercise test result (Table 2). Reocclusion occurred in 27% 
(14/52) of patients with a positive or inconclusive (abnormal) X-ECG versus 11% (10/88) 
of patients with a negative X-ECG (p=0.02, Figure 3). Sensitivity of X-ECG to predict 
reocclusion was 58% with a negative predictive value of 89%. Baseline characteristics of 
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patients with a positive or inconclusive X-ECG and patients with a negative test result 
are presented in Table 3. 
Table 2  Bicycle exercise test variables with a univariate association with reocclusion
Exercise test variable OR (95% CI) p Wald score
Positive or inconclusive versus negative test result
Proportion of age-predicted maximal heart  
rate achieved (%)
Maximal heart rate (beats per minute)
Increase of Pressure Rate product / 1000
2.87 (1.19-7.06)
0.96 (0.92-0.99)
0.98 (0.96-0.99)
0.91 (0.84-0.99)
0.02
0.03
0.04
0.04
5.29
4.99
4.33
4.22
Figure 3  Rates of reocclusion in patients with a positive or inconclusive X-ECG and patients with 
a negative X-ECG
Between the X-ECG and repeat angiography 2 patients had a reinfarction and 10 
patients were readmitted for unstable angina. This occurred in 14% (7/52) of patients 
after a positive or inconclusive X-ECG and in 6% (5/88) of patients after a negative X-
ECG (p=0.11).
At multivariable analysis the predictive value of bicycle X-ECG primarily depended 
on culprit stenosis severity. When adjusted for all relevant clinical and angiographic 
variables except culprit stenosis severity a positive or inconclusive test independently 
predicted reocclusion: OR 3.04, 95% CI 1.17-7.86, p=0.02. However, when culprit stenosis 
severity was added to the model the exercise test result was no longer predictive: OR 
2.24, 95% CI 0.74-6.82, p=0.16. 
0
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20
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Reocclusion 
%
27%
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Table 3  Characteristics of clinically stable patients undergoing bicycle exercise testing
Positive or inconclusive X-ECG
(n = 52)
Negative X-ECG
(n = 88) p
Baseline clinical characteristics
Men
Age (y)
Previous angina
Previous myocardial infarction
Current smoker
Diabetes
Hypertension
Family history of CAD
Hypercholesterolemia
Time symptoms – fibrinolysis (h)
Previous aspirin use
Fibrinolytic 
 Fibrin specific 
 Non-fibrin specific
Peak creatine kinase (units/L)*
Antithrombotic regimen 
 Aspirin and coumarin 
 Aspirin
 44  (85)
    58 ± 11
 26  (50)
 7  (14)
 29  (56)
 1  (2)
 13  (25)
 27  (52)
 30  (58)
     2.5 ± 1.3
 10  (19)
 
 26  (50) 
 26  (50)
 1207  (609-2114)
 
 26  (50) 
 26  (50)
 72  (82)
   54 ± 9
 41  (47)
 8  (9)
 58  (66)
 4  (5)
 19  (22)
 39  (44)
 55  (63)
     2.1 ± 1.2
 9  (10)
 
 40  (46) 
 40  (54)
 972  (518-2247)
 
 55  (63) 
 33  (37)
0.67
0.03
0.70
0.42
0.23
0.42
0.64
0.38
0.57
0.14
0.13
 
0.60 
0.90
 
0.15
Baseline angiographic characteristics
Infarct artery 
 LAD 
 LCX 
 RCA
Culprit stenosis severity (QCA, n=135) 
 overall 
 <50% 
 50-60% 
 60-70% 
 >70%
Lesion type 
 Smooth 
 Complex
Single vessel disease
Ejection fraction (%)
 
 16  (31) 
 13  (25) 
 23  (44)
 
    59.3 ± 15 
 11  (22) 
 13  (26) 
 14  (28) 
 12  (24)
 
 34  (65) 
 18  (35)
 29  (56)
    52.8 ± 9
 
 32  (36) 
 11  (13) 
 45  (51)
 
  54.4 ± 15 
 24  (28) 
 23  (27) 
 31  (37) 
 7  (8
 
 55  (63) 
 33  (37)
 52  (59)
   53.5 ± 9
 
0.17
 
 
 
0.07 
 
 
 
 
0.73 
0.70
0.67
Data are presented as number of subjects (%) for discrete variables, values as mean ± standard deviation unless indicated 
otherwise; * median (25th-75th percentile). CAD = coronary artery disease, LAD = left anterior descending coronary artery, 
LCX = left circumflex coronary artery, RCA = right coronary artery, QCA = quantitative coronary angiography
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Revascularization
Based on the results of X-ECG and follow-up angiography 25% (35/140) of patients 
underwent revascularization. Revascularization rates were 42% (22/52) in patients with 
a positive or inconclusive X-ECG and 15% (13/88) in patients with a negative X-ECG 
(p<0.01).
Long-term clinical outcome 
Five-year survival data were complete. Five-year survival rates were 96% in patients with 
a positive or inconclusive X-ECG and 98% in those with a negative test (p=ns). Patients 
with an abnormal X-ECG result had impaired five-year infarct-free survival: 85% versus 
95% (Figure 4, p=0.02). Five-year survival free from reinfarction and revascularization 
was also significantly lower in patients with a positive or inconclusive X-ECG: 46% 
versus 78%, p<0.01.
Figure 4  Estimated infarct-free survival in patients with a positive or inconclusive X-ECG and 
patients with a negative X-ECG
At Cox-regression analysis a positive or inconclusive X-ECG was independently 
associated with impaired five-year infarct-free survival: HR 4.87, 95%CI 1.29-18.4, p=0.02. 
Stenosis severity did not predict long-term outcome: HR 0.85, 95% CI 0.61-1.06, p=ns.
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Discussion
In this study on patients with no or stable angina (NYHA class I-II) in the first month after 
successful fibrinolysis for ST-elevation myocardial infarction a positive or inconclusive 
X-ECG result was associated with a more than two-fold increased risk of reocclusion 
and impaired five-year infarct-free survival. The value of X-ECG to predict reocclusion 
was attributed to more severe infarct-related stenoses in patients with a positive or 
inconclusive test result.
Exercise electrocardiography in the prediction of reocclusion
To our knowledge this is the first study on the value of X-ECG in the prediction of 
reocclusion. The increased risk of reocclusion with an abnormal X-ECG applied to 
clinically stable patients with exercise induced ischemia (positive test) or patients who 
achieved a maximal heart rate <70% of predicted without ischemic ST-segment changes 
(inconclusive test).
The increased risk of reocclusion in patients with an abnormal X-ECG was primarily 
attributed to more severe culprit stenoses. Our results implicate that the additional 
value of X-ECG over stenosis severity in the prediction of reocclusion is limited. 
However, they also suggest that the binary X-ECG result might be used as a surrogate 
non-invasive predictor. Despite the limited sensitivity (58%) of X-ECG to predict 
reocclusion, a negative test result was associated with a low risk of reocclusion (11%). In 
contrast to stenosis severity, which did not identify patients at increased risk of adverse 
long-term clinical outcome, the X-ECG result independently predicted five-year death 
and reinfarction. Patients with a negative test result had excellent long-term infarct-free 
survival.
Interestingly, more than two-thirds of patients with an abnormal X-ECG had an 
inconclusive test result, based on the 70% maximum heart rate limit 16,22. The very high 
use of betablockers (94%) in our study may have limited the sensitivity of X-ECG to 
detect ischemia in these patients 25. Although betablockers frequently cause chronotropic 
incompetence 26, more than 70% of patients in our study achieved a maximal heart rate 
over the 70% limit. Given the inverse relationship between (predicted) maximal heart rate 
and reocclusion in our study (Table 2), chronotropic incompetence itself may therefore 
be a marker of an increased risk of reocclusion. An impaired chronotropic response 
without ischemic ST-changes has been associated with increased mortality in patients 
after myocardial infarction 16,27. The exact mechanism behind this adverse impact on 
prognosis is unclear, autonomic dysfunction as a reflection of more severe cardiovascular 
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perturbations has been suggested as a potential explanation 27. This mechanism could 
also be involved in the adverse prognostic consequences of reocclusion. It is still unclear 
whether the relationship between reocclusion and adverse long-term outcome is causal, 
or that reocclusion is merely a marker of poor prognosis 9. 
Exercise electrocardiography and long-term clinical outcome
As a result of the design of our study five-year death and reinfarction rates were low. We 
only included patients with a patent infarct artery after fibrinolysis who were clinically 
stable when they performed symptom-limited exercise testing a median of 30 days after 
the infarction. Nevertheless, a positive or inconclusive X-ECG independently predicted 
five-year death and reinfarction. The vast majority of long-term clinical events were 
late reinfarctions, which mainly occurred in patients in whom the infarct artery was still 
patent at three-month angiography. Thus, X-ECG identified both patients at increased 
risk of reocclusion at three months and patients at increased risk of five-year clinical 
reinfarction. In contrast, stenosis severity strongly predicted reocclusion, but was not 
associated with an increased risk of late reinfarction in this study. 
The value of exercise testing in the prediction of clinical outcome after fibrinolysis 
has been addressed in several previous studies. In the TIMI-II trial exercise induced 
ST-depression was associated with impaired 1-year survival 28. In DANAMI-2 ST-
depression independently predicted 3-year death and reinfarction in patients treated 
with fibrinolysis 22. In the overall population of this study, including patients undergoing 
primary angioplasty, an inconclusive test result was also strongly associated with 
adverse outcome. However, in other reports exercise testing did not identify patients 
at high risk for recurrent events 29,30. 
Implications
Our results show that clinically stable patients with an abnormal X-ECG after successful 
fibrinolysis are at increased risk of reocclusion and adverse five-year outcome. In 
patients with a positive exercise test after fibrinolysis revascularization is currently 
recommended as it has been shown to reduce the risk of recurrent ischemic events 31. A 
novel finding of this study is that in clinically stable patients receiving betablockers after 
successful fibrinolysis also an inconclusive test result, i.e. maximal heart rate <70% of the 
age-predicted maximum without ischemic ECG-changes, is associated with an increased 
risk of reocclusion and impaired long-term outcome. Further studies are warranted to 
determine whether these patients, despite the lack of unstable symptoms, may also 
benefit from more aggressive treatment strategies including revascularization.
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In contrast, patients with stable or no recurrent angina in the first month and a negative 
X-ECG, which accounted for more than 60% of our study population, have a low risk of 
reocclusion and excellent five-year clinical outcome, allowing a follow-up strategy of 
watchful waiting.
Limitations
This is a post-hoc analysis of data from a randomized trial referring to low-risk clinically 
stable patients after successful fibrinolysis, who were able to perform bicycle X-ECG 
at a median of 30 days after the infarction. Therefore our data should be considered 
as hypothesis generating and require prospective confirmation in larger study 
populations.
Although 94% of patients in our study used beta-blockers the exact dosage used, and 
possible differences in dosage between groups were not accounted for.
Whereas guidelines usually recommend predischarge X-ECG, for logistic reasons most 
patients in our study underwent stress testing a few weeks after discharge during 
outpatient cardiac rehabilitation. Of the 251 patients with two angiograms 23 (9%) 
developed reinfarction or unstable angina after discharge but before the planned X-
ECG. Potentially these patients might have been identified as high risk if a predischarge 
X-ECG was performed, with subsequent changes in management.
Conclusions 
In patients with no or stable angina (NYHA class I-II) in the first month after successful 
fibrinolysis, a positive or inconclusive X-ECG is associated with a more than two-fold 
increased risk of reocclusion and impaired five-year infarct-free survival. The value of X-
ECG to predict reocclusion was attributed to culprit stenosis severity, the independent 
invasive predictor of reocclusion. These findings implicate that the binary result of this 
widely available non-invasive test may be used as a surrogate for stenosis severity in the 
prediction of reocclusion after successful fibrinolysis. In contrast to stenosis severity, 
which did not identify patients at increased risk of adverse long-term clinical outcome, 
the X-ECG result independently predicted five-year death and reinfarction. Clinically 
stable patients with a negative X-ECG had a low risk of reocclusion and excellent long-
term clinical outcome.
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Abstract
Background  In smokers treated with fibrinolysis for ST-elevation myocardial infarction 
(STEMI) a paradoxical beneficial short-term outcome has been reported. This was 
attributed to favorable clinical and angiographic baseline variables and a better 
response to fibrinolysis. During follow-up infarct artery reocclusion is an important 
prognosticator. We studied the effects of smoking on reocclusion and long-term cardiac 
outcome after successful fibrinolysis.
Methods  In the Antithrombotics in the Prevention of Reocclusion In COronary 
Thrombolysis trials (APRICOT-1 and -2) 499 STEMI patients with an open infarct artery 
<48 hours after fibrinolysis received randomized antithrombotic treatment until 
3-month follow-up angiography. Five-year clinical follow-up was complete.
Results  Current smokers (317 patients, 64%) had favorable clinical (age 54 versus 60 
years, p<0.01) and angiographic (single vessel disease 61% versus 49%, p=0.02) baseline 
characteristics.
Reocclusion rates were 21% (67/317) in smokers versus 32% (59/182) in non-smokers 
(p<0.01). Five-year infarct-free cardiac survival did not differ: 82% versus 85%.
Reocclusion (HR 2.41, 95%CI 1.05-5.56, p=0.04) independently predicted cardiac mortality. 
Smoking was independently associated with a reduced risk of reocclusion (OR 0.58, 
95%CI 0.37-0.91, p=0.02), but not with improved 5-year cardiac outcome (HR 1.34, 95%CI 
0.79-2.25, p=ns).
Conclusions  After successful fibrinolysis, smoking is independently associated with 
a more than 40% reduced risk of reocclusion, which is an independent predictor of 
adverse outcome. However, even with more favorable baseline characteristics smokers 
did not have improved five-year cardiac outcome in this low-risk population.
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Introduction
Many epidemiological studies have shown that cigarette smoking is associated with an 
increased risk of myocardial infarction and death from coronary artery disease, including 
sudden death 1-3. However, after acute myocardial infarction short-term clinical outcome 
in smokers is more favorable than in non-smokers. In patients treated with fibrinolysis 
for acute myocardial infarction this so called ‘smoker’s paradox’ has been attributed to 
more favorable clinical and angiographic baseline characteristics in smokers 4-6. Several 
studies reported higher rates of good early antegrade epicardial flow (Thrombolysis 
in Myocardial Infarction (TIMI) 3 flow) in smokers 7, suggesting a better response to 
fibrinolysis 5,6,8-11.
After successful fibrinolysis, outcome is strongly related to reocclusion of the infarct 
artery, which portends an increased risk of death, reinfarction and revascularization 12-14. 
Notably, most reocclusions occur without clinical reinfarction 12-14. Even in these cases, 
reocclusion has adverse impact on recovery of left ventricular function 15. Previously 
we have shown that reocclusion is a strong predictor of 10-year cardiac mortality, 
independent of left ventricular ejection fraction, and even when presenting without 
signs of reinfarction or recurrent ischemia 16. 
Data on the risk of reocclusion in smokers are scarce and conflicting. In GUSTO-1 current 
smokers had a lower risk of in-hospital reocclusion than non-smokers 5, whereas no 
difference was observed in the TAMI trials 6.
In the angiographic follow-up studies APRICOT-1 and APRICOT-2 the effect of different 
antithrombotic regimens on 3-month reocclusion was studied in patients with a patent 
infarct artery after fibrinolysis 17,18. For the present analysis we assessed differences in 
clinical and angiographic baseline variables between smokers and non-smokers and the 
effect of smoking on reocclusion and short- and long-term cardiac outcome.
Methods
Protocol
The study protocols of the APRICOT-1 (1987-1991) and APRICOT-2 (1995-2000) trials have 
been reported in detail previously 17,18. 
Patients received fibrinolysis for suspected acute ST-elevation myocardial infarction 
(STEMI) followed by infusion of unfractionated heparin. In the case of clinical and/or 
electrocardiographic signs of reperfusion, stable patients were asked informed consent 
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to undergo coronary angiography within 48 hours after fibrinolysis. Patients with a 
patent infarct artery were eligible for the study. 
In the APRICOT-1 trial patients were randomly allocated to one of three arms: blinded 
treatment with either 325 mg of aspirin or placebo, or open-label coumarin including 
continued heparinization until the target INR (2.8-4.0) was reached. After follow-up 
angiography the study medication was discontinued and, unless they had an indication 
for oral anticoagulation, all patients received aspirin based on the ISIS-2 results 19, which 
became available shortly after initiation of the trial.  
In APRICOT-2 patients were randomized to two arms. In one arm patients continued 
treatment with aspirin 80 mg with discontinuation of heparin at 48 hours. In the other 
arm coumarin was added to aspirin 80 mg with continuation of heparin until moderate-
intensity anticoagulation (target INR 2-3) was achieved. 
Cardiac catheterization
Follow-up angiography was scheduled at three months to assess reocclusion, the 
primary endpoint of the APRICOT trials. In APRICOT-1 reocclusion was defined as ECSG 
grade 4 (91% to 99% diameter stenosis, no complete filling within 3 cycles) or grade 5 
stenosis (total occlusion with or without collateral filling) 17. In APRICOT-2 the definition 
of reocclusion was TIMI flow grade 2 or less 18. Anatomical reocclusions were defined as 
ECSG grade 5 and TIMI flow 0 or 1, respectively.  An ischemia-guided revascularization 
strategy was adopted 17. If coronary angioplasty was performed before the planned 
repeat angiography, the patency status of the infarct artery before wire crossing was 
scored as follow-up endpoint. 
At baseline angiography quantitative coronary angiography (QCA) of the culprit 
lesion was performed, providing a precise estimation of the diameter stenosis with 
low interobserver and intraobserver variability 20. For this analysis the optimal single 
projection with the most severe measured stenosis was used. Morphology of the culprit 
lesion was scored according to the Ambrose criteria 21.
Clinical follow-up
Five-year clinical and survival data were collected from medical charts, civil registries, or 
by written or telephone contact with the patient, relatives or the general practitioner. 
All deaths were confirmed by civil registry data. Patients participating in APRICOT-2 
were systematically questioned about their smoking behavior at follow-up visits.
Cardiac mortality was defined based on the information of the treating physician, and 
only in the case of a confirmed cardiac diagnosis. An instantaneous death, for which 
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the cause could not be determined with certainty, was scored as a death of cardiac 
origin. Confirmed vascular deaths (strokes, aneurysms, aortic dissections, pulmonary 
embolisms) were not considered as cardiac death. If the cause was unknown/uncertain 
and death did not occur instantaneously it was classified as ‘cause undetermined’.
An event was qualified as reinfarction (infarct artery related) when at least 3 of the 4 
GUSTO-1 criteria were met 22: 1) recurrent ischemic symptoms lasting >15 minutes after 
resolution of symptoms of the index infarction, 2) new ST-T wave changes or new Q-
waves in the same area as the index infarction, 3) a second elevation in cardiac enzymes 
over the normal upper limit (or by a further 20% if already elevated), and 4) reocclusion 
of the infarct artery. Reinfarctions not meeting these electrocardiographic criteria or 
attributed to a different coronary artery at urgent repeat angiography were considered 
to be not infarct artery related.
Recurrent ischemic events were defined as the combination of reinfarction, 
unstable angina and recurrent angina with documented ischemia at stress testing. 
Revascularization of the infarct artery was scored in the case of percutaneous coronary 
intervention (PCI) of the index infarct vessel or coronary artery bypass grafting 
(CABG).
Statistics
Statistical analysis was performed with SPSS 14.0 (SPSS Inc. 2005, Chicago, USA). For 
comparison of continuous variables the Student t-test and Mann-Whitney-U-test were 
used whenever appropriate. Comparisons of proportions between groups were performed 
with the χ2-test. Statistical significance was defined as a two-sided p-value <0.05.
Multivariable logistic regression analysis was used to determine the association 
between smoking status at baseline and reocclusion. Variables included in the model 
were baseline characteristics that were imbalanced between smokers and non-
smokers (p<0.10, see Results), predictors of reocclusion at univariable analysis and the 
antithrombotic regimen (prespecified).
Long-term survival analysis was performed according to Kaplan and Meier, using the 
log rank test for comparison between groups. To determine the association between 
smoking status at baseline and 5-year (infarct-free) cardiac survival multivariable Cox-
regression analysis using forward logistic regression was performed. TIMI risk score 
variables 23 and the antithrombotic regimen were prospectively chosen to be included 
in the model. Baseline characteristics that were imbalanced between smokers and non-
smokers and univariate predictors of long-term outcome completed the model.
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Results
Of the 558 patients enrolled in the APRICOT-1 and APRICOT-2 trials the current report 
includes the 499 patients with complete angiographic follow-up (Figure 1). Patients 
without follow-up angiography were significantly older (62 ±	8 versus 56 ±	 10 years, 
p<0.01), more often female (33% versus 17%, p<0.01), and tended to have more often a 
history of previous myocardial infarction (16% versus 9%, p=0.09). The proportion of 
current smokers at enrollment did not differ from patients with angiographic follow-up 
(59% versus 64%, p=ns).
Figure 1  Flow chart showing number of patients from APRICOT-1 and APRICOT-2 excluded and 
number remaining with follow-up angiography and long-term clinical follow-up
APRICOT-1
300 patients randomized
APRICOT-2
308 patients randomized
Inclusion
n = 284
Inclusion
n = 274
Total
inclusion
n = 558
APRICOT-1
2nd angiography
n = 248
APRICOT-2
2nd angiography
n = 251
Total
2nd angiography
n = 499
Long-term clinical follow-up
Exclusion: n = 16
No ECSG 1-3
(angiographic committee)
No 2nd angiogram n = 36
 Refusal n = 28
 Death n = 2
 CABG n = 6
Exclusion: n = 34
No TIMI 3 flow
(core lab)
No 2nd angiogram n = 23
 Refusal n = 19
 Death n = 1
 CABG n = 3
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Baseline characteristics
At baseline 317 (64%) of the 499 patients were current smokers. Baseline characteristics 
of smokers and non-smokers are listed in Table 1. With respect to clinical characteristics 
smokers were younger, and had less often a history of prior myocardial infarction, 
diabetes, hypertension or a positive family history. 
At baseline angiography smokers had less severe residual infarct-related stenoses, more 
smooth infarct lesions and more often single vessel disease. Smokers tended to have 
more often an infarction related to the left coronary artery. Peak CK-levels were higher 
in smokers, but baseline ejection fraction did not differ from non-smokers.
Reocclusion
Follow-up angiography was performed after a median of 89 (interquartile range 64-
97) days. Reocclusion rates were 21% (67/317) in smokers versus 32% (59/182) in non-
smokers: RR 0.56, 95%CI 0.37-0.84, p<0.01. When only anatomical reocclusions were 
considered the rates were 16% (49/317) and 25% (45/182), respectively: RR 0.56, 95%CI 
0.35-0.88, p=0.01.
Exploratory analysis showed that the reduced risk of reocclusion observed in smokers in 
the overall study population was generally consistent across many different subgroups 
(Figure 2). No significant interaction (p<0.01) between the effect of smoking and any of 
the subgroup variables was observed.
At multivariable analysis smoking was independently associated with a markedly 
reduced risk of reocclusion of the infarct artery: OR 0.58, 95%CI 0.37-0.91, p=0.02. If 
only anatomical reocclusions (ECSG grade 5, TIMI 0,1) were considered the adjusted 
odds ratio was 0.59, 95%CI 0.35-0.97, p=0.04. Baseline culprit stenosis severity also 
independently predicted reocclusion: OR 1.07, 95%CI 1.05-1.09, p<0.01.
Compared with placebo, antithrombotic treatment with aspirin alone (325 mg or 80 
mg, n=221; OR 0.51, 95%CI 0.27-0.98, p=0.04) or in combination with coumarin (n=123; 
OR 0.29, 95%CI 0.13-0.65, p<0.01) was independently associated with a reduced risk of 
reocclusion. Coumarin alone (n=81; OR 0.71, 95%CI 0.33-1.53, p=ns) was not superior to 
placebo.
Clinical outcome – short-term
Table 2 lists the three-month rates of recurrent ischemic events and revascularizations in 
smokers and non-smokers. Reinfarction rates were similar in smokers and non-smokers. 
Smokers had lower rates of unstable angina and revascularization. The proportion of 
patients with recurrent ischemic events who underwent revascularization was 43% 
(39/90) in smokers and 49% (37/75) in non-smokers (p=ns).
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Table 1
Baseline characteristics
Smokers
(n = 317)
Non-smokers
(n = 182) p
Clinical characteristics
Men  260  (82)  154  (85) 0.46
Age (y)    54 ± 9    60 ± 9 <0.01
Previous angina  161  (51)  106  (58) 0.28
Previous myocardial infarction  18  (6)  25  (14) <0.01
Diabetes  11  (4)  15  (8) 0.02
Hypertension  68  (22)  57  (31) 0.02
Family history of CAD  107  (34)  85  (47) <0.02
Hypercholesterolemia  213  (67)  123  (68) 0.93
Time symptoms – fibrinolysis (h)       2.2 ± 1.2       2.2 ± 1.2 0.87
Peak creatine kinase (units/L)  1116  (563-2146)  862  (401-1825) <0.01
Antithrombotic regimen 
 Coumarin 
 Aspirin 325 mg 
 Placebo 
 Aspirin 80 mg 
 Aspirin 80 mg + Coumarin
 
 60  (19) 
 57  (18) 
 52  (16) 
 71  (22) 
 77  (24)
 
 21  (12) 
 36  (20) 
 22  (12) 
 57  (31) 
 46  (25)
 
 
 
0.06
Angiographic characteristics
Infarct artery
 LAD
 LCX
 RCA
 138  (44)
 54  (17)
 125  (39)
 68  (37)
 23  (13)
 91  (50)
0.06
Culprit stenosis severity (%, QCA)     58.8 ± 14     61.6 ± 12 0.02
Culprit lesion morphology
 Smooth
 Complex
 204  (64)
 113  (36)
 94  (52)
 88  (48) <0.01
Single vessel disease  192  (61)  90  (49) 0.02
Left ventricular ejection fraction (%)     52.4 ± 11     53.5 ± 10 0.29
Data are presented as number (%) of subjects for discrete variables and mean ± standard deviation for continuous 
variables, except for peak creatine kinase which is presented as median (interquartile range)
CAD = coronary artery disease; LAD = left anterior descending coronary artery; LCX = left circumflex coronary artery;  
RCA = right coronary artery; QCA = quantitative coronary angiography
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Figure 2  Subgroup analyses on the odds of reocclusion in smokers and non-smokers after 
successful fibrinolysis
Variable Odds ratio (95% CI)
Overall 0.56 (0.37-0.84)
Sex
Male
Female
0.61 (0.39-0.95)
0.35 (0.12-1.03)
Age
>65 y
<65 y
1.28 (0.54-3.04)
0.47 (0.29-0.76)
Previous MI
yes
no
0.26 (0.06-1.11)
0.62 (0.40-0.96)
Diabetes
yes
no
1.14 (0.22-5.84)
0.54 (0.34-0.87)
Hypertension
yes
no
0.45 (0.19-1.07)
0.57 (0.36-0.92)
Family history of CAD
yes
no
0.59 (0.30-1.13)
0.53 (0.31-0.90)
Cholesterol
>5.0 mmol/L
<5.0 mmol/L
0.61 (0.38-0.99)
0.42 (0.18-0.96)
Infarct artery
LAD
LCX
RCA
0.66 (0.35-1.25)
0.22 (0.07-0.65)
0.63 (0.33-1.18)
Culprit stenosis severity (QCA)
>50 %
<50 %
0.60 (0.38-0.94)
0.34 (0.08-1.37)
Culprit lesion morphology
smooth
complex
0.51 (0.30-0.86)
0.57 (0.29-1.13)
Extent of CAD
single vessel disease
multi vessel disease
0.55 (0.31-0.97)
0.59 (0.33-1.08)
Ejection fraction
>50 %
<50 %
0.56 (0.33-0.93)
0.53 (0.26-1.09)
Antithrombotic regimen
Coumarin
Aspirin 325 mg
Placebo
Aspirin 80 mg
Aspirin 80 mg + Coumarin
0.19 (0.06-0.55)
0.61 (0.23-1.57)
0.44 (0.16-1.25)
0.86 (0.40-1.86)
0.61 (0.23-1.65)
0.0 0.5 1.0 1.5 2.0
smoking better non-smoking better
MI = myocardial infarction; CAD = coronary artery disease; LAD = left anterior descending coronary artery; LCX = left circumflex coronary artery; RCA
= right coronary artery: QCA = quantitative coronary angiography
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Table 2  Three-month clinical outcome
Smokers
(n = 317)
Non-smokers
(n = 182) p
Recurrent ischemic events
 Reinfarction*
 Unstable angina
 Recurrent angina with  
 documented ischemia†
 90  (28)
 20  (6)
 49  (16)
 21  (7)
 75  (41)
 14  (8)
 46  (25)
 15  (8)
<0.01
0.56
<0.01
0.50
Revascularization*
 PCI
 CABG
 43  (14)
 41  (13)
 5  (2)
 41  (23)
 40  (22)
 4  (2)
0.01
<0.01
0.62
Data are presented as number of subjects and proportions (%) per study group. 
Patients may have had events in more than one category. PCI = percutaneous coronary intervention. CABG = coronary 
artery bypass grafting. * infarct artery related; † positive stress test
Clinical presentation of reocclusion
Reocclusion presented with reinfarction in 21% (26/126) of cases. The proportion of 
reocclusions presenting with reinfarction did not differ between smokers and non-
smokers: 21% (14/67) versus 20% (12/59), p=ns. In both groups the proportion of 
reocclusions occurring with recurrent ischemic events was also similar: 51% (34/67) 
versus 58% (34/59), p=ns.
Of the patients with reocclusion 27% (34/126) underwent revascularization at the time 
of follow-up angiography with no difference between groups: 25% (17/67) in smokers 
versus 29% (17/59) in non-smokers (p=ns). 
Clinical outcome – long-term
Data on five-year survival were complete in all 499 patients (100%). The long-term use 
of antithrombotic agents (99%), beta-blockers (70%), ACE-inhibitors (45%) and statins 
(70%) did not differ between smokers and non-smokers. 
During follow-up 38 deaths were observed, 29 (76%) of which were cardiac. Five-year 
survival was 93% in smokers and 92% in non-smokers (p=ns). Cardiac survival did not 
differ either: 94% and 94%, respectively. Cardiac survival free from infarct artery related 
reinfarction was 82% in smokers and 85% in non-smokers (Figure 3, p=ns). Including 
revascularizations event-free five-year survival did not differ either: 58% and 54%, 
respectively (p=ns).
At multivariable Cox-regression analysis reocclusion (HR 2.41, 95%CI 1.05-5.56, p=0.04) 
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and left ventricular ejection fraction (HR 0.93, 95%CI 0.90-0.97, p<0.01) independently 
predicted 5-year cardiac mortality. Smoking was neither predictive of long-term cardiac 
survival (HR 1.42, 95%CI 0.55-3.63, p=ns) nor of infarct-free cardiac survival (HR 1.34, 
95%CI 0.79-2.25, p=ns). 
Figure 3  Estimated cardiac survival free from infarct artery related reinfarction in smokers and 
non-smokers after successful fibrinolysis
Discussion
This is one of the largest observations on the impact of smoking on reocclusion in patients 
with a patent infarct artery after fibrinolysis for STEMI. Smoking was independently 
associated with a markedly reduced risk of reocclusion at three months. However, even 
with more favorable clinical and angiographic baseline characteristics, smokers did not 
have improved 5-year cardiac outcome.
Baseline characteristics of smokers after successful fibrinolysis
In previous studies after fibrinolysis the paradoxical beneficial short-term outcome 
of smokers has been attributed to more favorable clinical and angiographic baseline 
characteristics and a better response to fibrinolytic therapy 4-6, 8-11. Consistent with 
0 1 2 3 4 5
0
25
50
75
100
years
log-rank
p=ns
Smokers
Non-smokers
Infarct-free cardiac survival 
n = 317 278 270 264 262 254
n = 182 167 163 159 152 150
Pe
rc
en
t s
ur
vi
va
l
%
Patients at risk*
*Patients dying from non-cardiac causes were censored at the time of death
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the latter observation we found a rate of current smokers in patients after successful 
fibrinolysis which is considerably higher than reported in the overall fibrinolysis 
population in contemporary megatrials: 64% versus 44% 22,24. Also in our study smokers 
had a more favorable clinical risk profile with younger age and less concomitant risk 
factors for coronary artery disease. At baseline angiography smokers had less extensive 
coronary artery disease with a higher rate of single vessel disease, less severe residual 
infarct-related stenoses, and more smooth infarct lesions. 
Whereas in previous trials smokers most often had infarctions related to the right 
coronary artery 4,5,8, left coronary artery infarctions predominated in smokers in our 
study. Besides a different timing of angiography (24 hours versus 90 minutes), this 
may be explained by the inclusion of only patients with a patent infarct artery. Smoking 
status predicts TIMI 3 flow independent of the infarct artery 11.
 Smoking and reocclusion
Given the strong relationship between reocclusion and outcome after successful 
fibrinolysis 12-14, previous studies addressed the risk of reocclusion in smokers in search 
for potential mechanisms explaining their favorable outcome. Results of these studies 
have been conflicting. In GUSTO-1 5-7 day follow-up angiography was performed in 75% 
of patients with a patent infarct artery (TIMI 2,3) at 90-minute angiography who were 
randomized to undergo a second angiogram 25. The unadjusted reocclusion rate (TIMI 
0,1) was significantly lower in current smokers than in non-smokers: 2.7% versus 7.7% 5. 
However, in the TAMI trials predischarge reocclusion rates in the subgroup of patients 
who did not undergo acute angioplasty were similar in smokers and non-smokers: 7.3% 
versus 9.3% 6. After primary angioplasty (half of patients receiving stents) crude 7-month 
reocclusion rates did not differ either: 7.7% versus 9.3% 26. 
The APRICOT-trials were specifically designed for the study of reocclusion in patients 
with a patent infarct artery after fibrinolysis and included mandatory follow-up 
angiography, which was performed in 89% of patients (Figure 1). Whereas previous 
studies only reported unadjusted reocclusion rates, we found a more than 40% reduced 
risk of reocclusion in smokers, even after multivariable analysis. The reduced risk was 
observed consistently across many different subgroups and occurred independent 
of antithrombotic regimen and culprit stenosis severity, a known strong predictor of 
reocclusion in this setting 27-29. The majority of reocclusions have been shown to occur 
without clinical reinfarction 12-14. In our study reocclusion occurred without clinical 
reinfarction in almost 80% of cases, while 46% of patients with reocclusion did not 
experience recurrent ischemic events. The clinical presentation of reocclusion did not 
differ between smokers and non-smokers.
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The mechanism behind the reduced risk of reocclusion in smokers may be related 
to the nature of coronary occlusions in smokers. Coronary lesions in smokers, with 
their younger age and less extensive coronary artery disease, are presumably more 
thrombotic than atherogenic in nature 6. Thrombotic lesions are more susceptible 
to regression of the culprit stenosis, which has been shown to occur before hospital 
discharge in patients treated with fibrinolysis 30. Whereas stenosis severity between 
smokers and non-smokers did not differ in studies with 90-minute angiography 5,6,9,10, a 
lower diameter stenosis has been reported in smokers before discharge 6. In our study 
with 24-hour angiography smokers also had a lower culprit diameter stenosis. These 
findings suggest that regression of the culprit stenosis in the first days after fibrinolysis 
may be more pronounced in smokers than in non-smokers. Resolution of thrombus 
material on a primarily non-atherogenic lesion may reduce the residual culprit stenosis 
and thereby the risk of reocclusion.
Smoking and clinical outcome
A lower risk of short-term mortality in smokers has been reported in a broad range 
of patients after acute myocardial infarction: after fibrinolysis 4-6,9,10,31 after primary 
angioplasty 26 and in patients with heart failure or left ventricular dysfunction 32. In most 
4-6,9,10,26, but not all 31 of these reports, the survival benefit was attributed to the favorable 
clinical and angiographic baseline characteristics in smokers. In our study smokers also 
had a more favorable clinical and angiographic risk profile. Moreover, smokers had a 
more than 40% reduced risk of reocclusion. As previously observed with respect to 
10-year cardiac outcome in APRICOT-1 16, also in the present study reocclusion was 
independently associated with a more than two-fold increased risk of long-term cardiac 
mortality. Nevertheless, no survival difference was found between smokers and non-
smokers. Notably, both in smokers and non-smokers most patients had preserved left 
ventricular function (mean ejection fraction >50%). This may explain the low five-year 
cardiac mortality rate (about 6%) in our study and also that, as a consequence, the 
moderate absolute difference in risk of reocclusion (11%) was not large enough to yield 
a difference in survival between smokers and non-smokers. Our findings resemble 
observations from GUSTO V 24, in which study a significant reduction in reinfarction did 
not result in improved short-term survival, despite the strong independent relationship 
between reinfarction and mortality after fibrinolysis 33. Analogous to that finding, a 
reduced risk of reocclusion may not automatically confer improved outcome, especially 
in a low-risk population. 
Besides the adverse impact on long-term survival, reocclusion also impairs left 
ventricular recovery 15. The lower reocclusion rate in smokers may therefore confer a 
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beneficial effect on remodeling and a lower risk to develop heart failure. Although we 
did not assess patients’ functional status, admissions for heart failure were infrequent 
and did not differ between groups.
Several studies have reported lower reinfarction rates in smokers as compared to 
non-smokers 4,5,26,31,32. In one study current smoking was independently associated 
with a lower risk of reinfarction 42 days after fibrinolysis 4. Despite the independently 
reduced risk of reocclusion in smokers in our study, the risk of reinfarction at three 
months did not differ from non-smokers. The proportion of reocclusions presenting 
with reinfarction was only about 20%, and did not differ between smokers and non-
smokers. With the 11% absolute difference in reocclusion rate between groups and the 
overall 3-month reinfarction rate of only 7% this did not result in a difference in risk of 
reinfarction between smokers and non-smokers. Notably, after fibrinolysis about half 
of the reinfarctions occur in the first 48 hours 33. The design of our study, with inclusion 
of only clinically stable patients with a patent infarct artery at 24-48 hours, precluded 
detection of a difference in the rate of these very early reinfarctions.
Non-smokers had a higher rate of early recurrent ischemic events, and, as a result 
of the ischemia-guided revascularization strategy, more often underwent early 
revascularization. Whereas routine revascularization early after fibrinolysis may be 
preventive of recurrent events 34, ischemia-guided revascularization was not associated 
with improved outcome in this study.
Data on smoking cessation during follow-up were only available in patients from 
APRICOT-2. About half of the smokers stopped immediately at the time of the index 
infarction and did not resume smoking. Despite the strong association between smoking 
cessation after acute myocardial infarction and improved outcome in past trials 35,36, five-
year infarct free survival in these ‘quitters’ did not differ from patients who continued to 
smoke or non-smokers (data not shown).
Limitations
Our observations apply to a well defined, but selected group of low-risk patients. 
Although this is a post hoc pooled analysis from two trials, the study protocols were 
almost identical and the reduced risk of reocclusion in smokers was present in both 
trials and consistent across many different subgroups.
The definition of reocclusion differed between APRICOT-1 and APRICOT-2. However, if 
only anatomical reocclusions (ECSG grade 5 and TIMI 0,1) were considered the observed 
effect of smoking on reocclusion did not change.
Five-year survival data were complete in all patients and all deaths were confirmed by 
civil registry data. Despite strenuous efforts to obtain detailed information about the 
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circumstances of death in all deceased patients and a strict definition of cardiac mortality, 
the adjudication of mortality may sometimes have been limited by the recollection of 
patients’ relatives and general practitioners. In addition, we cannot exclude that non-
fatal events may not have been reported.
The fact that APRICOT-2 was performed a decade later than APRICOT-1, in an era in 
which the use of ACE-inhibitors and statins became widespread, does not seem to have 
affected our results. To date treatment of patients after fibrinolysis is more aggressive 
than in the APRICOT trials, with higher rates of revascularization and improved 
antithrombotic therapy (new anticoagulants, clopidogrel). In the current era the risk of 
reocclusion and outcome in smokers after fibrinolysis may therefore be different than 
observed in this study.
Conclusions
Also in patients with a patent infarct artery within 48 hours after fibrinolysis, smokers 
have more favorable clinical and angiographic baseline characteristics than non-
smokers. Smoking was independently associated with a more than 40% reduced risk of 
reocclusion. However, although reocclusion independently predicted cardiac survival, 
the markedly reduced risk of reocclusion in smokers did not lead to improved outcome 
in this population of patients with a low a priori risk of adverse events. 
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Summary
The general introduction in Chapter 1 shows the beneficial effect of reperfusion 
therapy on survival in patients with ST-elevation myocardial infarction. With respect to 
fibrinolytic treatment, the importance of early patency is underlined, as well as the use of 
adjunctive antithrombotic therapy for the facilitation of reperfusion and the prevention 
of recurrent ischemic events. Subsequently, the risk and adverse clinical consequences 
of reocclusion after successful fibrinolysis are outlined. After that, a brief description of 
the design of the APRICOT-1 and APRICOT -2 trials is given, including the rationale for 
the ischemia-guided revascularization strategy which was followed. The remaining part 
of the introduction addresses the different study questions included in this thesis, with 
a focus on their scientific and clinical background, and the potential implications for 
future research and treatment.
Chapter 2 is a study on the relationship between stenosis severity, reocclusion and 
reinfarction after successful fibrinolysis. Past randomized studies on routine angioplasty 
after successful fibrinolysis were based on the premise that patients with a severe 
residual stenosis were at increased risk of reocclusion, and thereby at increased risk 
of reinfarction. However, an angiographic substudy from the TAMI trials, which was 
performed in the same era, did not find a relationship between a severe stenosis and 
recurrent events.
With a revascularization rate of only 11% at 3-months in APRICOT-1 we were able to 
study the ‘natural course’ of patients with a high-grade stenosis. In APRICOT-1 visually 
assessed stenosis severity independently predicted reocclusion. For this analysis we 
dichotomized the study population based on the optimal stenosis severity cut-point 
for reocclusion at quantitative coronary angiography. The reocclusion rate was 40% 
(47/118) in patients with a high-grade stenosis (≥ 62.7%) versus 16% (20/122) in patients 
with a low-medium-grade stenosis. At the time of follow-up angiography rates of death 
and reinfaction did not differ: 6% (7/118) versus 9% (11/122). This was explained by the 
observation that in patients with a severe stenosis reocclusion occurred without clinical 
reinfarction in 85% (40/47) of cases versus 45% (9/20) of cases in patients with a low-
medium-grade lesion (p<0.01). Although stenosis severity independently predicted 
reocclusion, it was not predictive of death or reinfarction, neither as dichotomous 
variable nor as continuous variable. Our findings suggest that periprocedural events 
were not the only explanation for the failure of routine angioplasty to reduce the risk 
of death or reinfarction in trials from the 1980s and 1990s. These trials, which primarily 
focused on dilatation of severe lesions, had clinical outcome as primary endpoint, but 
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did not include routine follow-up angiography. We found that the risk of reocclusion to 
occur with clinical reinfarction is markedly lower in patients with a high-grade residual 
stenosis than in patients with a low-medium-grade lesion. This may form an additional 
explanation for the lack of clinical benefit from routine angioplasty in these studies. 
Our findings not only complement the observations of the only previous report on this 
issue from the TAMI trials, but also extend into the long-term. Our results may carry 
important implications for the design of future trials re-evaluating a routine invasive 
strategy after successful fibrinolysis in the modern era.
Chapter 3 reports on the impact of late reocclusion on 10-year cardiac survival after 
fibrinolysis in the setting of an ischemia-guided revascularization strategy. Early 
reocclusion has been associated with a 2-fold increased risk of in-hospital mortality. After 
the acute phase higher rates of reinfarction and revascularization have been reported 
in patients with reocclusion, both on the short term and the long term. However, the 
impact of late coronary patency on long-term survival remains a matter of debate.
In APRICOT-1, 29% (71/248) of patients had a reoccluded infarct artery at 3-month 
follow-up angiography. At 10-year follow-up cardiac survival was markedly lower in 
the 71 patients with reocclusion when compared with the 177 patients with sustained 
patency: 73% versus 88%. Even in patients without recurrent ischemic symptoms (i.e. 
no reinfarction, unstable angina or stable angina with positive stress test) between 
the two angiograms, reocclusion was associated with impaired 10-year cardiac survival: 
70% cardiac survival in patients with reocclusion versus 86% in patients with sustained 
patency. Thus, even in patients without recurrent ischemia, in whom reocclusion was 
merely detected as a result of systematic follow-up angiography, reocclusion had 
adverse prognostic impact. The adverse impact was independent of left ventricular 
function, which was the only other independent long-term prognosticator in APRICOT-
1. Our findings implicate that future preventive strategies should not only focus on 
reinfarctions but also on ‘clinically silent’ reocclusions. To further optimize outcome 
after successful fibrinolysis identification of patients at increased risk of reocclusion 
and associated events is warranted. Improved antithrombotic regimens and a more 
aggressive invasive strategy appear to be key elements to reduce the risk of reocclusion 
in these patients. Long-term clinical follow-up is required to assess whether a reduction 
in reocclusion will translate in improved outcome.
In Chapter 4 the relationship between stenosis severity, reocclusion and long-term 
cardiac survival after fibrinolysis is studied. In Chapters 2 and 3, we showed that in 
APRICOT-1 stenosis severity independently predicted reocclusion, and that reocclusion 
was strongly associated with impaired 10-year cardiac survival. Therefore, it seems logical 
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to assume an association between stenosis severity and 10-year cardiac outcome. We 
dichotomized the APRICOT-1 patients in the same groups as in Chapter 2. Despite a 
more than 2-fold increased risk of reocclusion (40% versus 16%), 10-year cardiac survival 
(82% versus 86%) and infarct-free cardiac survival (70% versus 68%) did not differ 
between patients with a high-grade stenosis and patients with a low-medium-grade 
lesion. The adverse impact of reocclusion on long-term outcome was similar in the two 
groups: both patients with a high-grade stenosis and patients with a low-medium-grade 
stenosis had a 2-fold increased risk of cardiac death in case of reocclusion. Although 
the question remains whether the absence of an association between stenosis severity 
and cardiac mortality was due to a lack of power, our findings suggest that a routine 
revascularization strategy should not be restricted to patients with a severe residual 
stenosis.
In Chapter 5 the long-term follow-up results of the APRICOT-2 trial are reported. In this 
study, patients receiving a regimen of aspirin plus medium-intensity coumarin (INR 2-3), 
including prolonged heparinization until the target INR was reached, had a three-month 
reocclusion rate of 15% (19/123) when compared with a reocclusion rate of 28% (36/128) in 
patients treated with aspirin alone and standard heparinization. The combined regimen 
also resulted in lower three-month rates of reinfarction (2% versus 9%) and (ischemia-
guided) revascularization (13% versus 32%). After follow-up angiography, 66% (75/114) 
of patients, who were still using oral anticoagulation on top of aspirin, consented 
to continue this combination for a median of 9 months. The 3-month reduction in 
reinfarction was sustained at 8-year follow-up with long-term infarct-free survival 
rates of 86% in patients randomized to aspirin plus coumarin versus 71% in patients on 
aspirin alone. At multivariable analysis the beneficial effect of combination therapy was 
attributed to the reduced risk of reocclusion, which independently predicted long-term 
death and reinfarction. These observations provide mechanistic proof of the concept 
that an early reduction in reocclusion leads to improved long-term outcome and support 
a role for prolonged adjunctive anticoagulation after successful fibrinolysis.
In Chapter 6 the value of bicycle exercise testing in the prediction of reocclusion is 
studied in patients from APRICOT-2 with a stable clinical course in the first month after 
fibrinolysis. About half of reocclusions occur in patients without recurrent ischemic 
events. These reocclusions may also portend adverse cardiac outcome, as was shown 
in Chapter 3. Although stenosis severity independently predicts reocclusion, it is 
assessed invasively at angiography and a clinically useful cutoff level has so far not been 
established. A non-invasive test to discriminate between high-risk and low-risk patients 
would therefore be more ideal in the prediction of reocclusion.
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In APRICOT-2 140 patients with stable angina (NYHA class 1-2) underwent bicycle exercise 
testing (X-ECG) at a median of 30 days after fibrinolysis. At follow-up angiography the 
reocclusion rate in these patients was 17% (24/140). At the time of the X-ECG, 94% 
of patients used a beta-blocker. The strongest X-ECG variable to predict reocclusion 
was an abnormal test result, i.e. a positive test (ischemic ST-segment changes), or an 
inconclusive test (maximal heart rate less than 70% of predicted). Reocclusion rates were 
significantly higher in patients with a positive or inconclusive X-ECG than in patients 
with a negative X-ECG: 27% (14/52) versus 11% (10/88). A positive or inconclusive test was 
associated with a more than 2-fold increased risk of reocclusion and impaired five-year 
infarct-free survival. The value of X-ECG to predict reocclusion was mainly attributed 
to culprit stenosis severity, which independently predicted reocclusion, but not long-
term death or reinfarction in this study. Notably, most long-term recurrent events were 
reinfarctions occurring in patients with an infarct artery that was still patent at follow-up 
angiography.
These findings suggest that the binary result of X-ECG, which is a widely available 
non-invasive test, may be used as a surrogate for stenosis severity in the prediction of 
reocclusion in clinically stable patients. Moreover, in contrast to stenosis severity, which 
does not identify patients at increased risk of adverse long-term clinical outcome, the 
X-ECG result is an independent predictor of five-year death and reinfarction. Patients 
with a negative X-ECG are at very low risk of these events.
Chapter 7 is one of the largest studies ever reported on the impact of smoking on 
reocclusion and long-term clinical outcome in patients with a patent infarct artery 
after fibrinolysis for STEMI. Although epidemiological studies have shown that in the 
general population smokers are at increased risk of cardiovascular events, a paradoxical 
beneficial outcome has been reported in smokers with acute myocardial infarction. This 
benefit was attributed to favorable clinical and angiographic baseline variables and 
a better response to fibrinolysis. As outcome after successful fibrinolysis is strongly 
related to reocclusion, we studied the risk of reocclusion and long-term cardiac survival 
in smokers from the APRICOT-1 and APRICOT-2 trials.
At baseline 64% (317/499) of patients were current smokers. Smokers were younger (54 
versus 60 years) than non-smokers and had less risk factors for coronary artery disease. 
At baseline angiography smokers had more single vessel disease, more smooth infarct 
lesions and less severe residual stenosis of the infarct artery.
At 3 months reocclusion rates were 21% (67/317) in smokers versus 32% (59/182) in 
non-smokers (p<0.01). At multivariable analysis reocclusion independently predicted 5-
year cardiac outcome. Although smoking was independently associated with a more 
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than 40% reduced risk of reocclusion, it was not predictive of improved 5-year cardiac 
outcome in this population of patients with a low a priori risk of adverse events. These 
findings resemble observations from GUSTO V, in which a significant reduction in 
reinfarction did not improve survival, despite the well-established adverse prognostic 
impact of reinfarction. Analogous to these findings, a reduced risk of reocclusion 
may not automatically confer a beneficial effect on outcome, especially in a low-risk 
population.
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Epilogue
This thesis primarily focused on the adverse long-term prognostic consequences of 
reocclusion in patients with a patent infarct artery after fibrinolysis for acute ST-elevation 
myocardial infarction (STEMI). In addition, we studied predictors of reocclusion, 
and assessed whether these predictors were also associated with adverse long-term 
outcome. Third, we investigated whether prevention of reocclusion would translate in 
improved long-term clinical outcome. 
Our data refer to a unique study population of patients participating in the angiographic 
follow-up trials APRICOT-1 and APRICOT-2. No less than 90% of patients underwent 
follow-up angiography and 5 to 10 year clinical follow-up was nearly complete. With this 
unique design new mechanistic and clinical insights were gained. These findings may 
have important consequences for the design of future trials and, subsequently, for the 
further improvement of treatment of patients after STEMI. Based on our findings, and 
the current scientific insights, a concept for a randomized re-evaluation of routine early 
percutaneous coronary intervention after successful fibrinolysis is proposed, including 
modern reperfusion therapy, state-of-the-art revascularization techniques and intensive 
antithrombotic treatment.
Reperfusion therapy
Primary PCI has been shown to reduce 30-day mortality with 2% when compared with 
in-hospital fibrinolysis, in a meta-analysis of randomized trials 1. As a result, worldwide the 
number of STEMI patients treated with primary PCI is increasing 2. However, if primary PCI 
cannot be performed within 90-120 minutes after first medical contact, and in the absence 
of contraindications, current guidelines recommend fibrinolytic therapy 3. When compared 
to in-hospital treatment, pre-hospital fibrinolysis results in a one-hour reduction in time 
to treatment and a 1.6% reduction in in-hospital mortality 4. In the setting of a liberal 
revascularization strategy, recent studies have shown similar mortality rates with pre-
hospital fibrinolysis, when compared with primary angioplasty 5,6. Thus, when fibrinolysis 
is the reperfusion therapy of choice, treatment should be initiated prior to the patients’ 
arrival at the hospital, preferably with the use of a fibrin-specific agent 3. 
Revascularization strategy
After fibrinolysis, rescue PCI can be considered in the first 12 hours after symptom 
onset, in patients without signs of reperfusion, and with electrocardiographic signs 
of a large infarct 3. In patients with clinical signs of reperfusion (relief of pain, ST-
segment resolution, reperfusion arrhythmias), current guidelines recommend routine 
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angiography within 3 to 24 hours. These guidelines are based on several safety and 
feasibility studies on routine PCI after fibrinolysis, which showed that PCI with stenting 
can be safely performed within this time window 7-10. In contrast to the negative trials 
from the 1980s and 1990s with routine balloon angioplasty 11, combined data of these 
studies from the ‘stent era’ suggest a favorable effect of routine PCI on the combination 
of death and reinfarction 12. Importantly, in contrast to the APRICOT trials, which only 
included patients with patent infarct arteries, these studies also included a substantial 
proportion of patients with occluded infarct arteries. This results in a population with a 
higher a priori risk of both mortality and (re)occlusion 13,14, which may have contributed 
to the observed results. 
The need for routine PCI in patients with angiographically documented successful 
fibrinolysis (patent infarct artery) is less clear. To demonstrate an effect in a population 
like in the APRICOT trials in the modern era, a randomized re-evaluation of early routine 
PCI in patients with a patent infarct artery after fibrinolysis is warranted. Besides routine 
stenting, adjunctive antithrombotic therapy, i.e. glycoprotein IIb/IIIa receptor blockers 
or bivalirudin, should be used during the intervention. These agents can reduce the 
risk of procedure related events 15,16, which occurred frequently in past trials 11. Many of 
these trials used a visually assessed 60% or 70% stenosis as a cutoff point to perform 
angioplasty. In APRICOT-1, we demonstrated that reocclusion of a less severe residual 
lesion is also a frequent cause of clinical reinfarction 17. The routine intervention arm of 
a future trial should therefore not prescribe a certain cutoff point for severity of the 
culprit lesion, but target all amenable lesions. Intravascular ultrasound may guide the 
intervention, both to improve procedural outcome, and to gain detailed identification 
and characterization of the culprit lesion 18. This may have prognostic consequences, 
as previous studies suggested an association between complex lesions and impaired 
clinical outcome after angioplasty 19.
Antithrombotic treatment
Not only have the past decades shown better interventional techniques, great 
improvements have also been made in the pharmacological treatment of patients 
after STEMI. Beneficial effects have been observed with the use of ACE-inhibitors and 
statins, and antithrombotic strategies have been improved 20. Especially in patients with 
lesions not amenable for PCI, and in the setting of an ischemia-guided revascularization 
strategy, more effective antithrombotic treatment may have a beneficial effect. In 
APRICOT-2 we showed that a reduction in reocclusion with intensive antithrombotic 
therapy favorably affects long-term clinical outcome 21. 
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In an era, in which aspirin resistance has gained the interest of both researchers and 
clinicians 22, beneficial effects have been observed with the short-term addition of 
clopidogrel to aspirin. After fibrinolysis, 2 to 8 days of dual antiplatelet therapy improves 
in-hospital patency rates, a benefit that is attributed to facilitated reperfusion and a 
reduction in early reocclusion 23. In patients, who do not undergo primary PCI for STEMI, 
the addition of clopidogrel to aspirin for a mean of 15 days reduces the risk of early 
death and reinfarction 24.
With respect to anticoagulation therapy, 5-7 days of treatment with low molecular 
weight heparin tends to improve patency rates, and significantly reduces the risk of 
early reinfarction after fibrinolysis, when compared to a standard 48-72 hour regimen 
of unfractionated heparin 25-28. Lower reinfarction rates have also been observed with 
in-hospital treatment with the indirect Xa-blocker fondaparinux 29, and the direct 
thrombin inhibitor bivalirudin 30. Notably, bivalirudin can also be used as an alternative 
for glycoprotein IIb/IIIa receptor blockers and unfractionated heparin during early PCI 
after acute coronary syndromes, with a similar efficacy 16.
In trials comparing low molecular weight heparin until discharge with 48-72 hours of 
unfractionated heparin, partial or complete loss of the 30-day benefit has been observed 
at 1 year, suggesting a role for prolonged anticoagulation after discharge 20,31. This is 
supported by the observed benefits from long-term adjunctive medium-intensity oral 
anticoagulation 32, and the 6-month addition of an oral direct thrombin inhibitor to aspirin 
after myocardial infarction 33. Prolonged treatment adjunctive to aspirin with new oral 
antiplatelet agents, new oral anticoagulants, or both, is currently under investigation in 
large-scale clinical trials. The optimal duration of prolonged adjunctive antithrombotic 
therapy in addition to aspirin after fibrinolysis is yet unknown. With oral anticoagulants 
beneficial effects have been observed with 3 months to 4 years of treatment 32. Whereas 
after STEMI only short-term data on dual antiplatelet therapy with aspirin and clopidogrel 
are available 23,24, after non-ST-elevation ACS a 9-12 month period of adjunctive clopidogrel 
markedly reduced recurrent events 34. Such a period may also be considered for adjunctive 
antithrombotic treatment after fibrinolysis. However, the benefits of prolonged 
antithrombotic treatment are at the cost of an increased risk of bleeding.
In patients undergoing routine early PCI after fibrinolysis, the recommended duration 
of adjunctive treatment with clopidogrel primarily depends on the type of stent that 
is implanted and varies between one month (bare metal stents) and 6 months to one 
year (drug eluting stents) 35. In the proposed trial, the duration of adjunctive antiplatelet 
therapy and anticoagulation therapy should be identical in the routine intervention arm 
and the control arm with ischemia-guided revascularization.
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Design and endpoints
The clinical endpoint of trials on routine PCI after fibrinolysis traditionally includes a 
combination of death, reinfarction and recurrent ischemic events. So far, a beneficial 
effect on survival has not been demonstrated 12. Trials on a routine invasive strategy 
after non-ST-elevation ACS have shown that the clinical benefit of such a strategy highly 
depends on the definition of reinfarction 36. Prerequisites for a conclusive trial are a 
uniform definition of reinfarction, which should be identical in both arms, with routine 
blood sampling for cardiac markers before, and in the first 24 hours after PCI, for the 
detection of procedure related infarctions 37.
Because of the a priori low event rates after successful fibrinolysis, large patient 
numbers and long-term follow-up are required for a conclusive clinical efficacy study. 
The APRICOT studies have shown that reocclusion independently predicts long-term 
cardiac outcome after successful fibrinolysis, even if it occurs without recurrent 
ischemic events 21,38-40. Previously the beneficial effects of sustained patency on recovery 
of left ventricular function were demonstrated 41. To reduce the number of patients 
required for a conclusive study a primary angiographic endpoint could therefore also 
be considered, i.e. the incidence of reocclusion, or improvement in left ventricular 
ejection fraction between baseline and follow-up. With routine follow-up angiography 
included in the protocol the observations reported in this thesis can be prospectively 
tested in the modern era of improved pharmacological and interventional strategies. In 
addition, routine angiographic follow-up will provide important additional insights in 
the relationship between reocclusion and clinical outcome. Reported reocclusion rates 
after stenting are much lower than after fibrinolysis, with an incidence of about 5% 
to 6% in the first 6 months after primary PCI 42. However, many of these reocclusions 
are attributed to stent thrombosis, which is associated with a very high risk of death 
and reinfarction. Mortality rates of up to 45% have been reported with thrombosis of 
drug eluting stents 43. Therefore, it remains to be determined whether a reduction in 
reocclusion with routine stenting will improve prognosis after successful fibrinolysis. 
Besides the insights gained with follow-up angiography, the inclusion of other substudies 
in the study protocol may add important scientific value. Markers of inflammation and 
genetic profiles could potentially be used to predict reocclusion, clinical events, or the 
response to therapy. Furthermore, it would be of interest to investigate whether new 
non-invasive imaging techniques have the potential to obviate the need for invasive 
procedures in subsets of patients. 
This thesis illustrates that conceptual studies initiated by clinicians themselves can 
provide novel scientific insights, that may have great value for the development of future 
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research and further improvement of patient care. Unfortunately, funds to perform 
these studies are hard to acquire, and mechanistic studies often are not powered to 
be conclusive with respect to clinical outcome. In contrast, industry sponsored clinical 
mega-trials are powered to be conclusive with respect to the primary clinical endpoint, 
but not always include conceptual substudies to confirm the suggested mechanism of 
benefit of a new agent or treatment strategy. This may occasionally lead to a situation 
in which the exact cause of a negative study result cannot be determined. The scientific 
question, whether a lack of benefit is attributed to lower than expected event rates, 
or whether the suggested mechanism of benefit failed to improve clinical outcome, 
remains unresolved. In this respect, the landmark GUSTO-1 trial is the best example, 
that incorporation of an angiographic substudy in a large-scale clinical trial, with 
mortality as primary endpoint, can offer unique insights and understanding 13. Most of 
our knowledge on the pathophysiological aspects, risk stratification and mechanism 
of benefit of reperfusion therapy for acute ST-elevation myocardial infarction was 
derived from this study. Although the role of fibrinolysis in the treatment of STEMI 
patients may be declining, both clinicians and researchers in the field of acute coronary 
syndromes should take advantage from the lessons that can be learned from GUSTO-
1 and other historical reperfusion trials. Instead of focusing on a positive trial result 
alone, the incorporation of mechanistic substudies in the design of future clinical trials 
may lead to new, and sometimes unexpected, scientific insights, that may guide the way 
for future research and further improvement of treatment.
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Samenvatting
In de algemene introductie in Hoofdstuk 1 wordt het gunstige effect van reperfusie 
therapie op de overleving van patiënten met een ST-elevatie myocardinfarct getoond. 
Ten aanzien van fibrinolyse wordt het belang van vroege reperfusie onderstreept en 
is er aandacht voor aanvullende behandeling met antithrombotica om reperfusie te 
faciliteren en (dreigende) recidief infarcten te voorkomen. Vervolgens komen het risico 
op reocclusie en de nadelige klinische consequenties daarvan aan bod. Daarna volgt 
een korte beschrijving van de studie opzet van de APRICOT-1 en APRICOT-2 studies en 
wordt uitgelegd waarom in deze studies een dotterbehandeling (PCI) of bypass-operatie 
(CABG) alleen plaats vond als er aanwijzingen waren voor ischemie. 
Het overige deel van de introductie betreft een beschrijving van de verschillende 
studievragen die in dit proefschrift aan de orde komen. Daarbij gaat de aandacht 
met name uit naar de wetenschappelijke en klinische achtergronden en de mogelijke 
implicaties voor onderzoek en behandeling in de toekomst. 
Hoofdstuk 2 is een studie naar de relatie tussen de ernst van de vernauwing (stenose) 
in het infarct vat, met enerzijds de kans op reocclusie en anderzijds de kans op recidief 
infarct na succesvolle behandeling met fibrinolyse. Vroegere gerandomiseerde 
onderzoeken naar routinematige PCI waren gebaseerd op de veronderstelling dat een 
ernstige resterende stenose na fibrinolyse was geassocieerd met een verhoogd risico op 
reocclusie en daarmee met een verhoogd risico op recidief infarct. In een angiografische 
substudie van de TAMI-trials uit dezelfde periode werd echter geen relatie gevonden 
tussen een ernstige stenose en de kans op terugkerende ischemische gebeurtenissen.
In de eerste 3 maanden van de APRICOT-1 studie onderging slechts 11% van de patiënten 
een dotterbehandeling of CABG. Dit bood ons de gelegenheid om het ‘natuurlijke 
beloop’ van een ernstige resterende stenose in het infarct vat na succesvolle fibrinolyse 
te bestuderen. In de APRICOT-1 studie was een op het oog meer dan 90% stenose 
van het infarct vat een onafhankelijke voorspeller van reocclusie. Voor dit onderzoek 
bepaalden we met quantitatieve coronair angiografie zo precies mogelijk de stenose 
graad die de kans op reocclusie optimaal voorspelde. Zo konden we onderzoeken of 
patiënten met een ernstige stenose, die een verhoogde kans op reocclusie hadden, 
ook een verhoogde kans op een recidief infarct hadden. Bij patiënten met een ernstige 
stenose (≥ 62.7%) bedroeg het reocclusie percentage 40% (47/118), vergeleken met 
16% (20/122) bij patiënten met een milde of matig ernstige stenose. Ten tijde van het 
follow-up angiogram was er geen verschil in de percentages van recidief infarct in beide 
groepen: 6% (7/118) versus 9% (11/122). Dit werd verklaard door de observatie dat bij 
Peter Kievit-boek.indb   159 12-02-2009   17:50:11
Chapter 9
160
patiënten met een ernstige stenose reocclusie in 85% (40/47) van de gevallen optrad 
zonder dat er klinisch sprake was van een recidief infarct, terwijl dit bij patiënten met een 
milde of matig ernstige vernauwing slechts bij 45% (9/20) van de reocclusies het geval 
was. Hoewel de ernst van de stenose onafhankelijk de kans op reocclusie voorspelde, 
was het geen voorspeller van dood of recidief infarct, noch als binaire variabele noch als 
continue variabele. Onze bevindingen suggereren dat peri-procedurele infarcten niet 
de enige verklaring waren voor het feit dat routinematig dotteren in studies uit de jaren 
’80 en ’90 van de vorige eeuw geen klinische verbetering gaf. In deze studies werd 
ballondilatatie verricht van voornamelijk ernstige stenoses en werd alleen gekeken naar 
klinische eindpunten, terwijl er niet routinematig follow-up angiografie verricht werd. 
Bij patiënten met een ernstige stenose presenteert reocclusie zich klinisch minder vaak 
met een recidief infarct. Dit vormt mogelijk een additionele verklaring voor het gebrek 
aan profijt van een dotterbehandeling in deze studies. 
Niet alleen complementeren onze bevindingen de observaties van de enige voorgaande 
angiografische studie betreffende dit onderwerp afkomstig uit de TAMI-trials, maar ze 
breiden deze ook uit naar klinische uitkomsten op de lange termijn. Onze resultaten 
kunnen belangrijke consequenties hebben voor de opzet van toekomstige studies naar 
een moderne routinematige invasieve strategie na succesvolle fibrinolyse.
Hoofdstuk 3 beschrijft de gevolgen van late reocclusie op de 10-jaars cardiale overleving 
na succesvolle fibrinolyse. Vroege reocclusie is geassocieerd met een tweevoudig 
verhoogd risico op overlijden in het ziekenhuis. Als reocclusie optreedt na de acute fase 
is er een verhoogde kans op recidief infarct en klinische noodzaak tot PCI of CABG, 
zowel op de korte als de lange termijn. Over het belang van een open infarct vat voor de 
lange termijn overleving bestaat echter nog steeds discussie.
In de APRICOT-1 studie trad bij 29% (71/248) van de patiënten binnen 3 maanden reocclusie 
op van de infarct arterie. Na 10 jaar follow-up was de cardiale overleving duidelijk lager 
in de 71 patiënten met reocclusie vergeleken met de 177 patiënten bij wie het vat open 
gebleven was: 73% versus 88%. Zelfs bij patiënten die geen klinische tekenen hadden van 
terugkerende ischemie (dat wil zeggen geen recidief infarct, instabiele angina pectoris 
of stabiele angina pectoris met een positief inspanningsonderzoek) was reocclusie 
geassocieerd met verminderde 10-jaars cardiale overleving: 70% cardiale overleving bij 
patiënten met reocclusie versus 86% bij patiënten met een open vat. Reocclusie had dus 
zelfs negatieve prognostische consequenties bij patiënten zonder recidief ischemie, bij 
wie de reocclusie louter vastgesteld was door het systematisch verrichten van follow-
up angiografie. Het negatieve prognostische effect van reocclusie was onafhankelijk 
van linker ventrikel functie, de enige andere onafhankelijke voorspeller van de kans op 
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overlijden aan een cardiale oorzaak na 10 jaar follow-up in APRICOT-1. Onze bevindingen 
impliceren dat toekomstige preventieve strategieën zich niet alleen moeten richten 
op het voorkomen van klinische recidief infarcten, maar ook op preventie van de 
zogenaamde ‘stille’ reocclusies.  Om de klinische uitkomst na succesvolle fibrinolyse 
verder te verbeteren, dienen patiënten met een verhoogd risico op reocclusie en de 
daarmee gepaard gaande klinische complicaties geïdentificeerd te worden. Betere 
antithrombotische therapie en een aggressievere revascularisatie strategie lijken de 
belangrijkste pijlers te worden van toekomstig beleid ter preventie van reocclusie bij 
deze patiënten. Lange termijn klinische follow-up zal nodig zijn om na te gaan of het 
reduceren van de kans op reocclusie leidt tot verbetering van de prognose.
In Hoofdstuk 4 wordt de relatie tussen ernst van de stenose, reocclusie en lange termijn 
cardiale overleving na fibrinolyse bestudeerd. Gezien enerzijds de onafhankelijke relatie 
tussen ernst van de stenose en reocclusie en anderzijds de relatie tussen reocclusie 
en lange termijn cardiale sterfte, is het voor de hand liggend om een relatie tussen 
stenose ernst en lange termijn cardiale sterfte te veronderstellen. We verdeelden de 
APRICOT-1 patiënten in dezelfde twee groepen als in Hoofdstuk 2. Ondanks een meer 
dan verdubbeling van de kans op reocclusie (40% versus 16%), verschilden cardiale 
overleving (82% versus 86%) en cardiale overleving zonder recidief infarct (70% versus 
68%) na 10 jaar follow-up niet tussen patiënten met een ernstige stenose en patiënten 
met een milde of matige resterende stenose in het infarct vat. Het ongunstige effect van 
reocclusie op de lange termijn prognose was vergelijkbaar in de twee groepen: zowel 
patiënten met een ernstige stenose als patiënten met een milde of matige resterende 
stenose hadden tweemaal zoveel kans op cardiale sterfte in geval van reocclusie. 
Hoewel het de vraag blijft of de afwezigheid van een relatie tussen stenose ernst en 
cardiale sterfte het gevolg was van onvoldoende power van het onderzoek, suggereren 
onze resultaten wel dat strategieën om reocclusie te voorkomen na fibrinolyse, zoals 
routinematige revascularisatie en intensievere antithrombotische therapie, niet beperkt 
moeten blijven tot patiënten met een ernstige stenose.
In Hoofdstuk 5 worden de lange termijn follow-up resultaten van het APRICOT-2 
onderzoek gerapporteerd. In dit onderzoek bedroeg het reocclusie percentage na 3 
maanden 15% (19/123) bij patiënten die behandeld werden met aspirine plus matige 
intensiteit orale antistolling (INR 2-3), inclusief verlengde heparine infusie tot een 
adequate INR was bereikt. Het reocclusie percentage in de groep patiënten die alleen 
aspirine kreeg met standaard heparine infusie was 28% (36/128). De combinatie van 
aspirine en orale antistolling resulteerde ook in minder recidief infarcten (2% versus 
9%) en minder revascularisaties (13% versus 32%) na 3 maanden. Na het follow-up 
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angiogram stemde 66% (75/114) van de patiënten, die naast aspirine nog steeds orale 
antistolling gebruikten, er mee in om deze combinatie voor de duur van maximaal 1 jaar 
te continueren. De lagere kans op een recidief infarct na 3 maanden bleek ook na 8 jaar 
follow-up nog aanwezig. De overleving zonder recidief infarct was beduidend hoger bij 
patiënten die gerandomiseerd waren naar aspirine en antistolling: 86% versus 71%. Bij 
multivariabele analyse bleek dat het gunstige effect van combinatie therapie was toe te 
schrijven aan een verminderde kans op reocclusie, wat een onafhankelijke voorspeller 
was van de kans op overlijden of recidief infarct op de lange termijn. Deze observaties 
verschaffen mechanistisch bewijs voor het concept dat reductie van reocclusie leidt 
tot verbetering van de klinische uitkomst op de lange termijn. Tevens ondersteunen 
onze bevindingen het nut van het gedurende langere tijd toevoegen van antistolling 
aan aspirine na succesvolle fibrinolytische therapie.
In Hoofdstuk 6 wordt de waarde van inspanningselektrocardiografie onderzocht bij 
het voorspellen van reocclusie bij patiënten uit APRICOT-2 met een stabiel klinisch 
beloop in de eerste maand na fibrinolyse. Ongeveer de helft van de reocclusies treedt 
op zonder dat er klinisch sprake is van een terugkerende ischemische gebeurtenis. 
Zoals beschreven in Hoofdstuk 3 kunnen ook dergelijke reocclusies de lange termijn 
prognose ongunstig beïnvloeden. Hoewel de ernst van de stenose een onafhankelijke 
voorspeller is van reocclusie, kan deze alleen invasief worden bepaald bij angiografie 
en is er nog nooit een klinisch bruikbare grenswaarde vastgesteld. Een niet-invasief 
onderzoek, dat op eenduidige wijze onderscheid kan maken tussen patiënten met 
een hoog risico en patiënten met een laag risico, heeft dan ook de voorkeur bij het 
voorspellen van reocclusie.
In APRICOT-2 ondergingen 140 patiënten met stabiele angina pectoris (NYHA klasse 1-2) 
in de eerste maand na fibrinolyse inspanningselectrocardiografie (X-ECG) door middel 
van fietsergometrie. Zeventien procent (24/140) van deze patiënten had reocclusie van 
de infarct arterie bij follow-up angiografie. Ten tijde van het X-ECG gebruikte 94% van de 
patiënten een beta-blokker. De sterkste voorspeller van reocclusie bij het X-ECG was een 
afwijkend testresultaat, dat wil zeggen een positieve of inconclusieve test. Deze waren 
respectievelijk gedefinieerd als ischemische ST-segment veranderingen bij inspanning, 
dan wel een maximale hartfrequentie minder dan 70% van voorspeld, op grond van de 
leeftijd. Het reocclusie percentage was beduidend hoger bij patiënten met een positieve 
of inconclusieve inspanningstest dan bij patiënten met een negatief testresultaat: 27% 
(14/52) versus 11% (10/88). Patiënten met een positieve of inconclusieve inspanningstest 
hadden een meer dan tweevoudig verhoogde kans op reocclusie en minder kans om in 
de eerstkomende 5 jaar te overleven zonder een recidief infarct te krijgen. De waarde 
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van het inspannings-ECG om reocclusie te voorspellen berustte voornamelijk op de 
ernst van de resterende stenose in het infarct vat. In deze patiënten groep was de ernst 
van de stenose een onafhankelijke voorspeller van reocclusie, maar niet van de kans 
op overlijden of recidief infarct in de komende 5 jaar. Hierbij moet worden opgemerkt 
dat de meeste lange termijn klinische gebeurtenissen in deze studie recidief infarcten 
betroffen, die optraden bij patiënten bij wie het infarct vat bij follow-up angiografie nog 
open was. Deze bevindingen suggereren dat de binaire uitkomst van het inspannings-
ECG, wat een makkelijk toegankelijk non-invasief onderzoek is, gebruikt kan worden 
als surrogaat voor ernst van de stenose bij het voorspellen van reocclusie bij klinisch 
stabiele patiënten na succesvolle fibrinolyse. In tegenstelling tot de ernst van de 
stenose bij angiografie, die geen voorspeller is van lange termijn klinische uitkomst, is 
het resultaat van het inspannings-ECG bovendien een onafhankelijke voorspeller van 
de kans op overlijden of recidief infarct in de eerste 5 jaar. Patiënten met een negatief 
inspanningsonderzoek hebben een uitstekende 5-jaars prognose.
Hoofdstuk 7 betreft een van de grootste studies die ooit gepubliceerd is naar de 
effecten van roken op enerzijds de kans op reocclusie en anderzijds de lange termijn 
prognose bij patiënten met een doorgankelijk infarct vat na fibrinolyse. Epidemiologische 
onderzoeken hebben laten zien dat in de algemene bevolking rokers die niet bekend 
zijn met hart- en vaatziekten een verhoogde kans hebben om een myocardinfarct te 
krijgen. Bij rokers die een myocardinfarct doormaken daarentegen, is juist een gunstige 
korte termijn prognose beschreven. Deze paradoxale bevinding wordt toegeschreven 
aan gunstige klinische en angiografische baseline karakteristieken en een betere 
respons op fibrinolyse bij rokers. Omdat de prognose na succesvolle fibrinolyse sterk 
samenhangt met het optreden van reocclusie, bestudeerden we de kans op reocclusie 
en de lange termijn cardiale overleving bij rokers, die participeerden in de APRICOT-1 
en APRICOT-2 studies.
Bij aanvang van de studie rookte 64% (317/499) van de patiënten. Rokers waren 
gemiddeld jonger dan niet-rokers (54 jaar versus 60 jaar) en hadden minder traditionele 
risicofactoren voor coronaire hartziekte. Bij angiografie aan het begin van de studie 
hadden rokers meer 1-vatslijden, meer gladde infarct letsels en minder ernstige stenoses 
in de aan het infarct gerelateerde coronairarterie.
Na 3 maanden had 21% (67/317) van de rokers reocclusie ten opzichte van 32% (59/182) 
van de niet-rokers (p<0.01). Bij multivariabele analyse was reocclusie een onafhankelijke 
voorspeller van cardiale sterfte en recidief infarct. Hoewel roken onafhankelijk 
geassocieerd was met een 40% lagere kans op reocclusie, hadden rokers in deze 
populatie van laag risico patiënten geen betere cardiale prognose. Onze uitkomsten 
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vertonen gelijkenis met observaties in GUSTO V, waarin een significante reductie 
in de kans op recidief infarct niet leidde tot een verbeterde overleving, ondanks de 
onafhankelijke relatie tussen recidief infarct en overleving na fibrinolyse. Analoog aan 
deze bevindingen, leidt een verminderde kans op reocclusie niet automatisch tot een 
verbetering van de prognose, zeker niet in een laag-risico populatie.
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Epiloog
Dit proefschrift heeft zich met name gericht op de ongunstige effecten van reocclusie 
op de lange termijn overleving van patiënten met een open infarct gerelateerde arterie 
na fibrinolyse voor een acuut ST-elevatie myocardinfarct (STEMI). Daarnaast werden 
voorspellers van reocclusie bestudeerd en werd vastgesteld of die voorspellers ook 
geassocieerd waren met een slechte klinische uitkomst. Tenslotte werd onderzocht of 
preventie van reocclusie ook leidt tot verbetering van de lange termijn prognose.
De beschreven patiënten namen deel aan de APRICOT-1 en APRICOT-2 studies en 
vertegenwoordigen een unieke studie populatie. Routinematige follow-up angiografie 
vond plaats bij bijna 90% van de patiënten en 5- tot 10-jaars klinische follow-up was 
vrijwel compleet. Met deze unieke studieopzet zijn nieuwe mechanistische en klinische 
inzichten verworven, die belangrijke consequenties kunnen hebben voor het protocol 
van toekomstige studies en de verdere verbetering van de behandeling van patiënten 
met een STEMI.
Op basis van onze bevindingen en de huidige wetenschappelijke inzichten wordt een 
concept voor een gerandomiseerde studie voorgesteld, om het effect van routinematige 
vroege percutane coronaire interventie (PCI) na succesvolle fibrinolyse te herevalueren. 
Hierbij dient gebruik gemaakt te worden van moderne reperfusie therapie, state-of-the-
art revascularisatie technieken en intensieve antithrombotische behandeling.
Reperfusie therapie
Een meta-analyse van gerandomiseerde studies heeft laten zien dat primaire PCI de 
30 dagen sterfte na een STEMI met 2% vermindert ten opzichte van behandeling met 
fibrinolyse in het ziekenhuis 1. Wereldwijd neemt het aantal STEMI patiënten dat een 
primaire PCI ondergaat dan ook toe 2. Echter, als primaire PCI niet binnen 90-120 minuten 
na het eerste medische contact kan worden uitgevoerd en er geen contra-indicaties 
bestaan, bevelen de huidige richtlijnen fibrinolyse aan 3. Vergeleken met behandeling in 
het ziekenhuis, vermindert pre-hospitale fibrinolyse de tijd tot het starten van reperfusie 
therapie met één uur, met als gevolg een 1.6% reductie in sterfte in het ziekenhuis 4. In 
recente studies, waarin een liberaal revascularisatie beleid gevolgd werd na fibrinolyse, 
is de sterfte na pre-hospitale fibrinolyse vergelijkbaar met de sterfte na primaire PCI 
5,6. Wanneer er gekozen wordt om te behandelen met fibrinolyse, heeft het daarom de 
voorkeur om de behandeling aan te vangen voordat de patiënt het ziekenhuis bereikt, 
liefst met gebruik van een fibrine-specifiek fibrinolyticum 3. 
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Revascularisatie strategie
Na fibrinolyse kan bij patiënten zonder tekenen van reperfusie en met electrocardio-
grafisch aanwijzingen voor een groot myocardinfarct, tot 12 uur na het ontstaan van 
klachten een zogenaamde ‘rescue’ PCI worden overwogen 3. Bij patiënten met klinische 
tekenen van reperfusie (afname van pijn, ST-segment resolutie, reperfusie aritmieën), 
wordt door de huidige richtlijnen aanbevolen om binnen 3 tot 24 uur routinematig 
angiografie te verrichten. Deze richtlijnen zijn gebaseerd op enkele recente studies naar 
de veiligheid en uitvoerbaarheid van routinematige vroege interventie na fibrinolyse, 
waaruit is gebleken dat PCI met stentimplantatie binnen dit tijdsbestek veilig kan worden 
uitgevoerd 7-10. In tegenstelling tot de negatieve resultaten van studies uit de jaren ’80 
en ’90 van de vorige eeuw, waarin alleen ballondilatatie werd verricht 11, suggereren 
gecombineerde data van deze studies dat in het huidige ‘stent-tijdperk’ routinematige 
PCI wel een gunstig effect heeft op het optreden van overlijden of recidief infarct 12. In 
tegenstelling tot de APRICOT-studies, waaraan alleen patiënten met een open infarct 
arterie deelnamen, zat in deze onderzoeken ook een substantieel aantal patiënten met 
een geoccludeerd vat. De hogere vooraf kans op dood en (re)occlusie bij deze patiënten 
heeft mogelijk bijgedragen aan de behaalde resultaten 13,14. 
Het is nog onduidelijk of routinematige PCI noodzakelijk is bij patiënten met angiografisch 
bewijs voor succesvolle fibrinolyse (open infarct gerelateerde arterie). Om in het huidige 
tijdperk een effect aan te tonen in een populatie zoals in de APRICOT studies, is een 
gerandomiseerd onderzoek noodzakelijk naar het effect van routinematige PCI bij 
patiënten met een open infarctvat na fibrinolyse. Naast routinematig stenten, dient 
tijdens de interventie aanvullende antithrombotische therapie toegediend te worden 
in de vorm van glycoproteïne IIb-IIIa receptor blokkers of bivalirudine. Deze middelen 
kunnen het risico verminderen op het optreden van procedure gerelateerde infarcten 
15,16, die in de vroegere studies frequent voorkwamen 11. Veel van deze studies gebruikten 
een visueel bepaalde 60% of 70% vernauwing als grenswaarde voor het verrichten van 
ballondilatatie. In de APRICOT-1 studie hebben wij echter laten zien dat reocclusie van 
een minder ernstige vernauwing ook vaak gepaard gaat met een klinisch recidief infarct 
17. In een toekomstige studie moet de arm met routinematige interventie daarom geen 
grenswaarde voor de ernst van de stenose hanteren, maar alle letsels die toegankelijk 
zijn voor PCI attaqueren. De interventie zou verricht kunnen worden op geleide van 
intravasculair ultra geluidsonderzoek (IVUS), enerzijds om een beter procedure resultaat 
te behalen, en anderzijds om een gedetailleerd beeld van de culprit laesie te verkrijgen 
18. Dit heeft mogelijk prognostische consequenties, aangezien vroegere angiografische 
studies suggereerden dat patiënten met complexe letsels een slechtere uitkomst 
hebben na PCI 19.
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Antithrombotische therapie
Naast de beschreven verbetering van de interventie technieken, is er in de afgelopen 
decennia ook grote vooruitgang geboekt in de farmacologische behandeling van 
patiënten met een STEMI. Het gebruik van ACE-remmers en statines heeft een gunstig 
effect laten zien en de antithrombotische behandeling is verder verbeterd 20. Met name 
bij patiënten met letsels die niet geschikt zijn voor PCI of wanneer revascularisatie alleen 
plaatsvindt bij terugkerende ischemie, lijkt effectievere antithrombotische therapie een 
gunstig effect te kunnen hebben. Zo hebben we in de APRICOT-2 studie laten zien dat 
een reductie in reocclusie met intensieve antithrombotische therapie de kans verlaagt 
om op lange termijn te overlijden of een recidief infarct te krijgen 21.
In het huidige tijdperk, waarin zowel clinici als onderzoekers geïnteresseerd zijn geraakt 
in aspirine-resistentie 22, zijn goede resultaten behaald met het kortdurend toevoegen van 
clopidogrel aan aspirine. Na fibrinolyse leidt dubbele antiplaatjes therapie gedurende 2 
tot 8 dagen tot meer open infarct gerelateerde bloedvaten tijdens de ziekenhuisopname. 
Dit gunstige effect wordt toegeschreven aan verbeterde reperfusie en een reductie in 
vroege reocclusie 23. Bij patiënten, die niet met primaire PCI worden behandeld voor een 
STEMI, reduceert het gedurende 15 dagen toevoegen van clopidogrel aan aspirine het 
korte termijn risico op overlijden en recidief infarct 24.
Bij de anticoagulantia levert 5-7 dagen behandeling met laag moleculair gewicht heparines 
een trend op ten aanzien van meer open vaten en een significante reductie in de kans 
op een vroeg recidief infarct, als vergeleken wordt met standaard behandeling met 
ongefractioneerde heparine gedurende 48-72 uur 25-28. Met behandeling gedurende de 
ziekenhuisopname zijn eveneens lagere percentages van recidief infarct waargenomen 
met de indirecte factor Xa blokker fondaparinux 29 en de directe thrombine remmer 
bivalirudine 30. Bivalirudine kan bovendien gebruikt worden als alternatief voor de 
combinatie van glycoproteïne IIb-IIIa receptor blokkers en ongefractioneerde heparine 
tijdens vroege PCI na een acuut coronair syndroom 16.
In verschillende studies waarbij het gebruik van laag moleculair gewicht heparines tot 
ontslag wordt vergeleken met ongefractioneerde heparine, is de winst in de eerste 
30 dagen na een jaar gedeeltelijk of soms zelfs geheel verdwenen 20,31. Deze bevinding 
suggereert dat er met het continueren van anticoagulantia na ontslag nog winst geboekt 
zou kunnen worden. Deze suggestie wordt ondersteund door de gunstige resultaten 
van het langdurig continueren van matige intensiteit orale antistolling naast aspirine 
32 of het gedurende 6 maanden toevoegen van een orale directe thrombine remmer 
aan aspirine 33. Het effect van langdurige behandeling met aspirine in combinatie 
met nieuwe orale antiplaatjes therapie, nieuwe orale anticoagulantia, of beide, wordt 
momenteel onderzocht in enkele grootschalige klinische studies. De optimale duur 
Peter Kievit-boek.indb   167 12-02-2009   17:50:13
Chapter 9
168
van lange termijn behandeling met antithrombotica naast aspirine na fibrinolyse is 
nog niet bekend. Met orale antistolling toegevoegd aan aspirine zijn gunstige effecten 
gezien met behandeling gedurende 3 maanden tot maximaal 4 jaar 32. Hoewel na STEMI 
alleen korte termijn gegevens voorhanden zijn van dubbele antiplaatjes therapie 23,24, 
reduceert het toevoegen van clopidogrel aan aspirine gedurende 9 tot 12 maanden na 
een non-ST-elevatie acuut coronair syndroom de kans op terugkerende ischemische 
gebeurtenissen 34. Een dergelijke periode zou ook overwogen kunnen worden voor 
aanvullende antithrombotische behandeling na fibrinolyse. Men moet zich echter wel 
realiseren dat de baten van het langdurig toevoegen van antithrombotica aan aspirine 
gepaard gaan met een verhoogd bloedingsrisico.
Bij patiënten die routinematig een vroege PCI ondergaan na fibrinolyse hangt de duur 
van aanvullende behandeling met clopidogrel in eerste instantie af van het type stent 
dat geïmplanteerd wordt. De behandelingsduur varieert van 1 maand bij een ‘bare metal’ 
stent tot 6-12 maanden na implantatie van een ‘drug-eluting’ stent 35. In de voorgestelde 
studie moet de duur van toegevoegde antiplaatjes en antistollings therapie identiek 
zijn in de arm met routinematige interventie en de arm met revascularisatie op geleide 
van terugkerende ischemie. 
Studie opzet en eindpunten
Het klinische eindpunt van studies na routinematige PCI omvat doorgaans een combinatie 
van dood, recidief infarct en andere terugkerende ischemische gebeurtenissen. 
Een gunstig effect op overleving is tot dusverre niet aangetoond 12. Studies, die een 
routinematige invasieve strategie na non-ST-elevatie acute coronaire syndromen 
onderzochten, hebben laten zien dat de effectiviteit van een dergelijke strategie nauw 
samenhangt met de definitie van recidief infarct die wordt gehanteerd 36. Voorwaarden 
voor een conclusieve studie zijn dan ook een uniforme definitie van recidief infarct, die 
in beide armen van het onderzoek identiek moet zijn, terwijl vóór en in de eerste 24 
uur na een PCI de cardiale markers vervolgd moeten worden ter detectie van eventuele 
procedure gerelateerde infarcten 37.
Gezien de lage event rates, die inherent zijn aan succesvolle fibrinolytische behandeling, 
zijn grote patiënten aantallen dan wel langdurige klinische follow-up nodig voor een 
conclusieve studie met een primair klinisch eindpunt. De APRICOT studies hebben 
laten zien dat reocclusie een onafhankelijke voorspeller is van de lange termijn cardiale 
prognose na succesvolle fibrinolyse, zelfs wanneer reocclusie optreedt zonder dat er 
sprake is van een nieuwe ischemische gebeurtenis 21,38-40. Eerder heeft onze studiegroep 
reeds laten zien dat een persisterend open infarct gerelateerd vat een gunstig effect 
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heeft op herstel van linker ventrikel functie na succesvolle fibrinolyse 41. Om het aantal 
patiënten dat voor een conclusief studieresultaat noodzakelijk is te reduceren, kan 
daarom ook overwogen worden om in het voorgestelde onderzoek gebruik te maken 
van een primair angiografisch eindpunt, zoals reocclusie of linker ventrikel functie. Het 
toevoegen van routinematige follow-up angiografie aan het studie protocol biedt de 
mogelijkheid om de bevindingen uit dit proefschrift prospectief te onderzoeken in het 
huidige tijdperk van verbeterde farmacologische therapie en interventie technieken. 
Daarnaast kan routinematige follow-up angiografie belangrijke nieuwe inzichten 
opleveren in de relatie tussen reocclusie en klinische uitkomst. Zo is de kans op 
reocclusie na stentimplantatie veel lager dan na fibrinolyse. Reocclusie treedt in de 
eerste 6 maanden na primaire PCI met stentimplantatie op bij ongeveer 5-6% van de 
patiënten 42. Veel van deze reocclusies zijn echter het gevolg van stent thrombose. Stent 
thrombose gaat gepaard met een sterk verhoogd risico op dood en recidief infarct. Bij 
thrombose van drug eluting stents zijn mortaliteitspercentages tot 45% beschreven 43. 
Het blijft daarom de vraag of met routinematig stenten na succesvolle fibrinolyse een 
reductie in de kans op reocclusie ook zal leiden tot een verbetering van de prognose. 
Naast de inzichten die met follow-up angiografie worden verkregen, kan het toevoegen 
van andere substudies de wetenschappelijke waarde van het voorgestelde onderzoek 
verder vergroten. Markers van inflammatie en genetische profielen zouden gebruikt 
kunnen worden om de kans op reocclusie, klinische events en de respons op therapie 
te voorspellen. Verder is het interessant om na te gaan of nieuwe non-invasieve 
beeldvormende technieken de noodzaak voor invasieve procedures bij sommige 
patiënten groepen kunnen verminderen.
Dit proefschrift illustreert dat door clinici zelf opgezette conceptuele studies nieuwe 
wetenschappelijke inzichten kunnen opleveren met grote waarde voor het ontwikkelen 
van toekomstig onderzoek en de verdere verbetering van de patiëntenzorg. Helaas is 
het vaak moeilijk om genoeg fondsen voor dergelijk onderzoek te verkrijgen, waardoor 
mechanistische studies vaak niet groot genoeg zijn om conclusies te kunnen trekken 
ten aanzien van het effect op klinische uitkomsten. Dit in tegenstelling tot door de 
industrie gesponsorde mega trials, die opgezet zijn om een klinisch effect aan te 
tonen, maar veelal een conceptuele substudie ontberen, die het veronderstelde 
werkingsmechanisme van de nieuwe behandeling zou kunnen bevestigen. Hierdoor 
kan een situatie ontstaan, waarin de oorzaak van een negatief studieresultaat niet 
kan worden achterhaald. De wetenschappelijke vraag of een gebrek aan klinisch 
effect het gevolg is van een lager dan verwacht aantal klinische eindpunten, of dat het 
veronderstelde werkingsmechanisme niet leidde tot een gunstig klinisch effect, kan 
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dan niet worden opgehelderd. In dit opzicht is de fameuze GUSTO-1 studie het beste 
voorbeeld, dat het toevoegen van een angiografische substudie aan een grote klinische 
trial met mortaliteit als primaire eindpunt, unieke inzichten kan opleveren 13. De meeste 
van onze huidige kennis ten aanzien van de pathofysiologie, risicostratificatie en het 
werkingsmechanisme van reperfusietherapie voor het acute ST-elevatie myocardinfarct 
is afkomstig uit deze landmark studie. Hoewel de rol van fibrinolyse bij de behandeling 
van patiënten met een STEMI aan het afnemen is, zouden zowel clinici als onderzoekers 
op het gebied van acute coronaire syndromen hun voordeel moeten halen uit de lessen 
die we hebben geleerd uit GUSTO-1 en andere historische studies op het gebied van 
reperfusie therapie. In plaats van louter het nastreven van een positief studieresultaat 
op klinische eindpunten, zou het toevoegen van mechanistische substudies aan de 
opzet van toekomstige klinische studies kunnen leiden tot nieuwe en soms onverwachte 
wetenschappelijke inzichten. Deze kunnen vervolgens weer dienen als leidraad voor 
toekomstig onderzoek en de verdere verbetering van behandelmethoden.
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Het naderen van de eindstreep vraagt om een terugblik op de weg die ik de afgelopen 
negen jaar als onderzoeker heb afgelegd. Dit gaat gepaard met wisselende emoties. 
Enerzijds is er natuurlijk blijdschap en trots, anderzijds melancholie bij het afsluiten 
van een periode waarin ik als dokter, onderzoeker en mens gevormd ben. Naast een 
wetenschappelijk leerproces, is het schrijven van een proefschrift een confrontatie met 
je eigen kwaliteiten en tekortkomingen. Zonder hulp van anderen is het onmogelijk 
om de finish te bereiken. Wat overheerst is daarom een gevoel van dankbaarheid aan 
iedereen die mij in de afgelopen jaren geholpen heeft met de totstandkoming van dit 
proefschrift. Een aantal personen heeft hieraan een bijzondere bijdrage geleverd.
De bijna 500 patiënten, die in het kader van de APRICOT-studies tweemaal een 
hartcatheterisatie hebben ondergaan, vormen de basis van dit proefschrift. Mede 
dankzij de bereidwilligheid van deze patiënten, hun familieleden en huisartsen is het 
gelukt om 7 tot soms 15 jaar na dato vrijwel complete cardiologische follow-up gegevens 
te verkrijgen. 
Mijn promotor, professor Freek Verheugt. Door uw enthousiasme heb ik tijdens mijn 
studie aan de VU een warm hart gekregen voor de cardiologie en ben ik later in Nijmegen 
terecht gekomen. Bedankt voor het creëren van de mogelijkheden om dit onderzoek te 
verrichten en tijdens mijn opleiding af te ronden. Zeker als beginnend onderzoeker was 
het erg prettig om een promotor te hebben die mijn pennevruchten altijd snel nakeek en 
van opbouwend commentaar voorzag. De afronding van mijn opleiding en proefschrift 
vallen nu samen met uw terugkeer naar Amsterdam. Een nieuw tijdperk breekt aan 
met nieuwe uitdagingen. De goede herinneringen blijven: uw encyclopedische kennis 
van cardiologische studies, de onnavolgbare one-liners tijdens de overdracht en de 
ontspanning tijdens de buitenlandse congressen.  
Mijn co-promotor, Marc Brouwer. Beste Marc, je bent een unieke figuur met unieke 
kwaliteiten. Als er iemand is die mij van start tot finish gesteund heeft, ben jij het. Waar 
ik in de beginperiode nog op zoek was naar een plaatje voor de toekomst, heb jij deze 
domineeszoon geleerd hoe belangrijk het is om te geloven in een goede afloop. Op ‘de 
Experimentele’ heb je mij vervolgens via het ‘winkeldochterstuk’ het onderzoekersvak 
bijgebracht. Dankzij deze leuke en intensieve tijd is een half woord nu voldoende om 
elkaar te begrijpen. Onze samenwerking kenmerkt zich door plezier, synergie, en het 
gevoel van Oranje ’74 / Ajax ‘95. Ik kijk er naar uit om binnenkort samen weer ouderwets 
te ‘knallen’.
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De leden van de manuscriptcommissie, prof. dr. ir. H.A. van Swieten, prof. dr. F.W.H.M. 
Bär en prof. dr. A.L.M. Verbeek, dank ik voor de tijd die zij hebben willen nemen voor het 
kritisch lezen en beoordelen van het manuscript. 
Van de APRICOT-onderzoekers ben ik speciale dank verschuldigd aan Gerrit Veen voor 
het verrichte monnikenwerk aan de angiografische data van APRICOT-1 en later het 
beoordelen van de APRICOT-2 films samen met Wim Aengevaeren. Ik heb jaren na dato 
dankbaar van deze gegevens gebruik kunnen maken. Daarnaast dank ik Paul van den 
Bergh voor het jarenlang verzamelen van survival data van de APRICOT-2 patiënten.
In de eerste jaren op ‘de Experimentele’ waren de statistische tips van ‘eminence grise’ 
Gerard Uijen waardevol. De ICT ondersteuning van Rudi Hoekema, Truus Pijnenburg, 
Noortje Rubbens en Gabe Greijdanus is door de jaren heen altijd perfect geweest. Eén 
telefoontje en er werd actie ondernomen om het probleem op te lossen.
De staf en assistenten Cardiologie van het UMC St Radboud wil ik bedanken voor de 
mogelijkheid die ik in 2007 heb gehad om tijdens mijn opleiding aan mijn proefschrift te 
kunnen werken. Deze periode was cruciaal om tot een succesvolle afronding te kunnen 
komen. 
De cardiologen en secretariaten van de deelnemende centra aan de APRICOT studies 
dank ik voor de plezierige samenwerking en de hulp bij het completeren van de lange 
termijn follow-up. Vooral de afdeling research van het CWZ (Astrid Schut, Tineke Tiemes) 
verdient complimenten voor de perfecte organisatie en de gezelligheid. De bezoekjes 
aan het Trial Coordination Center in Groningen boden altijd een prima gelegenheid om 
het nuttige en aangename te combineren.
Mijn vriend, fiets- en schaatsmaatje, wapenbroeder en paranimf Jaap Remmen. Vanaf 
onze eerste ontmoeting januari 1998 tot heden is onze vriendschap gegroeid en zijn 
onze wegen zowel qua werk als privé parallel gelopen. In de regel liep jij altijd iets voor, 
maar uiteindelijk hebben we allebei het punt bereikt waar we nu staan. Hoeveel uren 
hebben we niet op de fiets, op de schaats of achter een goed glas gepraat over de 
hobbels  en frustraties die we onderweg tegenkwamen. Maar vooral hebben we altijd 
erg genoten van alle leuke en leerzame dingen die we samen hebben meegemaakt, 
zowel in het ziekenhuis als daarbuiten. Het is onbetaalbaar om een vriend te hebben die 
alle ‘ins and outs’ van zowel opleiding, onderzoek als een opgroeiend gezin begrijpt!
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Erwin Zegers. Ik heb jou leren kennen als een perfecte collega, die altijd zijn zaakjes goed 
regelt en die nooit te beroerd is om een dienst over te nemen of op een andere manier 
te helpen als er een beroep op hem gedaan wordt. Daarnaast schept het vaderschap en 
de gezamenlijke belangstelling voor voetbal een band. Jij hebt een duidelijke interesse 
en talent voor onderzoek en wetenschap. Hoewel je nu een iets ander pad ingeslagen 
bent, denk ik dat de drang naar verdieping aanwezig blijft. Ik zou het mooi vinden als 
jouw rol als paranimf je stimuleert en motiveert om met je eerdere voornemens voor 
onderzoek door te gaan. 
Etienne Cramer, Hendrik-Jan Dieker, Wessel Keuper en Nick Clappers. Destijds kwamen 
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op 9 februari 1971 in Schelluinen. Hij groeide op 
in Wageningen en volgde het Voorbereidend 
Wetenschappelijk Onderwijs aan het Christelijk 
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studie geneeskunde aan de Vrije Universiteit 
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wetenschappelijke stage met als onderwerp ‘Het 
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Nijmegen (opleider: prof. dr. F.W.A. Verheugt). Sinds zijn registratie als cardioloog op 
1 januari 2009 is hij als staflid Cardiologie werkzaam op de afdelingen Cardiologie en 
Cardiothoracale Chirurgie van het UMC St Radboud.
In 2002 is hij getrouwd met Joke de Lange. Samen hebben zij drie kinderen: Douwe 
(2003), Charlotte (2005) en Babette (2007).
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